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Most microbial natural product discovery programs rely on the growth of bacteria 
in the laboratory, yet it is now well established that the vast majority of bacteria in the 
environment have not been cultured, particularly from the diverse soil microbiota. By 
extracting DNA directly from soil samples to construct large archived environmental 
DNA (eDNA) libraries, thousands of genomes from both cultured and as yet uncultured 
bacteria can be simultaneously screened for gene clusters encoding natural products of 
interest. Several natural products with pharmaceutically relevant biological activity arise 
from the dimerization of tryptophans, such as staurosporine, rebeccamycin, and violacein. 
To discover novel tryptophan dimers (TDs), we have designed a metagenomics-based TD 
natural product discovery and development pipeline that consists of seven steps: 1) soil 
eDNA extraction; 2) eDNA library construction; 3) homology-based screening; 4) 
bioinformatics analysis; 5) heterologous expression; 6) characterization of compounds 
and their biosynthesis; 7) target identification.  
Using a degenerate primer set that targets the CPA synthase gene, one of the 
conserved genes of tryptophan dimer biosynthesis, we screened the equivalent of ~1 
million (over 1 tera base pairs) bacterial genomes from the eDNA libraries, resulting in 
the discovery of 14 unprecedented TD gene clusters, almost tripling the number of TD 
gene clusters that have previously been characterized. Using heterologous expression 
strategies that involve 1) shuttling of pathways into diverse bacterial hosts, 2) 
overexpression of positive transcriptional regulator, 3) synthetic refactoring of complete 
pathways, and 4) co-expression of deficient biosynthetic genes, we successfully 
expressed nine of the 14 gene clusters. This led to the functional characterization of three 
novel TD families (i.e. indolotryptoline, carboxy-indolocarbazole, and 
bisindolylmaleimide), consisting of 15 novel natural products (e.g. BE-54017s, 
borregomycins, erdasporines) with therapeutically relevant bioactivities (e.g. antitumor, 
antibacterial). Linking biologically active natural products to their cellular targets 
remains a challenging and critical process in the development of therapeutic agents and 
small-molecule probes, especially for cytotoxic agents that might serve as anticancer 
agents. Using multidrug resistance-suppressed (MDR-sup) fission yeast resistant mutant 
screening, the molecular target of the indolotryptoline family of TD was identified and 
validated to be the proteolipid subunits of vacuolar H+-ATPase (V-ATPase) at a putative 
binding site that is distinct from the previously described V-ATPase inhibitors. Together, 
we demonstrate the utility of this pipeline in the isolation, characterization, and 
development of novel natural products from the soil bacterial metagenome.  
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Chapter 1 
1. Introduction and background 
1.1 Bacterial natural products and their applications 
 Natural products are small molecules, typically less than 3000 Da in size, that 
living organisms produce as part of their biological process. Small molecular weight 
compounds can broadly be classified into two classes: primary metabolites that are 
essential for the growth and maintenance of an organism and thus their production are 
conserved spanning diverse phyla of life (e.g. amino acid, nucleic acid, sugar), verses 
secondary metabolites that are only made by specific groups (e.g. species, strains) of 
organisms because they are not directly involved in cellular growth (1). Although the 
precise role for many of these compounds is yet to be characterized, they are generally 
presumed to provide the producer with some selective advantage in their living 
environment (2), such as intercellular communication (e.g. quorum sensing) (3) and 
growth inhibition of competitors (e.g. bacteriocin) (Figure 1) (4). Different species of 
organisms interact with various environments, and thus the chemical structure and 
biological property of secondary metabolites that they generate are diverse (5). As such, 
natural product research primarily involves the discovery and characterization of 
secondary metabolites.  
Natural products have long served as a prolific source of novel chemical entities 
(6). Common source of natural products include plants and fungi, but yet another 
important source has been bacteria. Bacterial metabolites have themselves been used as 
therapeutic drugs, such as antibacterial (e.g. vancomycin, daptomycin), anticancer (e.g. 
doxorubicin, mitomycin C), antifungal (e.g. amphotericin B, nystatin), antiparasitic (e.g. 
 2 
avermectin), and immunosuppressive (e.g. FK-506, rapamycin) agents, and many more 
have served as leads or scaffolds to synthetic drugs (Figure 2) (7). As such, 
approximately 64% of the FDA approved therapeutic agents are derived from or inspired 
by natural products (6). Because a metabolite must bind to a molecular target to exert its 
biological activity, natural products are also used in basic biology as small-molecule 
inhibitors and activators to elucidate biological processes by perturbation, such as FK-
506 for the calcineurin-mediated signaling pathway (8) and lactacystin for proteasome 
activity (9).  Furthermore, natural products have found its use as tools for biological 
 
	  	  
 
Figure 1. Examples of natural product secondary metabolites with the predicted 
ecological role in parenthesis. 
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engineering, such as resistance markers (e.g. kanamycin, apramycin) and small-molecule 
mediated promoters (e.g. tetracycline/TetR) (10).  
1.2 Limitations of traditional natural product discovery 
 Considering the significance of natural products in therapeutic, research, and 
engineering settings, it is disconcerting that the trend of discovering novel natural 
products is in a steady decline over the past few years (11). A strong repercussion is 
particularly observed in drug discovery with the decreasing number of novel FDA 
approved drugs (6). With the emergence of multiple drug resistant pathogens (12) and 
	  
 
Figure 2. Examples of natural product secondary metabolites that have been FDA 
approved as therapeutic agents. 
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various cancer phenotypes increasing the demand for novel therapeutic agents (13), the 
diminishing returns of natural product isolation calls for a serious reinvestigation into our 
traditional approaches of natural product discovery. 
 Soil represents one of the richest environments in bacterial biodiversity, where the 
number of microbial species in a single gram of soil is roughly equivalent to the number 
of plant species in the entire Amazon rainforest (14). Since different species produce 
distinct collections of secondary metabolites, one should theoretically expect the isolation 
of various natural products from different soil samples. In reality, however, natural 
product chemists have been repeatedly recovering the same compounds with high 
duplication rate using conventional methods, which involve the random screening of 
biologically active compounds from extracts of laboratory-cultured soil bacteria (15). 
Upon closer inspection of the soil microbiota, it has been found that the fraction of 
bacterial species that has been cultured in the laboratory is 1%, and thereby traditional 
natural product discovery techniques do not permit the recovery of metabolites that are 
produced by the remaining 99% of the as yet uncultured microbial majority (16-19). 
1.3 Metagenomics-based natural product discovery 
 In order to access the metabolites that come from uncultured bacteria, we propose 
a natural product isolation strategy that avoids microbial culture, and instead harnesses 
the rapid advancement in DNA sequencing and bioinformatics technology by employing 
a metagenomic approach. Metagenomics refers to the study of genetic materials that are 
directly isolated from environmental samples (20, 21). From an environmental sample, 
DNA can be directly extracted instead of culturing the bacteria (Figure 3). The resulting 
environmental DNA (eDNA) can then be cloned into E. coli to construct eDNA libraries 
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(22). For prokaryotes, the genes that are required for natural product biosynthesis, 
including biosynthetic, regulatory, and resistance genes, are often encoded on one 
contiguous stretch of DNA in the host bacterial genome (23). Bacterial natural product 
biosynthetic gene clusters can therefore be captured on a single or multiple overlapping 
	  
 
Figure 3.  Culture-dependent (Left) versus culture-independent (Right) natural product 
programs from soil bacteria.  Traditional culture-based strategy suffers from low 
culturability rate of soil microbes and high re-isolation rate of known compounds. 
Metagenome-based strategy allows access to the biosynthetic potential from the 
uncultured microbial majority. 
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eDNA clones. High-throughput survey of eDNA libraries then allows for a simultaneous 
and systematic screening of thousands of genomes from both cultured and uncultured 
bacteria for biosynthetic gene clusters of interest. The recovered gene clusters can be 
sequenced for bioinformatics analysis and expressed for small molecule production and 
isolation.  
1.4 Phenotype- versus homology-based screening 
 Current eDNA library screening approaches can be broadly classified into two 
types: phenotype-based and homology-based (Figure 3) (24). Phenotype-based approach 
refers to the screening of eDNA-harboring clones for small molecule-producing 
phenotypes, which can range from coloration and zone of inhibition of individual 
colonies grown on solid media, to presence of novel LC/MS peaks in the organic extracts 
of serially diluted eDNA-harboring bacterial cultures. This screening process is 
independent of DNA sequence that dictates chemical structure, and therefore permits the 
discovery of novel compounds that are encoded by hypothetical genes, such as long-
chain N-acyl amino acids (25), turbomycins (26), and isocyanide metabolites (27) (Figure 
4). 
However, this approach is limited to the recovery of natural products encoded by 
gene clusters that can be captured on a single clone. While natural product gene clusters 
typically span 10-100 kbp in nucleotide length, most gene clusters that are discovered 
from this strategy is less than 10 kbp in length (Figure 4) because large, multimillion 
membered eDNA libraries can currently only be constructed using cosmid-based methods 
that harbor 30-40 kbp of eDNA insert (28). Also, the gene cluster must be natively 
expressed in the eDNA-harboring heterologous host for phenotypic detection. Gene 
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clusters that satisfy this criterion are limited due to two reasons. First, phylogenetically 
distant DNA is generally not correctly recognized or realized by the bacterial host, 
possibly due to the lack of compatible RNA polymerase, transcription factor, codon 
usage/tRNA, molecular chaperone, post-translational modification enzyme, molecular 
starting unit, and so forth (29). While smaller eDNA libraries have been constructed in 
diverse proteobacteria (Agrobacterium tumefaciens, Burkholderia graminis, Caulobacter 
vibroides, Pseudomonas putida, Ralstonia metallidurans) (30) and Streptomyces lividans 
(31), routine large eDNA library construction has thus far been limited to E. coli. Second, 
even phylogenetically related DNA can be tightly repressed because secondary 
metabolites have the tendency to be produced only in response to certain conditions, such 
as in low iron environment for siderophores (32). Bacterial whole-genome sequencing 
demonstrates that the number of putative biosynthetic gene clusters far exceeds the 
number of characterized secondary metabolites in most cases, suggesting that the 
majority of gene clusters have remained silent (33). 
	  
 
Figure 4.  Compounds found from phenotype-based eDNA screening and their 
corresponding biosynthetic gene clusters. 
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 Homology-based screening serves as an alternative approach. This method 
requires the identification of a conserved DNA sequence region from previously 
characterized biosynthetic genes. A set of degenerate primers is designed based on this 
region and used to survey and recover, by PCR, the eDNA clones that harbor the target 
conserved region. Although the screening is dependent on known sequence information, 
it is independent of phenotypic detection, implying that gene clusters that are silent or 
span multiple overlapping clones can be recovered. Although these gene clusters may not 
be expressed natively in the eDNA-harboring host, the genetic information can be used 
for bioinformatics analysis and heterologous expression using alternative bacterial hosts 
and genetic engineering methods. 
In terms of the conventional approaches to genomic natural product discovery (34, 
35), homology-based screening is analogous to the data mining of sequenced bacterial 
genomes for novel biosynthetic gene clusters based on sequence homology. However, 
even the largest high-throughput eDNA sequencing project (36), generating one billion 
base pairs of nonredundant sequence, covers the bacterial diversity that is contained in 
~0.1 gram of soil (assuming 10,000 species per gram of soil (37) and 1,000 kbp genome 
size (38)). Thus, homology-based screening serves as an alternative method of surveying 
the astronomically large sequence space in the environmental genome, without the 
expenditure of time and labor for high-throughput sequencing.  
 The choice of target conserved region becomes an important aspect in homology-
based screening. For example, nonribosomal peptides and polyketides are two major 
classes of microbial natural products, and the adenylation and ketosynthase domains have 
been well established as conserved regions in their respective gene clusters that encode a 
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myriad of structurally diverse compounds (Figure 5) (39, 40). The thorough knowledge 
regarding the biosynthetic genes of these two natural product classes have greatly 
facilitated the discovery and generation of additional compounds of these classes (41-43). 
A similar trend can now be observed for the recently characterized ribosomal peptide 
class of natural products (44).  However, with regards to biosynthetic classification based 
on sequence homology, the remaining bacterial natural products have been largely 
unexplored. Finding sequence homology regions for these natural product classes should 
permit their global screening from the metagenome, and contribute to the expansion of 
these underexplored natural product classes through the discovery of novel members and 
the characterization of their biosyntheses.  
	  
 
Figure 5.  Multimodular nonribosomal peptide synthetase (NRPS) and polyketide 
synthase (PKS) that contains a conserved adenylation (Ad) and ketosynthase (KS) 
domain, respectively (red box). 
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1.5 Tryptophan dimer natural products 
 A number of bacterial natural products arise from the coupling of two tryptophans 
(45). Referred to as tryptophan dimers (TDs), these compounds take on a variety of 
different chemical structures, depending on how the two tryptophans dimerize and 
functionalize (Figure 6). TDs are also found to be frequently associated with clinically 
relevant biological activities, suggesting that the TD motif may be a privileged natural 
substructure (46). The myriad bioactivities of TD have been believed to come from their 
ability to target protein kinases or other entities containing ATP-like binding sites, such  
as DNA topoisomerases, ABC transporters, and intercalative sites of DNA (47). In 
particular, staurosporine is a potent protein kinase inhibitor (48), and its discovery has 
spearheaded the research of kinase inhibitors as potential anticancer drugs (47). 
Meanwhile, rebeccamycin is a TD that is structurally similar to staurosporine, but it 
inhibits DNA topoisomerase I instead (49). Natural and synthetic derivatives of 
staurosporine and rebeccamycin have entered clinical trials for cancer, neurodegenerative 
disorders, and diabetes-associated pathologies (Figure 6) (50-55). From a practical 
standpoint, TD class is especially amenable to genome-based natural product discovery 
because the known TD biosynthetic gene clusters are relatively short in length (10-30 
kbp), making them genetically tractable for small molecule expression (46). Moreover, 
the tryptophan moiety renders the compounds UV active and thereby easier to detect and 
isolate (46). The structural diversity, biological significance, and technical compatibility 
of TD make it an attractive natural product class for homology-based eDNA screening. 
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1.6 Tryptophan dimer product discovery and development pipeline 
 Here we describe a metagenomics-based natural product discovery pipeline that 
allows for the culture-independent isolation of secondary metabolites, using tryptophan 
dimer natural product discovery as a model case. The general process involves 1) soil 
eDNA extraction; 2) eDNA library construction; 3) homology-based screening; 4) 
bioinformatics analysis; 5) heterologous expression; and 6) characterization of 
compounds and their biosynthesis (Figure 7). In particular, bioinformatics analysis allows 
for the rapid dereplication of known compounds and focused recovery of metabolites 
	  
 
Figure 6.  Examples of tryptophan dimers (TDs). A) Natural TDs where biosynthesis is 
known. B) Natural TDs where biosynthesis is not known. C) Natural and synthetic TDs 
that have entered clinical trials. 
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from particularly interesting natural product families.  Considering that biological 
characterization of natural products is significant for their further development, we also 
incorporate into the pipeline 7) target identification of compounds (Figure 7). From 
screening the equivalent of ~1 million (over 1 Tbp) bacterial genomes from the eDNA 
libraries using this pipeline, we discovered 14 unprecedented TD gene clusters, almost 
tripling the number of TD gene clusters that have previously been characterized. We 
functionally characterized nine of the 14 gene clusters by heterologous expression, 
resulting in the elucidation of three novel TD families that consist of fifteen novel 
biologically active natural products. The primary resistance mechanism to the 
	  
 
 
Figure 7.  Seven-step overview of the metagenomics-based natural product discovery 
pipeline, from eDNA library construction to compound characterization. 
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indolotryptoline family of TD was also identified and validated, suggesting the molecular 
target and binding site. Taken together, we demonstrate how the power of metagenomics 
can be harnessed, both as a small-molecule discovery tool to isolate novel structural leads, 
identify their mode of action, and further find derivatives of interesting leads, as well as a 
chemical ecology investigation tool to survey small molecule biodiversity in the 
environment and characterize how these compounds are biosynthesized. 
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Chapter 2 
2. Screening for tryptophan dimer biosynthetic gene clusters 
2.1 Divergent biosynthesis of TDs 
  To discover tryptophan dimer (TD) natural products by homology-based 
screening, a target homology region must first be identified from analyzing the 
biosynthesis of known TDs. More than 100 bacterial TDs have been isolated from 
various microbes (45, 46). However, prior to our culture independent discovery efforts, 
gene clusters have been sequenced and functionally characterized in cultured-based 
studies for only five bacterial TDs: staurosporine (56), rebeccamycin (57), K252a (58, 
59), AT2433-A1 (60), and violacein (61). Despite the significant difference in the five 
chemical structures, these TDs share the same initial steps in their biosyntheses: 1) the 
oxidation of tryptophan by an indole-3-pyruvic acid imine (IPA imine) synthase (e.g. 
StaO, RebO, VioA), and 2) the dimerization of IPA imine by chromopyrrolic acid (CPA) 
synthase (e.g. StaD, RebD, VioB) to give CPA as a conserved TD intermediate (Figure 
8A, 34) (45, 46). Although there is no experimental evidence, it has been proposed based 
on the requirement of heme that the reaction mechanism of the CPA synthase proceeds 
via hydrogen abstraction of IPA imine and subsequent radical coupling (Figure 8B). The 
TD biosynthetic pathways subsequently diverge in their downstream biosynthetic 
enzymes to generate the different TD structures.  
 The primary reason that the genes responsible for the production of a particular 
natural product tends to be clustered together in the prokaryotic genome is presumed to 
be because bacteria can acquire genetic information by means of horizontal gene transfer 
(23, 62). The ability of bacteria to obtain foreign gene clusters facilitates the evolution of  
 15 
 
	  	  
 
Figure 8.  Conserved initial steps by IPA-imine synthase (e.g. StaO) and CPA synthase 
(e.g. StaD).  A) From the two conserved initial steps, the known bacterial TD 
biosynthetic pathways lead to the production of three TD substructures: pyrrolinone 
indolocarbazole, maleimide indolocarbazole, and violacein (colored in red). Target 
region was identified from CPA synthase genes. B) Proposed mechanism of CPA 
synthase-mediated tryptophan dimerization. 
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secondary metabolites and explains the formation of structural classes that are based on 
their biosynthesis (63, 64). For nonribosomal peptides and polyketides, their biosynthetic 
enzymes consist of multiple modules, each contributing to the construction of the end 
product by loading a particular subunit (Figure 5) (65). Therefore, when these gene 
clusters are shared amongst various bacteria by horizontal gene cluster, each strain can 
evolve to produce a different compound tailored to its specific environment simply by 
adding/deleting, switching around, or modifying the substrate specificity of the individual 
modules (66, 67). In contrast to the modular logic of NRPS and PKS-based compounds, 
TDs seem to have evolved by conserving the initial biosynthetic steps that allows for the 
tryptophans to dimerize, while diversifying the downstream steps to generate various 
structures (Figure 8).	   
 The biosynthetically characterized bacterial TDs can be classified into three 
structural families depending on their respective substructures (Figure 8) (68). The first 
two families are the indolocarbazoles, characterized by a pentacyclic core that is a fusion 
between an indole and a tricyclic carbazole moiety (46, 69). A pyrrole ring is attached to 
the center of the pentacyclic core, which is a pyrrolinone ring for one family (pyrrolinone 
indolocarbazole; e.g. staurosporine, K252a) and a maleimide ring for the other family 
(maleimide indolocarbazole; e.g. rebeccamycin, AT2433-A1) (46, 70). The third family 
is violacein, which is characterized by having an unusual C3-Cβ to C3-Cα carbon 
connectivity (Figure 8) (71). A number of TD natural products are comprised of one of 
three substructures (46), suggesting that, although their gene clusters have not yet been 
characterized, they each contain a homologous set of biosynthetic genes that give rise to 
its particular TD substructure.  
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2.2 Target homology region for TD screening 
 For the identification of an appropriate homology target for genetic screening, a 
conserved region within one of the genes that are involved in the downstream steps, and 
therefore the genes that are TD family-specific, should allow a focused screening of 
compounds containing a particular TD substructure, such as a collection of staurosporine 
derivatives. However, considering the unexplored biosynthetic potential of the uncultured 
microbial majority and a multitude of known TDs that do not fall within the characterized 
TD families (Figure 6B) (34), we wanted to use a homology target that can screen for 
gene clusters that encode novel TD families as well as derivatives. Since the three 
characterized TD families all share the same two initial steps in their biosynthesis, we 
hypothesized that many of the other unprecedented TD families are also biosynthesized 
by pathway divergence from these two conserved steps. Therefore, in order to conduct a 
more general screening of TD compounds that include previously uncharacterized TD 
families, we decided to identify a target region from one of the two conserved, upstream 
genes from the five known TD gene clusters. 
 A suitable gene for screening should be well conserved within the known gene 
clusters of interest (i.e. the five known bacterial TD clusters) to increase the probability 
of recovering positive hits, while also significantly distant from unrelated genes to 
minimize false positives. The IPA-imine synthase (i.e. staO, rebO, inkO, atmO, vioA) and 
CPA synthase (i.e. staD, rebD, inkD, atmD, vioB) genes from the staurosporine (A/N: 
AB088119.1), rebeccamycin (A/N: AJ414559.1), K252a (A/N: DQ399653.1) AT2433-
A1 (A/N: DQ297453.1), and violacein (A/N: AF172851.1) gene clusters were retrieved 
from the NCBI sequenced genome database and analyzed for sequence homology with 
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other genes in the sequenced genome database using NCBI BLAST searches. The four 
IPA-imine synthase genes from the indolocarbazole pathways (i.e. staO, rebO, inkO, 
atmO) were highly conserved (blastx: >90% query cover, ~60% identity), but they 
showed limited homology to vioA (blastx: <20% query cover) and further exhibited 
background homology (blastx: >90% query cover, ~30% identity) to tryptophan oxidase 
genes (A/N: WP_020389492.1, etc) that do not appear cluster with other TD biosynthetic 
genes. On the other hand, all five CPA synthase genes were sufficiently conserved 
(blastx: >95% query cover, ~50% identity) without showing significant background 
homology to unrelated genes (blastx: <30% query cover). The CPA synthase gene was 
thereby chosen as the target for homology-based screening.  
 To identify the conserved regions for PCR primer design, the five characterized 
CPA synthase genes were aligned by CLUSTALW. Several regions in the DNA 
sequence were found to be homologous (Figure 9), but ultimately the regions for primer 
design was chosen based on three criteria. First, the distance between the two regions for 
forward and reverse primer design is at least 500 bp, such that amplicon sequencing 
provides enough genetic information to determine positive hits, and no more than 1000 
bp to facilitate ease of PCR amplification. Second, to minimize background PCR 
reactions, the regions should permit the design of primers that are more than 20 bp long. 
Third, the regions’ encoding protein sequences should be as conserved as possible, with 
DNA sequence degeneracy mostly coming from the third-base wobble in the genetic code. 
Conservation in protein sequence is prioritized over gene sequence because protein 
sequence is determined based more on function and less on species-dependent factors, 
such as codon usage bias (72, 73). Based on these criteria, regions corresponding to 
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2086-2108 bp and 2635-2655 bp of the staD gene were chosen for the design of CPA 
synthase-specific degenerate PCR primers to amplify CPA gene homologs from the 
eDNA libraries (Figure 9) (StaDVF: GTS ATG MTS CAG TAC CTS TAC GC; 
StaDVR: YTC VAG CTG RTA GYC SGG RTG). The fraction of degenerate bases is 
limited to 17% and 29% for the forward and reverse primers, respectively, yet the primer 
set still targets all five of the known CPA synthase genes. This primer set should thereby 
permit the screening of TD biosynthetic gene clusters encoding diverse TD families while 
minimizing false positives. 
 2.3 Construction of eDNA libraries  
A major factor to consider for eDNA library construction is the sample type. 
Many protocols have thus far been reported regarding the extraction of DNA from 
environmental samples (environmental DNA; eDNA) and its use for the construction of 
an eDNA library. The eDNA isolation strategies vary depending on the sample type, such 
as soil (74), marine sponge (75), bromeliad tank water (76), and human feces (gut) (77), 
with a possible enrichment of a specific cell type (78). An optional enrichment step, such 
as density gradient centrifugation, is convenient in cases where the cell type of interest is 
mixed with other cell types in an environmental sample, such as the construction of 
prokaryotic eDNA libraries from marine sponges. However, although not as drastic as 
direct cultivation, certain types of bacteria that are more amenable to enrichment will 
artificially dominate the resulting eDNA library. On the other hand, soil samples mostly 
consists of prokaryotic cells (79); by employing gentle lysis methods that preferentially 
disrupts the weaker cell membranes of prokaryotes over eukaryotes (38), eDNA that 
mostly consists of bacterial genomic DNA can be extracted from the soil without any 
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enrichment step. Soil sample is thereby suitable for library construction not only from the 
standpoint of bacterial biodiversity (refer to Chapter 1.2), but also in that it permits the 
isolation of eDNA without perturbing the natural bacterial populations.  
A soil sample that is suitable for eDNA construction satisfies two criteria: 1) high 
quality eDNA can be extracted efficiently, and 2) biosynthetic diversity is rich. 
Empirically, our lab has routinely found arid soils to be particularly capable of yielding a 
large quantity of eDNA that is both relatively low in short DNA fragment contamination 
and in inhibitory activity of downstream cloning reactions, and thus has been samples of 
choice for the construction of large eDNA libraries. Although the precise reason is not 
clear, we postulate that the relatively low abundance of plant and fungal-based biomass in 
arid samples minimizes the level of humic acids and other substances that may facilitate 
 
Figure 9. Degenerate PCR primer design for homology-based screening. Conserved 
regions (blue and red boxes) of staD-like CPA synthase genes were identified by 
CLUSTALW alignment. Regions corresponding to 2086-2108 bp and 2635-2655 bp 
(red boxes) of the staD gene (green arrow) were chosen for the design of a degenerate 
PCR primer pair (red text) that can target all the five known CPA synthase genes (blue 
text). 
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DNA degradation and inhibit eDNA cloning efficiency. In addition, arid soils are 
relatively rich in a group of bacteria called actinomycetes (80, 81), which is known to be 
one of the most prolific producers of secondary metabolites (82, 83). As such, a recent 
report shows that soils from dry area displays the richest observed biosynthetic diversity 
(84). Although the detailed correlation between soil type and biosynthetic diversity still 
remains to be investigated, previous empirical observations and experimental data 
support the construction of eDNA library using desert soil samples.  
The eDNA for library construction was isolated from soil samples using total 
extraction method (Figure 10A) (28). This procedure involves the removal of debris 
matters from the soil using a sieve, followed by resuspension in a detergent-containing 
buffer. The sample was shaken with moderate heating to gently lyse the soil bacteria for 
the liberation of eDNA from the soil. After the removal of soil particulates by 
centrifugation, eDNA was precipitated from the supernatant using isopropanol. Based on 
agarose gel electrophoresis analysis, much of this crude eDNA was sized at around 30-
100 kbp due to mechanical shearing from the extraction protocol thus far, with detectable 
levels of smearing that signify the minute presence of short DNA fragments below 30 
kbp. Preparatory agarose gel electrophoresis was used to purify high-molecular weight 
(HMW; >30 kbp) eDNA from crude eDNA. 
The construction of a clone library from HMW eDNA has generally been 
conducted in either a bacterial artificial chromosome (BAC)- (85-87) or cosmid/fosmid-
based (88-90) vector system. BAC is a single-copy vector that mimics the nature of 
chromosome and maintains long insert sizes (91). The clones from BAC eDNA libraries 
have thereby accommodated up to 200 kbp in insert size, which can capture the majority 
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of prokaryotic biosynthetic gene clusters. However, due to the mechanical shearing of 
DNA that arises from standard DNA extraction and purification protocols, a reliable 
isolation of large DNA suitable for BAC library construction (>100 kbp) proves to be  
technically challenging (92). Moreover, BAC eDNA libraries are typically contaminated 
with short insert clones because even a small fraction of short fragment DNA contained 
in purified HMW eDNA samples will become enriched in the subsequent ligation and 
transformation steps of library construction (92). As such, much of the previously 
constructed BAC eDNA libraries range about 10,000-50,000 members, with an average 
insert size of 100 kbp for smaller and 50 kbp for larger libraries, thereby reaching up to 4 
Gbp in total genome size. In contrast, cosmid (multi-copy) or fosmid (single-copy) is a 
 
Figure 10. Schematic of eDNA library construction. A) High-molecular weight (HMW) 
eDNA is purified from a soil sample by total extraction and used to construct a library 
using cosmid (transduction)-based approach. B) Cosmid-based approach allows for 
bacteriophage to select the size of the eDNA cosmid, such that each eDNA clone 
contains 30-40 kbp of eDNA insert. 
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plasmid that can be packaged into a lambda phage, which can then be transferred into a 
bacterial host for library construction (transfection/transduction) (93). Because the size of 
the cosmid is selected by the phage capsid, cosmid libraries have uniform sized inserts of 
30-40 kbp (28). In homology-based screening, the total genome size of the library is more 
important than the maximum insert size because, as long as the coverage of the library is 
sufficient such that entire biosynthetic gene cluster is captured in multiple overlapping 
vectors, it does not need to be captured in a single vector. Previous studies show that, in 
order for the library to capture most of biosynthetic capacity in a soil sample, it should 
have a total genome size of around 400 Gbp (94). Since a BAC eDNA library of such 
size remains to be constructed, we have chosen to construct multiple eDNA libraries 
using a cosmid-based approach. From soil samples collected in the Anza-Borrego desert 
of California (AB), the Sonoran desert of Arizona (AR), and the Chihuahuan desert of 
New Mexico (NM), three cosmid-based eDNA libraries were constructed, each 
consisting of about 15,000,000 unique cosmid clones (Figure 10B). By screening all three 
of these multimillion-membered eDNA libraries, an equivalent of ~1 million bacterial 
genomes (over 1 Tbp in total genome size) can be simultaneously surveyed for their 
biosynthetic potential.  
2.4 Screening for eDNA-derived TD gene clusters  
 To facilitate homology-based screening, each of the 15,000,000 cosmid-based 
eDNA libraries were archived into unique sublibraries that each consist of 5000 clones 
(~3000 sublibraries per eDNA library).  Matching DNA miniprep and glycerol stock 
pairs were made for each sublibrary, with the DNA minipreps arrayed such that sets of 8 
sublibraries were combined to generate unique “row pools” (~375 row pools per eDNA 
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library). To screen for TD gene clusters from the eDNA libraries, the “row pools” were 
used as PCR templates to detect and amplify ~570bp long CPA synthase PCR products 
with the previously described degenerate primer set (Figure 9). Approximately 10% of 
the “row pools” that were screened yielded an amplicon of the correct length. These 
amplicons were gel purified, re-amplified, and sequenced. Based on the NCBI homology 
search (blastx), ~80% of the sequenced amplicons were found to be come from CPA 
synthase genes and were followed up for the recovery of their encoding eDNA clones. 
 Each of the eDNA clones containing a unique CPA synthase amplicon was 
isolated using serial dilution strategy (Figure 11). First, a set of specific PCR primers that 
target each unique CPA synthase amplicon was designed and tested on the DNA 
minipreps of the 8 sublibraries that constitute the “row pool” hit to determine the 
sublibrary that contains the target clone. The matching glycerol stock of the eDNA 
sublibrary was then grown, diluted, and arrayed into sterile 96 well plates, such that each 
 
Figure 11. Schematic of eDNA clone recovery by serial dilution. Upon determining the 
sublibrary containing the clone of interest, the overnight culture of the sublibrary is 
diluted and arrayed into 96 well plates. The well containing the clone of interest is 
determined by whole cell PCR of the pooled “rows” and “columns” and subsequently 
plated onto solid media for single cosmid recovery. 
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well contains about 25 cells. The “rows” and “columns” of the wells are pooled and 
tested by whole cell PCR to determine the well containing the clone of interest. The 
culture broth from this well was grown on solid media and single colonies were screened 
by PCR to identify the specific eDNA clone harboring the targeted CPA synthase gene. 
After the first round of clone recovery, we empirically discovered that CPA synthase 
amplicon sequences sharing >95% identity came from the same TD gene clusters, and 
thus the amplicons were clustered at 95% identity in the subsequent rounds of clone 
recovery to avoid redundancy. In total, 16 unique CPA synthase amplicons and their 
harboring eDNA cosmid clones were found from the homology-based screening: 9 from 
the AB, 4 from the AR, and 3 from the NM libraries. 
 2.5 Bioinformatics analysis of TD gene clusters 
 The recovered eDNA clones containing the amplicon sequences were de novo 
sequenced using Next-Generation Sequencing technology. The sequences from the 
cosmid assemblies were annotated by FGENESB for gene (open reading frame) 
identification and by BLAST (blastp of the gene product) for the bioinformatic prediction 
of each gene product’s function (Appendix 1). Based on the annotation, all 16 eDNA 
clones harboring the amplicon sequences were identified to contain putative TD gene 
clusters, in that each possessed a set of genes, including a putative CPA synthase gene, 
that is similar to those found in previously annotated TD gene clusters (Figure 12). These 
putative gene clusters were all less than 27 kbp in length and, with the exception of one 
gene cluster (AR1973), a cosmid clone harboring the intact, complete gene cluster was 
found for each TD pathway. Two eDNA clusters, AB1350 and AR1455, were identical in 
gene content to the characterized staurosporine and rebeccamycin clusters, respectively 
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(56, 57). The remaining 14 TD gene clusters were unprecedented in gene content, almost 
tripling the number of bacterial TD gene clusters that have been previously characterized.  
For the comparative bioinformatics analysis of the relatively unexplored TD gene 
clusters, we considered employing phylogenetics used to visualize the evolutionary 
relationships of bacterial species. In the construction of a phylogenetic tree, a particular 
gene that is known to undergo a low evolutionary rate is chosen as the phylogenetic 
marker because its genetic variation will then be strongly linked to ancestral divergence 
events (80). The gene that is resilient to genetic change tends to be a housekeeping gene 
that is necessary for cellular viability and conserved across all bacteria. The 16S rRNA 
gene (83), in particular, has been well-established as a suitable phylogenetic marker, 
where the comparison of genetic variation in solely the conserved region of the 16S 
rRNA gene serves as a good proxy for the classification of bacterial species. 
The concept of phylogenetics can similarly be translated to natural product 
biosynthetic gene clusters, where natural product taxonomy can be defined based on the 
substructures of the compounds encoded by the gene clusters. For example, when a 
phylogenetic tree was constructed based on the ketosynthase beta (KSβ) domain from a 
collection of eDNA-derived type II polyketide gene clusters, the clusters were found to 
group together based on the particular polyketide substructures that they produce (42). 
Therefore, by using the KSβ domain as a phylogenetic marker or a sequence tag, eDNA-
derived gene clusters that encode for chemically novel or clinically relevant polyketide 
substructures can be rapidly detected on the phylogenetic tree and targeted for 
heterologous expression (82, 95). 
 27 
Since the CPA synthase gene is conserved across the 16 eDNA-derived TD gene 
clusters, we investigated the possibility of the CPA synthase gene as a phylogenetic 
marker. When the 16 eDNA-derived TD gene clusters and the 5 functionally 
characterized TD gene clusters were organized according to CPA synthase gene 
phylogeny, the clusters with similar gene content grouped together. CPA synthase genes, 
and in turn the TD clusters from which they arise, form 6 distinct clades (Figure 12; 
Groups A-F). Based on the TD chemical structures encoded by functionally characterized 
gene clusters, the groupings appear to correlate with the production of distinct TD 
substructures, suggesting the CPA synthase gene to be a suitable sequence tag for the 
classification of TD gene clusters (84). 
Group A contains violacein-like TD gene clusters, characterized by the presence 
of vioE homologs, which are responsible for introducing the unusual C3-Cβ to C3-
Cα carbon connectivity in violacein (89, 94) (Figure 8). The purple pigmentation of 
violacein enables its use as a reporter (91, 92), and its biological properties, such as 
antibacterial (93), antitrypanocidal (87), and anticancer (90) activities, are being 
investigated for medical applications. 
Group C contains gene clusters that encode for compounds with a pyrrolinone 
(monooxygenated) indolocarbazole core, like staurosporine. On the other hand, gene 
clusters from Group D encode for compounds with a maleimide (dioxygenated) 
indolocarbazole core, like rebeccamycin. While gene clusters from both groups contain a 
functionally equivalent cytochrome P450 enzyme (StaP/RebP) that catalyzes the 
formation of the pentacyclic structure of the indolocarbazole core, the oxidation state of 
the pyrrole ring of the indolocarbazole core is dictated by the FAD-binding 
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monooxygenase (StaC/RebC) that is functionally and bioinformatically distinct between  
the two groups (Figure 13) (96, 97). Although the difference in chemical structure is 
subtle between the Group C and D classes of TD, the biological ramification is 
significant in that they are known to have different primary molecular targets: Group C 
 
 
Figure 12. ClustalW-based phylogenetic tree based on culture-derived (Vio, Sta, Ink, 
Reb, Atm) and eDNA-derived (AB#, AR#, or NM#) CPA synthase genes. TD gene 
clusters are shown next to each CPA synthase gene. Six functionally distinct groups of 
TD clusters (A-F) are predicted based on the clustering of the tree. AR1973 is truncated 
by the vector. 
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compounds are protein kinase inhibitors (48), while Group D compounds are DNA 
topoisomerase I inhibitors (49). 
More than 100 TDs have been described from culture-based studies (45, 46). As 
the majority of these are not associated with a sequenced cluster, predicting whether a 
newly discovered TD cluster might encode for a novel metabolite is often challenging. 
Most known TDs are pyrrolinone indolocarbazole-based (Group C) compounds, making 
it particularly difficult to determine whether eDNA-derived Group C gene clusters 
(AR2194, AR654) encode for novel metabolites. In contrast, only a handful of maleimide 
indolocarbazole (Group D) metabolites are known. Group D eDNA-derived gene clusters 
(AB857, AB1533, TX747) all contain collections of genes that are predicted to allow 
them to encode for novel maleimide indolocarbazole-based TDs (e.g. additional 
halogenases and sugar tailoring enzymes). 
 The remaining Group B, E, and F contain no functionally characterized relatives, 
and their eDNA-derived gene clusters consist of biosynthetic genes that are 
 
Figure 13. Protein sequence alignment of StaC/RebC-like monooxygenases. The six 
active site residues that have been identified as being responsible for the functional 
difference between Group C and Group D are K47/R46, S49/G48, V221/F216, 
S236/A231, N244/R239, V246/T241. 
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unprecedented in known TD biosynthetic pathways, suggesting that gene clusters in these 
groups could encode for new TD motifs. For this study, we thereby focused on the 
functional characterization of Group B, E, and F that were predicted based on CPA 
synthase gene phylogeny to represent novel TD classes. 
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Chapter 3: Characterization of novel tryptophan dimer classes 
3.1 Heterologous expression strategies 
 Functional characterization of eDNA-derived natural product biosynthetic gene 
clusters requires heterologous expression, or the production of the pathway-encoding 
small molecules in a heterologous host. With increasing efficiency in DNA sequence and 
synthesis, heterologous expression is increasingly becoming more important in natural 
products research (98, 99). Its application is not just limited to metagenomics-based 
studies, but has also provided the means for the elucidation of compounds encoded in 
sequenced genomes (100), the characterization of natural product biosyntheses (101), 
modification of pathways for the generation of natural product derivatives (102), and 
optimization of product yield (103). However, despite its significance and the recent 
advances in its methodology, a reliable approach for heterologous expression that 
guarantees successful biosynthesis of the natural product does not currently exist. Thus, 
heterologous expression can be considered to be one of the largest bottlenecks in 
metagenomics-based natural product discovery efforts. To address the various factors that 
hinder the expression of gene clusters in a heterologous setting, the heterologous 
expression platform in our natural product discovery pipeline takes a multipronged 
approach that incorporates the use of a diverse set of bacterial hosts, as well as 
methodologies in genetic engineering to manipulate and synthetically refactor cryptic 
gene clusters (Figure 14). 
 One of the prominent reasons to the failure of small molecule production in a 
heterologous host is the host’s inability to recognize foreign DNA. All bacterial 
heterologous hosts are restricted by their intrinsic abilities to recognize and utilize the 
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foreign DNA captured within eDNA libraries (29). Factors that need to be compatible 
with the heterologous host include transcriptional elements (104, 105), such as regulatory 
elements, promoters, and ribosomal binding sites, as well as translational issues (106, 
107), such as codon usage and protein folding chaperones. As such, the use of a 
heterologous producer that is the closely related to the native host should more likely lead 
to successful expression than a phylogenetically distant counterpart (98). However, 
because the native hosts are unknown for gene clusters isolated from eDNA, one viable 
strategy for the heterologous expression of these gene clusters should be to introduce 
 
 
Figure 14. Overview of heterologous expression strategies used in our study: 1) Use of 
various hosts; 2) Genetic engineering by a) overexpression and co-expression of positive 
acting transcriptional regulators; b) induced expression of all biosynthetic genes within 
the cluster (synthetic refactoring); c) synthetic refactoring and co-expression of deficient 
genes. 
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them into multiple heterologous hosts, thereby increasing the chance of small molecule 
production in at least one host (Figure 14; #1). 
  Based on previous metagenomic studies, the majority of soil samples are mostly 
populated by bacteria from the phylum Proteobacteria (108). This has thereby motivated 
previous studies in our laboratory to design a broad-host range vector pJWC1 (109), 
which was then used to construct multiple soil eDNA libraries in six different 
Proteobacteria (Agrobacterium tumefaciens, Burkholderia graminis, Caulobacter 
vibroides, Escherichia coli, Pseudomonas putida, Ralstonia metallidurans) for the 
parallel phenotype-based screening of natural products (30). Various positive hits were 
recovered from different hosts, but this (30) and various other studies have found the 
Ralstonia (109) and Burkholderia (110) spp., in particular, to be prolific Proteobacteria 
hosts for small molecule production. Considering that much of the soil microbiota 
consists of Proteobacteria, we predicted that a large portion of eDNA may be recognized 
by one of the previously established Proteobacteria hosts (30). The eDNA-derived TD 
gene clusters were therefore introduced into different Proteobacteria hosts (E. coli, P. 
putida, R. metallidurans, B. graminis) by means of retrofitting the pathway-harboring 
cosmids with the previously constructed broad-host range vector pJWC1 (109), followed 
by introduction of each pathway-harboring clone via electroporation. However, none of 
the eDNA-derived TD clusters produced any metabolites when natively introduced into 
the four Proteobacteria hosts. 
 Aside from Proteobacteria, actinomycetes, or more specifically bacteria from the 
genus Streptomyces, have been explored as heterologous hosts for biosynthetic gene 
clusters (111, 112). This is because they are long known to be prolific producers of 
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natural products (82, 83) and are thereby ample in cellular machineries that facilitate the 
expression of biosynthetic gene clusters and the production of the encoding small 
molecules. Moreover, based on the annotation of the biosynthetic genes and the unrelated 
flanking genes that are captured in the TD pathway-harboring cosmids (Appendix 1; refer 
to NCBI database with the corresponding A/N for flanking genes), most of the eDNA 
inserts harboring the TD gene clusters resemble Streptomyces spp. and other related 
actinomycetes bacterial species as their phylogenetic origin. Furthermore, a significant 
number of known TD compounds (i.e. rebeccamycin, staurosporine) have been produced 
in Streptomyces spp. as heterologous hosts (56, 57, 113, 114). Streptomyces spp. should 
thereby be suitable candidates as heterologous hosts for the eDNA-derived TD gene 
clusters. 
 To introduce the TD gene clusters into various Streptomyces spp. (S. albus, S. 
lividans, S. coelicolor, S. venezuelae, S. griseus), the TD pathway-harboring cosmids 
were retrofitted with the E. coli/Streptomyces shuttle vector pOJ436 (115) and 
subsequently integrated into the host chromosome by bacterial conjugation. The 
transformation of S. albus with the rebeccamycin-like pathway AR1455 resulted in the 
production of the expected compound, rebeccamycin, suggesting S. albus to be an 
appropriate heterologous host for TD gene clusters. In addition, in S. albus, robust 
production of clone-specific metabolites were observed for pathway AB1650, while 
limited small molecule production was detected for pathway AB1091, both of which are 
classified in Group E based on CPA synthase gene phylogeny (Figure 12). 
In the case of AB1091, the level of small molecule production was insufficient for 
structural elucidation. For previous heterologous expression studies, it has been possible 
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to increase metabolite production from biosynthetic gene clusters by overexpressing 
positive acting transcriptional regulators found within gene clusters of interest (116, 117). 
A putative transcription factor from the AB1091 cluster, as predicted based on BLAST 
annotation, was therefore cloned into a Streptomyces expression vector (pIJ10257) (118) 
under the control of the strong constitutive ermE* promoter and co-transformed into S. 
albus with the cosmid AB1091 (Figure 14; #2a). The constitutive expression of the 
putative pathway-specific positive regulator using an artificial promoter resulted in 
increased production of clone-specific metabolites to a level that permitted their isolation 
and structural characterization. The functional characterization of the AB1650 and 
AB1091 gene clusters from Group E is described later in this chapter. 
The AB1091 pathway represents one of the many examples of gene clusters that, 
at their native and unmanipulated state, do not yield their encoding natural products at 
sufficient levels for functional characterization in laboratory fermentation conditions. The 
presence of such “cryptic” gene clusters, or putative biosynthetic gene clusters with little 
or no small molecule production at their native state, are not surprising, since the 
expression of secondary metabolite gene clusters tends to be only necessary under 
specific conditions (e.g. iron limiting environment for siderophores) and are therefore 
normally tightly controlled within the native host (33, 119, 120). 
The cryptic biosynthetic gene clusters are often repressed at the transcriptional 
level (121, 122), presumably because small molecule production level amplifies in each 
step of the process (i.e. transcription, translation, enzymatic catalysis) and therefore 
regulating the very first step provides the simplest and most responsive control. To 
overcome such transcriptional barrier, the silent gene clusters can be manipulated by 
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genetic engineering. One method, as described before for pathway AB1091, is to 
overexpress the putative transcriptional activator that is present in the gene cluster by 
cloning the activator gene under the control of an artificial promoter that the heterologous 
host can recognize (Figure 14; #2a). 
However, in some cases, the putative regulator may be inactive, irrelevant, or 
simply not present in the gene cluster. The alternative genetic engineering-based 
approach is to thereby redesign the entire gene cluster, such that all of the putative 
biosynthetic genes in the pathway are detached from their native regulatory elements and 
placed under the control of well-defined genetic parts (Figure 14; #2b). This 
methodology, originally coined by the synthetic biology community as “synthetic 
refactoring,” is increasingly being used in the natural products community for 
heterologous expression of biosynthetic pathways (98, 123, 124). We chose E. coli as the 
heterologous host for our synthetic refactoring pursuits because it is the most well-
established host for this type of studies (125, 126). Complete synthetic refactoring 
becomes increasingly more difficult and cumbersome for large gene clusters, so this 
method was successfully used for the functional characterization of relatively small (<10 
kb, ~5 genes) TD gene clusters, namely the AB339, AB234, AB1149, AR1973, AB1521, 
and NM1499 pathways from Group F and the NM343 pathway from Group B (Figure 12). 
For the NM343 pathway, an additional process was employed for its heterologous 
expression, where a biosynthetic gene that was predicted to be deficient was co-expressed 
with the synthetically refactored NM343 cluster (Figure 14; #2c). Details regarding the 
characterization of the Group F and B gene clusters are described later in this chapter. 
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3.2 Group E TD class: indolotryptoline – BE-54017 
Group E classification of the CPA synthase gene phylogeny contains gene 
clusters AB1650 (127) and AB1091 (128). The first gene cluster that we investigated, 
AB1650 (abe), consisted of a complete set of conserved indolocarbazole biosynthetic 
genes (abeO, D, C, P), as well as two monooxygenases (abeX1, X2), three 
methyltransferases (abeM1, M2, M3), and a halogenase (abeH) (Figure 15). The presence 
of the two predicted monooxygenases was unprecedented in known TD biosynthetic 
pathways, suggesting that the AB1650 gene cluster likely encodes the biosynthesis of a 
novel TD substructure. 
For heterologous expression, the native AB1650 pathway was introduced into S. 
albus by bacterial conjugation. Cultures of S. albus transformed with AB1650 produced 
one major clone-specific metabolite 1, as well as four minor clone-specific metabolites 3-
6 (Figure 16). The compounds were extracted from the aqueous bacterial culture broth by 
partitioning using an organic solvent (ethyl acetate), fractionated using normal phase 
flash chromatography, and purified using reverse phase HPLC.  
The chemical structures of the purified compounds 1 and 3-6 were determined 
using a combination of HR-ESI-MS and 1-D and 2-D NMR data (Figure 17, Appendix 2, 
3). HR-ESI-MS predicts the molecular formula of compound 1 to be C23H18N3O5Cl. The 
strong M+2 peak observed in the spectrum confirms the presence of a chlorine atom in 
the molecule. Based on the integration and chemical shifts of 1H 1-D NMR, compound 1 
consists of 7 aromatic protons (δ7.16, 7.26, 7.27, 7.52, 7.73, 8.09, 8.23), 2 hydroxyl 
protons (6.40, 6.67), and 3 sets of methyl protons (2.97, 4.09, 4.18). 13C and HMQC 
NMR spectra further indicate the presence of 3 methyl carbons (δ25.3, 34.1, 62.8), 2 
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oxygen-substituted tertiary carbons (δ75.6, 87.7), 7 disubstituted olefinic carbons 
(δ112.4, 116.7, 118.9, 121.0, 121.3, 123.7, 125.0), 9 trisubstituted olefinic carbons 
(δ104.6, 127.0, 127.2, 137.8, 123.4, 138.1, 114.7, 132.9, 139.3), and 2 carbonyl carbons 
(δ171.7, 174.7). Analysis of COSY and HMBC spectral data from 1 establishes three 
substructures (Figure 18; A, B, C). 
Substructure A. The methyl protons (H3-14, δ2.97) show HMBC correlations to 
the two carbonyl carbons (C-5, δ174.7; C-7, δ171.7). On the basis of empirical chemical 
 
Figure 15. Gene annotation of AB1650 (abe) and AB1091 (bor) gene clusters from 
Group E.  
 
Figure 16. Analytical HPLC-UV chromatograms of culture broth extracts of S. albus 
harboring an empty vector as a negative control (green) and the AB1650 (abe) pathway. 
Compounds 1-6 represent the metabolites that are produced by the abe gene cluster. 
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shift arguments (129), these two groups are separated by a nitrogen to form the N-methyl 
imido group. These protons also exhibit HMBC correlations to the two oxygen-
substituted tertiary carbons (C-4c, δ75.6; C-7a, δ87.7). The two hydroxyl protons (δ6.40, 
6.67) similarly show HMBC correlations to the two carbonyl carbons and the two 
oxygen-substituted tertiary carbons, thereby establishing the dihydroxysuccinimide 
substructure (substructure A; Figure 18).  
Substructure B. 1H-1H COSY experiments define a two-carbon aromatic spin 
system (H-1/H-2) that can be placed adjacent to the trisubstituted olefinic carbons C-3 
and C-13a by HMBC correlations from H-1 and H-2 to C-3 and C-13a. The absence of 
 
Figure 17. The eDNA-derived abe gene cluster encodes the biosynthesis of BE-54017 
(1), as well as novel derivatives 3-6 as minor metabolites. BE-54017 (1) and 
cladoniamide (2) share an indolotryptoline core. Here we show that indolotryptolines 
arise from indolocarbazole precursors.  
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proton and carbon signals associated with C-3 aside from this four-carbon substructure 
defines the remaining C-3 substitution to be chloride. An HMBC correlation from H-4 to 
C-2 and C3 extends it into a five-carbon substructure. An additional HMBC correlations 
shown in Figure 18, in particular HMBC correlations from H-1 and H-4 to C-4a, establish 
the six-membered aromatic ring. The substructure is further expanded by an HMBC 
correlation from the methyl protons (δ4.18) to C-13a, elucidating the methylation of the 
indolic nitrogen (substructure B; Figure 18). 
Substructure C. 1H-1H COSY establishes a four-carbon spin system (H-8, H-9, 
H-10, H-11), which is extended into a six-carbon aromatic ring by HMBC correlations 
from H-8 and H-11 to C-7c and C-11a. HMBC correlations from the methyl protons 
(δ4.18) to C-11a and C-12 and from H-11 to C-12 place the methoxylated C-12 adjacent 
to C-11a (substructure C; Figure 18). 
 
Figure 18. Key 2-D NMR (HMBC and COSY) correlations observed in the structural 
elucidation of 1-4.  
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HMBC correlations from the methyl H3-16 to C-12b and from H-4 to C-4b 
extends substructure B to an indole and connects to substructure A by an HMBC 
correlation from OH-4c to C-4b. This leaves one carbon and one nitrogen atom to bridge 
substructure A+B to C, based on the molecular formula. The C-7a and C-7c carbons have 
higher chemical shifts than their symmetric counterparts C-4c and C-4a, indicative that 
they are surrounded by a nitrogen heteroatom (129). The placement of the nitrogen atom 
at N-7b adjacent to C-7a and C-7c and the placement of the remaining carbon at C-12a 
complete the structure determination of 1 to be the antitumor substance BE-54017. 
Although HMBC correlation signals were not observed for C-12a in compound 1, we 
have later isolated compound 2, a desmethyl derivative of 1, which show HMBC 
correlations from NH-13 to C-13a, C-4a, C-4b, C-12b, and C-12a, validating the 
placement of the C-12a in 1. Furthermore, the NMR, UV, and HR-ESI-MS data for 1 
were identical to previously reported data for BE-54017 (130), confirming the chemical 
structure. 
Minor metabolites 3 and 4 each differ from 1 by the loss of 28 mass units, 
corresponding to “CO.” The NMR spectra for 3 and 4 are identical to 1 except for signals 
corresponding to substructure A. 1H NMR spectra of 3 and 4 each displays a loss of one 
hydroxyl proton and a gain of one amido proton. A new COSY spin system is present 
between the amido proton and H3-14 that now shows HMBC correlation to only one of 
the two carbonyl carbons (Figure 18). HMBC correlations from the C-4c hydroxyl proton 
to C-7a, C-5, C-4c, and C-4b in compound 3 and from the C-7a hydroxyl proton to C-7, 
C-7a, and C-4c in compound 4 allowed us the define the position of the N-methylamide 
in substructure A and elucidate their chemical structures (Figure 17). On the basis of 
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comparisons of HR-ESI-MS and 2-D NMR data, compounds 5 and 6 were determined to 
be the deschloro analogues of compounds 1 and 4, respectively. Compounds 3-6 are 
novel natural products. 
BE-54017 (1) and a related compound cladoniamide A (2) share a unique 
pentacyclic core structure consisting of an indole fused to a tryptoline moiety (Figure 17). 
In accordance to the nomenclature of the related indolocarbazole TD substructure, we 
named this pentacyclic core as the indolotryptoline TD substructure.  Previous studies on 
TD biosynthesis have suggested that the indolotryptoline core might arise either from the 
oxidation of an indolocarbazole precursor or from an indolocarbazole-independent 
pathway (45, 131). To elucidate the origin of the indolotryptoline substructure and assign 
specific functions to the individual genes found in the abe gene cluster, we carried out a 
transposon mutagenesis study on cosmid AB1650. Individual transposon mutants were 
sequenced to identify clones with insertions in key biosynthetic genes (Figure 19). This 
collection of transposon mutants was then conjugated back into S. albus, and the major 
clone-specific metabolites found in the culture broth extracts of each mutant were 
structurally characterized.  
Consistent with what is known about the biosynthesis of indolocarbazoles (Figure 
8), transposon insertions in predicted indolocarbazoles biosynthetic genes resulted in 
either the absence of organic-extractable clone-specific metabolites (abeO, D) or the 
production of the known indolocarbazole intermediate 3-chloro-chromopyrrolic acid 
(abeC, P) (Figure 19). Homologues of the two predicted oxidoreductases, abeX1 and 
abeX2, do not appear in any known TD biosynthetic gene clusters. Disruption of abeX2 
results in the accumulation of compound 8, and disruption of abeX1 leads to the 
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accumulation of the simple indolocarbazole 3-chloroarcyriaflavin (7) as determined 
based on comparison with previously published spectral data (114). The isolation of 
compound 7 confirmed the indolocarbazole origin of BE-54017. 
Based on HR-ESI-MS data, the molecular formula for compound 8 differs from 
compound 5 by “CH2O”. A comparison of the 1H NMR spectra of 5 and 8 showed that 8 
does not contain the C-12 methoxy protons and that it has a new NH hydrogen. Most of 
the HMBC correlations seen in 8 also appeared in 5, but new HMBC correlations from 
the C-7a OH to C-7b and from the NH to C-7b, C-12a, and C-11a indicated that the 
indole in 8 has not been flipped. 
 
Figure 19. Major metabolites produced by select transposon mutants. Sites on BE-
54017 where key biosynthetic enzymes are predicted to act are indicated in the inset.  
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Compound 8 contains the C-4c/C-7a diol seen in BE-54017, but has not 
undergone a rearrangement of the indolocarbazole core, while compound 7 contains 
neither the diol nor the flipped indole. AbeX1 and AbeX2 show homology to class-A 
flavoprotein monooxygenases, and therefore the oxidation reactions they carry out are 
predicted to proceed through epoxides (Figure 20) (132). The mutagenesis results 
coupled with homology arguments allowed us to construct a biosynthetic scheme for the 
formation of the indolotryptoline core in BE-54017 from indolocarbazole 7 (Figure 20). 
Consistent with the biogenesis as previously proposed (131), the diol is introduced by 
AbeX1 through the epoxidation of the C-4c/C-7a double bond. AbeX2 is then responsible 
for promoting the rearrangement of the indole via the introduction of a second epoxide at 
C-7b/C-12a. The opening of this epoxide is accompanied by fragmentation of the C-
7a/C-7b bond followed by rotation of the indole around C-12a/C-12b and finally the 
formation of the C-7a/N-7b bond. 
Whether the proposed epoxide hydrolysis and indole rearrangement reactions 
occur spontaneously, are catalyzed by the monooxygenases themselves, or are catalyzed 
by other enzymes is not clear. While AbeY shares the same α/β-hydrolase fold 
superfamily as most epoxide hydrolases (133), our studies suggest that it is dispensable in 
the biosynthesis of compounds 1 and 3-6, as all five compounds are produced by the 
abeY knockout mutant. The appearance of small quantities of low-molecular-weight 
clone-specific metabolites in extracts from cultures of the abeY mutant suggests that 
while AbeY is not required, it may be involved in enhancing the efficiency of one or 
more biosynthetic transformations, similar to the reported function of the FAD-binding 
monooxygenase, RebC/StaC, in rebeccamycin/staurosporine biosynthesis (134). 
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Alternatively, the role of AbeY may be complemented by the host’s endogenous 
biosynthetic machinery. 
A detailed accounting of the functionality that appears on the compounds 
produced in our transposon mutagenesis experiments allowed us to assign functions to 
the three methyltransferases and the predicted halogenase found in the abe gene cluster 
(Figure 19). Disruption of abeH, a homologue of the tryptophan halogenase found in the 
rebeccamycin pathway, led to the accumulation of deschloro derivative 5, thereby 
confirming its role as a halogenase. The absence of the chloride substituent on compound 
8 suggested that the transposon insertion in abeX2 disrupts the expression of downstream 
genes in the same operon. The gene abeM3 is positioned between abeX2 and abeH and is 
 
Figure 20. Two monooxygenases, AbeX1 and AbeX2, are responsible for the 
conversion of an indolocarbazole precursor into the indolotryptoline core of BE-54017. 
BE-54017 requires three methylations; the exact timing of these transformations is not 
known.   
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therefore predicted to be transcriptionally silenced in this transposon mutant. Since both 
the N-6 and N-13 methylations appear on 8, abeM3 is predicted to be responsible for the 
methylation of the C-12 hydroxyl in BE-54017. The regiospecificity of the two remaining 
N-methyltransferases, abeM1 and abeM2, was inferred from the accumulation of the O-
12,N-6 dimethylated derivative 2 (cladoniamide A) in the abeM2 transposon mutant. 
AbeM1, AbeM2, and AbeM3 are therefore N-6, N-13, and O-12 specific 
methyltransferases, respectively (Figure 19 inset). No gene in the abe cluster could be 
linked to the hydrolysis of the N-methylsuccinimide, suggesting that this reaction is either 
carried out by the host or occurs spontaneously during the fermentation process. 
Compounds 1-8 were assayed for antiproliferative activity against human colon 
cancer HCT116 cells. While 3-8 were not active below 8 µg/mL, 1 and 2 exhibited potent 
antiproliferative activities [IC50 (µg/mL): 0.079 for 1, 0.0088 for 2] (Table 1). 
Crystallographic studies have shown that the planar structure of indolocarbazoles is 
important for topoisomerase/DNA (rebeccamycin) and kinase (staurosporine) binding 
(48, 49). The C-4c/C-7a diol seen in indolotryptolines causes the N-methylsuccinimide to 
bend out of the bisindole plane, which may afford these compounds the ability to bind 
different cellular targets for their antitumor activity. Considerable progress in generating 
novel indolocarbazole analogues by combinatorial synthesis has been made, and the 
identification of AbeX1 and AbeX2 provides new tools for producing structurally and 
functionally diverse bisindole metabolites (114, 135). 
In summary, our metagenomic natural product discovery pipeline has allowed us 
to clone and characterize the first indolotryptoline biosynthetic gene cluster and 
establishes indolotryptoline as an interesting lead structure for its antiproliferative 
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activity. After the publication of this finding (127), the biosynthetic gene cluster of 
cladoniamides was discovered and reported by a different laboratory (136). 
3.3 Group E TD class: indolotryptoline – borregomycins 
The second gene cluster in Group E from cosmid AB1091 (bor) (128) resembles, 
but is noticeably distinct from, the BE-54017 (abe) gene cluster (Figure 15). As seen in 
the abe cluster, the bor cluster contains a complete set of conserved indolocarbazole 
biosynthetic genes (borO, D, C, and P), a single halogenase (borH), and homologs of the 
two oxidoreductase genes (borX1, borX2) that are known to encode the transformation of 
indolocarbazole precursors into indolotryptolines. Additionally, the bor cluster uniquely 
contains a third oxidoreductase gene (borX3) that is not seen in the abe cluster. Similar to 
the abe cluster, three methyltransferase genes (borM1, M2, and M3) are present in the bor 
cluster; however, borM2 and borM3 do not show significant sequence identity to any of 
the abe methyltransferases. The bor cluster was thus likely to encode for a new 
indolotryptoline-based metabolite. 
In an effort to access the metabolite(s) encoded by the bor gene cluster, the eDNA 
clone AB1091 was conjugated into S. albus. However, most clone-specific metabolites 
were produced by S. albus at such low levels that it was not possible to isolate sufficient 
quantities for structural elucidation. Therefore, as previously mentioned, a putative 
positive acting transcription factor from the bor cluster, borR, was cloned into a 
Table 1. IC50 data summary of BE-54017 compounds from the abe gene cluster (against 
human colon cancer HCT116 cells) 
Compound 1 2 3 4 5 6 7 8 
IC50 
(µg/mL) 
0.079 0.0088 20 21 8.7 29 13 11 
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Figure 21. Analytical HPLC-UV chromatograms of culture broth extracts of S. albus 
harboring an empty vector as negative control (green), the bor pathway alone (blue), or 
S. albus harboring the bor pathway as well as the borR overexpression construct (red). 
Compounds 9-13 represent all of the detected metabolites that are specific to the bor 
cluster. The shunt product 13 accumulates with the bor cluster alone, while the final 
products 1 and 2, accumulate at higher levels with borR overexpression. Peaks marked 
with an asterisk (*) are present in negative control and are thus not clone-specific. Peaks 
marked “A” are not present in negative control, but these low molecular weight 
compounds (179 and 195 mass units) are also seen in extracts from S. albus cultures 
harboring other indolotryptoline gene clusters and are therefore likely common shut 
products of indolotryptoline biosynthesis. 
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Streptomyces expression vector (pIJ10257) under the control of the strong constitutive 
ermE* promoter and co-transformed into S. albus along with the cosmid AB1091. 
Constitutive expression of borR in the S. albus background containing AB1091 resulted 
in increased production of clone-specific metabolites to a level that permitted their 
isolation and structural characterization (Figure 21).  
In the presence of the borR overexpression construct, the bor gene cluster encodes 
for the production of five detectable clone-specific metabolites in S. albus (9-13) (Figure 
22). The methodology for the structural elucidation of 9-13 was similar to that for 
compounds 1-8 with the combination of HR-ESI-MS and 1-D and 2-D NMR data (Figure 
23, Appendix 2, 3). HR-ESI-MS predicts molecular formulas of C23H17N3O4Cl2, 
C22H15N3O4Cl2, C21H13N3O4Cl2 for 10, 11, and 12, respectively. The strong M+2 and M+4 
peaks observed in these MS spectra confirm the presence of two chlorines in each 
molecule. The molecular formula differences of “CH2” and the similarity in their UV 
spectra suggest that the structures of 10-12 differ by their methylation patterns. This is 
confirmed by the differences in the number of methyl protons and methyl carbons in the 
1-D 1H and 13C NMR spectra. 
The numbers of unique chemical shifts seen in the 1H and 13C NMR spectra and 
the 1H signal integration ratios indicate that 12 is symmetric with one set of methyl 
protons along the plane of symmetry (3H, δ2.98, s). Each half of 12 contains one 
hydroxyl proton (2H, δ5.58, brs), three aromatic protons (2H, δ7.14, dd; 2H, δ7.49, d; 
2H, δ8.14, d) and one indolic amino proton (2H, δ10.76, brs). 13C and HMQC NMR 
spectra indicate that 12 has one methyl carbon along the plane of symmetry (δ25.4). Each 
half of 12 contains one carbonyl carbon (δ175.9), one oxygen substituted tertiary carbon   
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(δ77.2), five tri-substituted olefinic carbons (δ110.1, 126.9, 128.4, 128.6, 138.7) and 
three di-substituted olefinic carbons (δ112.3, 121.8, 123.7). Analysis of COSY and 
HMBC spectral data from 12 establishes two substructures (A and B; Figure 23).  
Substructure A. The methyl protons (H-14, δ2.98) on the plane of symmetry 
show an HMBC correlation to the carbonyl carbons (C-5/C-7, δ175.9). Based on 
symmetry and empirical chemical shift arguments, these two groups are separated by a 
nitrogen atom to form the N-methyl imido group. An HMBC correlation from the 
hydroxyl protons (δ5.58) to the oxygen substituted tertiary carbon (C-4c/C-7a, δ77.2) 
and the carbonyl (C-5/C-7, δ175.9) establishes the dihydroxysuccinimide substructure 
(Substructure A; Figure 23). 
Substructure B. 1H-1H COSY experiments define a two-carbon spin system (H-
8/H-9) that can be placed adjacent to C-7c and C-10 by HMBC correlations from H-8 and 
H-9 to C-7c and C-10. An HMBC correlation from H-11 to C-9 and C-10 extends this 
 
Figure 22. Borregomycins produced by the bor gene cluster. Indolotryptoline-based 
borregomycin A (9), dihydroxyindolocarbazole-based borregomycins B-D (10-12), 
dichlorochromopyrrolic acid (13), and O-methyl-borregomycin A (14) were isolated 
from S. albus harboring the eDNA-derived bor gene cluster. 
 
 51 
four-carbon substructure into a five-carbon substructure. Additional HMBC correlations, 
in particular HMBC correlations from H-11 and H-8 to C-11a, establish the six 
membered aromatic ring. HMBC correlations from the indolic amino proton to the C-7c 
and C-11a in the aromatic ring along with the remaining two tri-substituted carbons, C-7b 
and C-12a, form the indole substructure observed on each side of the plane of symmetry 
(Substructure B; Figure 23). Substructures A and B are connected across the plane of 
symmetry by HMBC correlations from OH-4c/OH-7a and H-4/H-8 to C-4b/C-7b. The 
placement of the chlorides at C-2/C-10 completes the structure determination of 12.	   
 
Figure 23. Key HMBC correlations observed in the structural elucidation of 
borregomycins. 
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Similar NMR arguments to those used to establish the structure of 12 were used to 
define the di- and tri- methylated dihydroxyindolocarbazole structure 10 and 11, which 
are additionally methylated on either the C-4c or the C-4c and C-7a hydroxyl groups, 
respectively. In each case, the position of the new methyl group was elucidated by the 
replacement of the hydroxyl proton signal with a new methyl proton signal that shows an 
HMBC correlation to either the C-4c or C-7a oxygen substituted tertiary carbon. 
Based on HR-ESI-MS, the molecular formulas of compound 9 is C23H17N3O6Cl2. 
The spectral data for 9 closely resembles that of the trimethylated 10, but differs by the 
appearance of a carbonyl carbon (δ194.4) and an oxygen substituted tertiary carbon 
(δ85.7) in place of two olefins, as well as the appearance of a hydroxyl proton (1H, δ7.72, 
brs) in place of one of the indolic amino proton. Similar arguments to those used in the 
structure determination of 12 allow for the construction of the trimethylated 
dihydroxysuccinimide substructure (Substructure C; Figure 23). However, unlike the 
trimethylated 10, one of the H-11 aromatic protons in 9 show an HMBC correlation to the 
new carbonyl carbon (C-11b) instead of a tri-substituted olefin, indicating that C-11a is 
substituted with C-11b to form Substructure D (Figure 23). HMBC correlations from 
the new hydroxyl proton (C12a-OH) to the new oxygen substituted tertiary carbon (C-
12a), the carbonyl carbon (C-11b) from Substructure D and C-12b from Substructure 
C connect these two fragments as shown in Figure 23. The final structure of 9 is 
completed by placing the remaining nitrogen (N-7b) required by the molecular formula 
into the structure to form an indolotryptoline. The placement of the nitrogen satisfies the 
remaining unsaturations required by the unsaturation index, and it is supported by the 
downfield shift of the three carbon atoms neighboring the nitrogen in the final structure 
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(Figure 23). The disappearance of one indolic amino proton is consistent with the flipping 
of the indole moiety seen in the final structure.  
 Compounds 9-12 have been named borregomycin A-D after the geographic origin 
of the soil from which the bor cluster was cloned (Anza Borrego desert; AB library). Two 
unnamed compounds, 13 and 14, were also isolated in this study (Figure 22). The 
structure of compound 13 (C22H13N3O4Cl2) was solved by comparison of its spectral data 
with the previously published spectral data (137) for chlorinated chromopyrrolic acid and 
confirmed by inspection of the HMBC and COSY NMR data (Figure 23). As for 
compound 14 (C24H19N3O6Cl2), the NMR spectral data for 14 only differ from that for 9 
by the appearance of an additional methoxy group (δ3.01). Based on an HMBC 
correlation from these additional methyl protons to C-12a, 14 was determined to be the 
C-12a methoxy analog of 9 (Figure 22). This compound is not seen in the crude extract 
(Figure 21) and is therefore assumed to be an artifact that arises from methanolysis of 
borregomycin A during the isolation protocol.  
 On the basis of their final structures, sequence homology arguments, and precedents 
from previous studies of TD biosynthesis, the biosynthesis of borregomycins A-D can be 
rationalized as outlined in Figure 24. Similar to the biosynthesis of rebeccamycin and 
BE-54017, the biosynthesis of the borregomycins is likely initiated by the chlorination of 
L-tryptophan by the halogenase BorH, followed by the construction of an 
indolocarbazole using the set of conserved indolocarbazole biosynthetic enzymes BorO, 
D, P and C. The resulting 2,10-halogenation pattern is not seen in any previously reported 
indolotryptoline or indolocarbazole based metabolite. This is consistent with the fact that 
BorH is more closely related to known tryptophan 6-halogenases than halogenases found 
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in other TD gene clusters. On the basis of sequence homology to enzymes from BE-
54017 biosynthesis, oxidoreductase BorX1 is predicted to install the C-4c/C-7a hydroxyl 
groups and putative N-methyltransferase BorM1 is predicted to methylate N-6 to generate 
borregomycin C (12). One of the two remaining methyltransferases unique to the bor 
cluster, collectively referred to as BorM2/BorM3, is then predicted to O-methylate 12 on 
either the C-4c or C-7a hydroxyl to yield dimethylated 11. The regiospecificity of this O-
methylation reaction is not known. 
 
Figure 24. Proposed scheme for the biosynthesis of the borregomycins. The 
borregomycins are predicted to arise form a branched biosynthetic pathway with one 
branch of the pathway giving rise to the indolotryptoline-based metabolite (9) and a 
second branch giving rise to dihydroxyindolocarbazole-based metabolites (10-12). 
Compound 13 is a known shunt product in tryptophan dimer biosynthesis. 
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 The concurrent production of both borregomycin A (9) and borregomycin B (10) 
from 11 can be rationalized by the existence of a branch in the biosynthetic scheme 
where 11 either initially undergoes oxidation by BorX2 or further methylation by 
BorM2/M3. Should BorM2/M3 act directly on 11 to generate the trimethylated 
borregomycin B (10), transformation of the indolocarbazole into an indolotryptoline by 
BorX2 is inhibited as a result of both the C-4c and C-7a hydroxyls being blocked with 
methyls, rendering 10 as the terminal product of one branch of the bor pathway. If 
however the C-7a hydroxyl of 11 is available for deprotonation, BorX2 can promote the 
rearrangement of the indole via epoxide-driven fragmentation of the C-7a/C-7b bond 
followed by rotation of the indole around the C-12a/C-12b axis and formation of the C-
7a/N-7b bond. The resulting indolotryptoline intermediate is then predicted to undergo 
methylation on the C-7a hydroxyl (BorM2/M3), followed by oxidation across the C-
12/C-12a bond to yield borregomycin A (9).  
 Branched biosynthetic pathways are quite common in natural product biosynthesis. 
In most cases, however, they either generate collections of compounds from the same 
structural family or relatives of a single major product that are labeled as intermediates, 
degradation products or shunt products (138, 139). In rarer cases, for example in 
methymycin/pikromycin biosynthesis in Streptomyces venezuelae (140) and 
saliniketal/rifamycin biosynthesis in Salinispora arenicola (141), pathways have been 
found to produce terminal biologically active metabolites that are representative of 
different structural classes. 
 Borregomycins were assayed for cytotoxicity against a panel of model organisms 
(Table 2). Both borregomycin A (9) and borregomycin B (10) exhibit low micromolar 
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antiproliferative activities against human colon cancer HCT116 cells, comparable to the 
activity reported for the extensively studied indolocarbazole rebeccamycin (IC50: 0.72 
μM) (142). Borregomycin B (10) is also a Gram-positive antibiotic, however, at the 
highest concentration tested, borregomycin A (9) did not inhibit the growth of any of the 
bacteria we tested (Table 2). The bor pathway therefore not only encodes for metabolites 
from distinct structural families, but also metabolites with distinct bioactivities. 
 Close structural relatives of indolotryptolines, including tryptoline-based (143), 
indolo-β-carboline (fascaplysin)-based (144) and indolocarbazole-based (47) compounds 
have all been explored as protein kinase inhibitors. The final products of the two bor 
biosynthetic pathway branches, borregomycin A (9) and B (10), were therefore tested for 
inhibitory activity against a panel of 59 diverse disease-relevant kinases (KinaseProfiler, 
Millipore). Borregomycin B did not exhibit an IC50 of less than 10 μM against any 
kinases in the panel. At 10 μM, the most inhibited kinases PRAK, IGF-1R, and PI3KCδ 
showed residual activities of 66%, 67%, and 69%, respectively (Appendix 4). At the 
same concentration, borregomycin A exhibited a sub-10 μM IC50 against a single kinase, 
CaMKI (Figure 25). When borregomycin A was assayed against a more extensive panel 
of CaMKI-related kinases, it most strongly inhibited the CaMKIIδ kinase (IC50: 3.4 μM; 
Table 2. Cytotoxicity data summary of the borregomycins. 
Organism 9 (A) 10 (B) 11 (C) 12 (D) 13 14 
Human HCT116 IC50, µM 1.2 1.4 1.9 3.9 48 1.1 
S. aureus USA300 MIC, µg/mL >25 0.20 0.39 3.1 >25 >25 
B. subtillis Sr168 MIC, µg/mL >25 0.20 1.6 3.1 >25 >25 
E. coli EC100 MIC, µg/mL >25 >25 >25 >25 >25 >25 
S. cerevisae W303 MIC, µg/mL >25 >25 >25 >25 >25 >25 
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Appendix 4). Elevated levels of CaMKII, which is a Ca2+/calmodulin-dependent 
serine/threonine kinase that is involved in various signal transduction pathways, have 
been implicated in diseases such as heart failure (145) and cancer (146). As 
borregomycin A is active at comparably low micromolar levels against both HCT116 
cells and CaMKIIδ in vitro, the inhibition of CaMKIIδ may be a key contributing factor 
to its in vitro cytotoxicity. 
 Fascaplysin, a simple indolo-β-carboline, inhibits Cdk4-D1 kinase, however its 
planar structure also renders it a DNA intercalator (147). This has inspired the synthesis 
of nonplanar fascaplysin analogs in an attempt to eliminate the DNA intercalating 
property, thereby reducing its toxicity to normal cells (148). Similarly, the planar 
borregomycin B appears to be a general cytotoxin, while borregomycin A, which is 
rendered nonplanar by BorX2 catalyzed indole rearrangement followed by oxidation, 
appears to show more specificity in both the cell-based cytotoxicity assay and the kinase 
activity assay. The observed kinase inhibitory activity of borregomycin A suggests that 
oxidized indolotryptolines may warrant further investigation as potential lead structures 
for the development of novel protein kinase inhibitors. 
 
Figure 25. KinaseProfiler results. Residual protein kinase activity in the presence of 10 
µM borregomycin A is shown for a diverse set of disease-relevant kinases (n = 2). 
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 Based on the presence of a novel oxidoreductase BorX3 in the bor gene cluster, we 
initially predicted the C-12/C-12a oxidation in borregomycin A to be catalyzed by BorX3 
(Figure 24). However, recent mutational studies with the cladoniamide gene cluster (cla) 
suggests that the C-12/C-12a oxidation arises spontaneously in the absence of a 
methyltransferase that caps the C-12 hydroxyl (OH-12) moiety (149). Since the bor 
pathway lacks the OH-12 O-methyltransferase, this suggests that the C-12/C-12a 
oxidation occurs spontaneously and is not dependent on the BorX3 oxidoreductase. 
 While the abe and cla pathways that lack the C-4c and C-7a hydroxyl (OH-4c and 
OH-7a) O-methyltransferases yield indolotryptoline-based compounds with the 
hydrolyzed N-methylsuccinimide ring (3, 4, 6), compounds detected from the bor 
pathway lacks these structures. It has been found that these hydrolyzed indolotryptoline 
structure are unstable and undergo further spontaneous hydrolytic/oxidative degradation 
(150). Therefore, while the bor pathways permits oxidation across C-12/C-12a in the 
absence of OH-12 O-methyltransferase, the methyl capping of the C-4c and C-7a 
hydroxyls by the OH-4c and OH-7a O-methyltransferases in the bor pathway not only 
introduces a branch point in the pathway to produce compounds 9 and 10, but also 
protects the structural integrity of the borregomycins from the hydrolysis of the N-
methylsuccinimide ring. 
 The characterization of the abe gene cluster from the previous study establishes 
indolotryptoline as an interesting lead structure for its antiproliferative activity. However, 
most bacterial TD natural products that have been characterized to date are members of 
the indolocarbazole family, and indolotryptoline-based TD compounds have seldom been 
seen (46). Here we show that homology-based screening, coupled with the phylogenetic 
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profiling of eDNA-derived gene clusters, allows for the directed discovery of 
borregomycins, novel members within previously rare families (indolotryptoline) of 
bioactive natural products.  
3.4 Group F TD class: carboxy-indolocarbazole 
Group F gene clusters (84) are comprised of single operons containing three 
conserved indolocarbazole biosynthesis genes (espO, D, P), a predicted methyltransferase 
(espM) and a FAD-binding monooxygenase (espX) (Figure 12, 26).  Although Group F 
gene clusters were recovered from all three metagenomic libraries (AB234, AB339, 
AB1149, AB1521, AR1973, TX1499) (Figure 12), no clusters with the same gene 
content were found in the NCBI database of sequenced bacterial genomes. The TD 
cluster from clone AB339, which we have called the esp cluster, was selected as a 
representative member of Group F for heterologous expression studies. 
Initial heterologous expression efforts, including the introduction of the esp 
cluster into model bacterial hosts and induced expression of the esp operon under a T7 
promoter in E. coli did not yield any detectable clone specific small molecules. 
Therefore, we chose to synthetically refactor the esp cluster by individually cloning each 
esp gene in front of a T7 promoter and inducing the expression of the esp genes in E. coli 
using the Novagen Duet vector system. 
As homologs of espO, D and P are seen in a number of well-studied TD 
indolocarbazole biosynthetic gene clusters, their functions are predictable (134, 151). Co-
expression of these three genes in E. coli resulted in the low level production of the 
expected indolocarbazole-based intermediates (18-20), indicating that esp is, in fact, a TD 
gene cluster (Figure 26A, espODP 24 hr). Addition of espM, a predicted 
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methyltransferase gene, to espODP led to the appearance of compound 2 (espODPM 12 
hr).  After extended incubation periods, either in culture broth or as a purified compound 
in DMSO, 16 spontaneously oxidized to 17 (espODPM 36 hr). Interestingly, when espX, 
a predicted FAD-binding monooxygenase gene, was co-expressed with espODPM, no 
clone specific metabolites were detected in the culture broth extract (espODPMX 24 hr), 
mimicking the result from the expression of the native esp operon in E. coli. 
 
Figure 26. A) HPLC-UV traces of organic extracts from E. coli cultures expressing 
various combinations of esp genes. “+ 16” refers to the addition of compound 16 in the 
form of spent medium from EspODPM cultures. B) Schematic of the method used for 
the complete refactoring of the esp cluster. 
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Suspecting that the product of the entire esp operon might be rapidly degraded, 
we investigated the EspX-catalyzed transformation reaction by feeding compound 16 in 
the form of spent culture broth from cultures of E. coli expressing espODPM to EspX-
expressing E. coli cultures (Figure 26B).  Within a narrow time window (<6-8 hr) we 
observed the accumulation of a new compound (15) in concert with the disappearance of 
16 (Figure 26A, EspX + 2, 6 hr).  After longer incubations, neither 15 nor 16 could be 
detected in the culture broth. Retrospectively, we re-examined the espODPMX 
monoculture at shorter time points and were able to detect very small qualities of 15 in 
these E. coli cultures (Figure 26A, EspODPMX 12hr). Ultimately, the temporal control 
over individual esp gene expression that was possible in our refactoring study permitted 
the isolation of a natural product that would otherwise have been too transiently present 
to identify. Compound 15 was purified from the culture broth of espX expressing cultures 
fed with spent “espODPM” culture broth, while compounds 16 and 17 were isolated from 
E. coli cultures expressing espODPM.  
The structures of compounds 15-17 were elucidated using a combination of HR-
ESI-MS and 1-D and 2-D NMR data. The NMR spectra of compound 17 were similar to 
those of the known indolocarbazole, K252c (staurosporine aglycone) (134) with two 
major differences.  First, the proton signal from H-7 of compound 17 integrates to 1H 
instead of 2H and is shifted farther downfield than the corresponding proton signal from 
K252c.  Second, 17 has an additional carbonyl carbon and a set of proton and carbon 
signals corresponding to a methyl group in its NMR spectra that are not seen in the 
spectra of K252c. Based on HR-ESI-MS, 17 has the molecular formula C22H15N3O3, 
which differs from the molecular formula of K252c by the loss of a proton and the gain 
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of a methylcarboxy (CH3CO2) unit, thereby suggesting that compound 17 is a modified 
version of K252c with a methylcarboxy unit substituted at C-7. Extensive 2-D NMR 
correlations as shown, especially HMBC correlations from H3-15 to C-14 and from H-7 
to C-14, confirm the chemical structure of 17 (Figure 27).  
Based on HR-ESI-MS, compound 16 has the molecular formula C22H15N3O2, 
which differs from the molecular formula of 17 by the loss of an oxygen atom. The NMR 
spectra of 16 closely resemble 17, but differ by (i) the replacement of the C-7 tertiary 
carbon (δ60.6) seen in 17 with an olefinic carbon (δ113.0) and (ii) the replacement of the 
C-5 carbonyl carbon (δ173.4) seen in 17 with an olefinic carbon (δ115.4). These 
differences are accompanied by the loss of the proton signal (δ5.94) seen at C-7 in 17 and 
the gain of a proton signal (δ8.27) at C-5. These changes indicate that the oxygen at C-5 
of 17 is replaced by a proton such that compound 16 is the deoxygenated form of 17.  
      
 
Figure 27. 2-D NMR correlations observed for the structural determination of 
erdasporine A-C (15-17). 
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This final structure is supported by the extensive 2-D NMR correlations as shown (Figure 
27). 
Compound 15 has a UV spectrum that closely resembles that of 16, but 15 has the 
molecular formula C22H15N3O3, which differs from that of 16 by the addition of an 
oxygen atom. The NMR spectra of 15 are similar to that of 16, but differ by the 
replacement of the H-2 aromatic proton seen in 16 (δ7.31) with a hydroxyl proton 
(δ9.22). The downfield shift of C-2 from δ123.7 in 16 to 154.2 and the HMBC 
correlations from OH-2 to C-1, C-2, and C-3 suggest that compound 15 is the C-2 
hydroxylated form of 16. This chemical structure is confirmed by the extensive 2-D 
NMR correlations as shown (Figure 27). 
Compounds 15-17 have novel methylcarboxylated indolocarbazole structures and 
were named erdasporine A-C, respectively (Figure 28). The erdasporines were found to 
be potent cytotoxins with low µM activity against bacteria and human cell lines (Figure 
28). 
Based on our heterologous expression studies and previous studies on 
indolocarbazole biosynthesis with well-characterized transient indolocarbazole 
intermediates (134, 151, 152), erdasporine biosynthesis is proposed to initially proceed 
like many other indolocarbazole pathways, with EspO, D, and P giving rise to dicarboxy-
indolocarbazole (21) from two tryptophans (Figure 29).  In the absence of additional 
enzymes, this intermediate is known to spontaneously decarboxylate and oxidize to form 
three indolocarbazole products (18-20). In many previously characterized 
indolocarbazole pathways, an FAD-binding monooxygenase (e.g. StaC/RebC) directs the 
formation of a single indolocarbazole product (monooxygenated 18 for Group C clusters 
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and dioxygenated 19 for Group D clusters). In the esp cluster, methylation by EspM 
appears to preclude these spontaneous oxidative decarboxylation events, resulting in the 
formation of 16 and, with time, 17.  In the presence of EspX, compound 16 undergoes 
oxidation to form 15 as the product of the esp cluster. 
 
Figure 28. Chemical structure and cytotoxicity data of erdasporine A-C (15-17) encoded 
by the esp gene cluster. The carboxy-indolocarbazole core that is representative of 
Group F is colored in red. Cytotoxicity (µM) against human HCT116 cells and 
Staphylococcus aureus is shown.  
 
 
Figure 29. Proposed biosynthetic scheme for the erdasporines. Key steps include 
methylation of the dicarboxy-indolocarbazole (21) by EspM to generate 16 and the 
hydroxylation of 16 by EspX to give 15. 
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The remaining eDNA-derived Group F clusters are predicted to contain the same 
five genes as the esp cluster. While EspODP homologs are functionally equivalent across 
all characterized TD clusters, the exact role of the EspM-like methyltransferases and the 
EspX-like monooxygenases in each Group F gene cluster was not certain. The remaining 
four complete Group F clusters were therefore characterized by expressing each unique 
EspM-like methyltransferase (AB234M, AB1149M, NM1499M, AB1521M) and unique 
EspX-like monooxygenase (AB234M, AB1149M, NM1499M, AB1521M) gene in the 
EspODP expression system that was used to characterize the original AB339 esp gene 
cluster.  In each case, the expression of the pathway-specific methyltransferase resulted in 
the accumulation of 16 and the subsequent expression of the monooxygenase led to the 
production of 15 (Figure 30).  Based on these studies, all Group F clusters were 
determined to be functionally equivalent to the esp cluster. 
The functional characterization of the esp cluster defines a new TD group (Figure 
12, Group F) that is based on a carboxy-indolocarbazole core substructure (Figure 28). 
 
Figure 30. HPLC-UV traces of organic extracts from E. coli cultures expressing the 
indicated EspM-like methyltransferase and EspX-like monooxygenase in the EspODP 
background.  “+ 16” refers to the addition of compound 16 in the form of spent medium 
from EspODP culture co-expressing each pathway-specific methyltransferase. 
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Bioinformatics analysis of the genes surrounding eDNA-derived Group F clusters 
suggests that they likely originate from diverse species within the phylum actinobacteria 
(Appendix 1; refer to NCBI database with the corresponding A/N for flanking genes). 
Although esp-like clusters were found in all three soil eDNA libraries examined, neither 
sequence nor functional analyses of cultured bacteria have identified this family of TDs, 
suggesting that these secondary metabolites are likely largely produced by as yet 
uncultured microbes.  
3.5 Group B TD class: bisindolylmaleimide 
Group B gene cluster from cosmid NM343 (mar) (153) is predicted to contain 
three or four biosynthetic genes: a CPA synthase (marB), a dioxygenase (marC), and a 
methyltransferase (marM) (Figure 12, 31). In addition, a vioE homolog gene (marE) is 
present immediately downstream of marC, which may also be involved in small molecule 
production. The dioxygenase MarC is unprecedented in known TD biosynthetic pathway 
and might direct the formation of a novel TD core structure.  
For initial heterologous expression efforts, the native mar cluster was introduced 
into a variety of model hosts for expression studies, but no clone-specific metabolites 
were detected in the culture broths.  In an effort to address potential transcriptional 
inefficiencies of mar gene cluster promoters in these hosts, we synthetically refactored 
the gene cluster by individually cloned the mar biosynthetic genes in front of T7 
promoters and introduced these constructs into E. coli. Unfortunately, this also failed to 
result in the production of any detectable clone-specific small molecules by E. coli 
cultures (Figure 32, MarBCEM). 
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Functionally characterized CPA synthases from other TD biosynthetic clusters 
have been found to accept oxidized tryptophan (IPA imine), but not tryptophan itself, as a 
substrate (154). Neither the mar cluster nor the E. coli genome contains an IPA imine 
synthase homolog.  Therefore, if MarB functions as a CPA synthase as predicted by its 
high sequence identity to known CPA synthases, an IPA imine synthase would have to be 
supplied in trans for mar biosynthesis to proceed in a heterologous expression setting.  A 
number of sequenced bacterial genomes contain isolated predicted IPA imine synthase 
 
Figure 31. eDNA-derived mar biosynthetic gene cluster that encodes for 
methylarcyriarubin. 
 
Figure 32. HPLC-UV traces of culture broth extracts from mar gene cluster expression 
studies in E. coli. IPA imine is reported to undergo spontaneous deamination to form 
IPA (23). The peak marked with an asterisk (*) is an uncharacterized by-product of the 
co-expression of an IPA imine synthase with a CPA synthase in E. coli. 
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genes, suggesting that IPA imine production may be encoded outside secondary 
metabolism in a variety of bacteria.  Therefore, we co- expressed the IPA imine synthase 
vioA from the violacein cluster (155) with the rest of the mar biosynthetic genes in E. 
coli.  This resulted in the production of a clone-specific metabolite (21) (Figure 32, VioA 
+ MarBCEM), which we had not observed in any previous TD studies, along with the 
expected TD intermediates, IPA (23) and CPA (24) (152, 154).  
Compound 21 was purified from large-scale cultures of E. coli transformed with 
the VioA + MarBCEM expression constructs.  The UV, HR-ESI-MS, and NMR (Figure 
33) data of 21 was consistent (156, 157) with the structure of the methylated 
bisindolylmaleimide methylarcyriarubin (21).  Although methylarcyriarubin has been 
made synthetically, to the best of our knowledge, this is the first reported case of 
methylarcyriarubin being isolated as a natural product. 
To elucidate the role of the individual mar biosynthetic genes in the biogenesis of 
methylarcyriarubin (21), culture broth extracts from E. coli strains expressing different 
combinations of the mar biosynthetic genes were characterized in detail. In E. coli 
lacking marM (Figure 32, VioA+MarBCE), arcyriarubin A (22), the desmethyl form of 
methylarcyriarubin (21), was produced along with 23 and 24.  Without the dioxygenase 
marC (Figure 32, VioA+MarBEM; VioA+MarB), accumulation of 23 and 24 was 
 
Figure 33. Numbering scheme and correlations observed in the HMBC and 1H-1H 
COSY NMR spectra of 21. 
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observed.  Replacement of MarB with the characterized CPA synthase from the violacein 
pathway (VioB) resulted in an identical metabolic profile (Figure 32, VioA+MarB; 
VioAB).  No difference in metabolic profile was observed between E. coli expressing all 
 
Figure 34. Biosynthesis of methylarcyriarubin alongside with that of other known 
bacterial tryptophan dimers, namely violacein and indolocarbazoles. VioA-like IPA 
imine synthase (*) is predicted to be encoded in the endogenous host’s genome. 
 70 
the mar biosynthetic genes (Figure 32, VioA+MarBCEM) and a strain lacking the 
predicted vioE homolog, marE (Figure 32, VioA+MarBCM). Based on these expression 
studies, the biosynthesis of methylarcyriarubin is predicted to share the same two initial 
biosynthetic transformations as all other biosynthetically characterized bacterial 
tryptophan dimers (Figure 34).  Specifically, tryptophan is first oxidized to IPA imine by 
an IPA imine synthase that is found outside the mar cluster in the endogenous host’s 
genome.  MarB then dimerizes IPA imine to give CPA.  The mar biosynthetic pathway is 
then predicted to diverge from known tryptophan dimer pathway in that MarC appears to 
function as a bisindolylmaleimide synthase by converting CPA into arcyriarubin A.  
MarM is predicted to methylate the bisindolylmaleimide to yield methylarcyriarubin (21). 
MarC is functionally similar to RebC from rebeccamycin biosynthesis in that they 
both produce a maleimide moiety from CPA.  RebC is an FAD-binding monooxygenase 
that reacts in tandem with RebP to produce maleimide indolocarbazole (96, 151, 158). 
Based on co-crystallization studies (97, 159-161), the likely substrate of RebC was found 
to be 7-carboxy-K252c, which is produced by RebP via the C-5 and C-5’ aryl-aryl 
coupling of CPA.  This led to a proposed mechanism for RebC involving hydroxylation 
of 7-carboxy-K252c at the α-carbon of the carboxyl group to facilitate decarboxylation 
and yield a pyrrole-diol moiety, followed by an oxidative rearrangement to generate the 
maleimide (Figure 35).  While MarC is also responsible for generating a maleimide 
moiety, it is predicted, based on sequence homology, to be a Rieske type dioxygenase. 
Rieske type dioxygenase contains a [2Fe-2S] iron-sulfur cluster, instead of FAD, as the 
cofactor (162). In MarC dependent bisindolylmaleimide biosynthesis, we propose that 
MarC hydroxylates the C2-C3 and C2’-C3’ olefins of CPA in two successive oxidations 
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to facilitate two decarboxylations and generate, without relying on a second enzyme, the 
pyrrole-diol that can similarly undergo oxidative rearrangement to yield the maleimide 
(Figure 35). While our data supports this simple model, the involvement of unknown host 
factors cannot be ruled out. 
 
Figure 35. Comparison of the proposed enzymatic oxidative mechanism between 
bisindolylmaleimide and indolocarbazole in the biosynthesis of a maleimide moiety. 
 
Figure 36. Soluble protein extract of marE/pETDuet harboring E. coli with or without 
IPTG induction (200 rpm, 37 °C, 2 hours after OD600 ~0.5).  IPTG-dependent expression 
of a protein with the size corresponding to MarE (~22 kDa) is observed. 
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Based on our in vivo analyses, no function can yet be assigned to MarE, a 
predicted VioE homolog.  Gel analysis of the soluble protein extract of marE harboring 
E. coli confirms that soluble MarE is produced in this system (Figure 36). In violacein 
biosynthesis, VioE is predicted to produce prodeoxyviolacein (25) by “interacting” with a 
transient intermediate of unknown structure that is produced by the violacein CPA 
synthase (Figure 34) (94, 163, 164). VioE is a small protein (191 aa) that lacks any 
functionally characterized homologs, any known catalytic residues or any recognized 
cofactor-binding motifs. Accordingly, the mechanistic details of its role in violacein 
biosynthesis remain unclear.  MarE shares high sequence identity to VioE, however in 
vivo MarE cannot complement the function of VioE in the production of 
prodeoxyviolacein (25) (Figure 32, VioA+MarBE versus VioAE+MarB).  Whether MarE 
is inactive in the mar cluster, plays a role that is redundant in E. coli, or functions in the 
biosynthesis of an as yet unidentified metabolite is subject for further investigation. 
Bisindolylmaleimide natural products share a common 3,4-di-1H-indol-3-yl-1H-
pyrrole-2,5-dione core structure (165) (Figure 37, red).  The discovery of the simplest 
bisindolylmaleimide natural product, arcyriarubin A (166), from a slime mold (Arcyria 
denudate) spearheaded the extensive study of this class of compounds, with more than 
2,400 and 4,000 bisindolylmaleimide-related references in the PubMed and SciFinder 
databases, respectively.  Bisindolylmaleimide analogs, with activities in cancer (167-
169), diabetes (170), cardiovascular (171) and neurodegenerative (172) disease models 
have now been synthesized, some of which have advanced into clinical trials (173-175) 
(Figure 37A). By the heterologous expression of the mar cluster, we hereby functionally 
characterized the first bisindolylmaleimide biosynthetic pathway.  
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A diverse collection of bisindolylmaleimides have been chemically synthesized 
and tested for bioactivity, with a particular focus on kinase inhibitory activity (176, 177). 
Arcyriarubin A (22) (Figure 37B) is a submicromolar inhibitor of protein kinase C (IC50: 
0.55 µM) (178). Interestingly, the addition of the N-methyl to give methylarcyriarubin 
(21) (Figure 37B) abolishes protein kinase C inhibitory activity (IC50: > 100 µM) (178), 
but leads to activity against mitogen-stimulated protein kinase p70s6k/p85s6k (IC50: 8 µM) 
(179). A number of synthetic bisindolylmaleimide derivatives, including ruboxistaurin, 
enzastaurin, and MKC-1, have undergone or are currently in clinical trials as potent and 
specific kinase inhibitors for use as cancer and diabetes therapies (Figure 37A) (173-
175). 
Indolocarbazole tryptophan dimers, which differ from bisindolylmaleimides by 
the coupling of the C-5 and C-5’ indole carbons, have also been extensively explored as 
kinase inhibitors (47). The additional C-C coupling forces indolocarbazoles to bind in a 
planar conformation, while the more flexible bisindolylmaleimides have been observed to 
bind in a nonplanar conformation (180, 181). This conformational flexibility is believed 
 
Figure 37. Bisindolylmaleimide compounds, with the 3,4-di-1H-indol-3-yl-1H-pyrrole-
2,5-dione core structure colored in red. A) Synthetic derivatives that have entered into 
clinical trials for drug therapy. B) Compounds that are encoded by the eDNA-derived 
mar biosynthetic gene cluster. 
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to be responsible for trends observed in tryptophan bioactivities.  Bisindolylmaleimides 
tend to be less potent, but more specific kinase inhibitors compared to their 
indolocarbazole counterparts (178, 182). Known indolocarbazole biosynthetic enzymes 
have been used, both in vitro in chemoenzymatic synthesis (183) and in vivo in 
combinatorial biosynthesis (113, 114), to generate many un-natural indolocarbazole 
analogs. Considering the significant clinical relevance of the bisindolylmaleimides, the 
identification of the mar biosynthetic gene cluster should facilitate the generation of 
additional collections of potentially pharmaceutically relevant tryptophan dimers using 
biosynthetic approaches. 
3.6 Expansion of bacterial tryptophan dimer biosynthetic scheme  
Using various heterologous expression strategies illustrated here, including the 
shuttling of pathways in multiple hosts, overexpression of predicted pathway-specific 
transcriptional regulators, complete synthetic refactoring of gene clusters, and the co-
expression of predicted deficient genes, we functionally characterized nine of the 14 
unprecedented gene clusters (AB1650, AB1091, AB339, AB234, AR1973, AB1149, 
AB1521, NM1499, NM343), resulting in the elucidation of three novel TD families that 
consist of biologically active natural products including BE-54017, cladoniamide A, 
borregomycins, erdasporines, and methylarcyriarubin. The dimerization of tryptophan by 
the tandem action of an IPA imine synthase and a CPA synthase generates a 
tremendously versatile intermediate (CPA) that appears to serve as a substrate for the 
biosynthesis of a diverse array of dimer substructures. The discovery of three novel TD 
families, namely indolotryptoline, carboxy-indolocarbazole, and bisindolylmaleimide, 
adds new branches to the meta-biosynthetic scheme of bacterial TDs (Figure 38).  As 
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only a small subset of known TD natural products have had their biosynthetic gene 
clusters characterized thus far, it is likely that the current global biosynthetic scheme is 
still incomplete and that there are more divergent tryptophan dimer pathways awaiting for 
discovery and characterization. 
 
Figure 38. Bacterial tryptophan dimer biosynthetic pathways that diverge from a 
common tryptophan dimer intermediate (highlighted in blue). Indolotryptolines branch 
out via formation of an indolocarbazole precursor, followed by two successive oxidative 
steps (green; Group E), carboxy-indolocarbazole branch out via indolocarbazole 
formation, followed by methylation of a carboxyl unit (red; Group F), and 
bisindolylmaleimide pathway branch out via oxidative decarboxylation (pink; Group B). 
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To qualitatively evaluate the exploration of the tryptophan dimer chemical 
diversity, the basic physiochemical properties of the three known and three novel TD  
families were calculated using JChem (ChemAxon) and used as variables for principle 
component analysis (PCA) to map out their structural variability using SPSS Statistics 
software (IBM). Maximal variation was observed when PCA axis 1 consisted mainly of 
variables: log, TPSA, chiral atoms, and H bond donors/acceptors, while PCA axis 2 
consisted mainly of variables: rotatable bonds and ring count. The resulting PCA plot 
 
Figure 39. Chemical space of tryptophan dimer natural product family as represented by 
PCA plot of basic physiochemical properties. reb = rebeccamycin-like maleimide 
indolocarbazole; sta = staurosporine-like pyrrolinone indolocarbazole; vio = violacein; 
bis = bisindolylmaleimide; car = carboxy-indolocarbazole; ind = indolotryptoline. 
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representing the chemical space of the TD core structures gives rise to four general 
groups (A, B, C, and D) that cluster based on structural relatedness (Figure 39). Group A 
consists of the bisindolylmaleimide and violacein families with relatively flexible 
structures, group B consists of the pyrrolinone and maleimide indolocarbazole families 
with relatively rigid structure, and group C and D each consists of carboxy-
indolocarbazole and indolotryptoline cores as singletons, respectively. The PCA-based 
chemical space illustrates that the discovery of the bisindolylmaleimide family has 
allowed for the deep mining of the chemical space related to the violacein family, while 
the discovery of the carboxy-indolocarbazole and indolotryptoline families has permitted 
expansion into the previously unexplored tryptophan dimer natural product chemical 
space.  
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Chapter 4: Investigation of tryptophan dimer’s mode of action 
4.1 Resistant mutant screening 
 Upon the discovery of novel bioactive natural products, identifying their 
molecular targets become a critical step for their development as therapeutic agents and 
small-molecule probes that allow temporal and spatial modulation of target function (184, 
185). However, linking bioactive small molecules to their cellular targets remains 
challenging and a general methodology for the rapid and systematic investigation of the 
compound’s mode of action has not yet been established. This is especially true when 
studying cytotoxic natural products that might serve as anticancer agents. 
One approach for investigating the mode of action of a small molecule involves 
the selection and full genome sequencing of mutants that acquire compound resistance 
(186). Upon the identification of resistance conferring mutations, a compound’s effect on 
the activity of both the mutant and wildtype gene products can be used to suggest the 
mutated protein as the putative molecular target. In addition, since the resistance 
conferring mutations perturb the interaction of the compound to the putative target, the 
mutations can be mapped onto the target’s structure to elucidate the putative binding site 
of the compound, information that would not be available in gene deletion- or 
overexpression-based genome-wide screening studies. 
Because bacteria are fast-growing and genetically tractable, resistant mutant 
screening approach is commonly employed for mode of action of antimicrobial natural 
products (187, 188). However, its application to antitumor natural product mode of action 
studies has been limited (189) due to the time consuming, costly, and cumbersome nature 
of carrying out these experiments using human cells (184, 185). Antitumor agent target 
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identification studies have turned to in vitro affinity-based methods (190, 191), but since 
the screening is conducted outside of the cellular environment, the positive hits may not 
be physiologically relevant. A rapid and systematic resistant mutant screening approach 
that is compatible with antitumor agents should thereby be preferable.  
4.2 MDR-sup fission yeast as model organism 
Yeasts are an attractive eukaryotic model for antineoplastic mode of action 
studies because of their small genomes, fast growth rates, and genetic tractability (192). 
Most previous mode of action studies using yeast have turned to the budding yeast 
Saccharomyces cerevisiae as a model organism (184, 185). In contrast to budding yeast, 
fission yeast (Schizosaccharomyces pombe) maintains many more of the basic cancer-
relevant cellular processes present in human cells (e.g. cell division, DNA replication, 
heterochromatin assembly), making it a potentially more general model for mode of 
action studies (193). Unfortunately, S. pombe’s lack of sensitivity to many cytotoxins due 
to its robust multidrug resistance (MDR) response has limited its use for genome-wide 
screening (194). A recent study identified five major contributors to fission yeast’s MDR 
phenotype (four drug-efflux transporters and a transcription factor) and showed that their 
deletion results in the increased sensitivity of S. pombe to a wide range of chemical toxins 
(195). This MDR-suppressed (MDR-sup) strain of S. pombe should be particularly well 
suited for antiproliferative natural product mode of action studies because of its broad 
sensitivity to cytotoxins and its reduced ability to acquire drug resistance through 
uninformative, non-specific MDR mechanisms. We thereby sought to establish a system 
for the genome-wide resistant mutant screening to antiproliferative natural products using 
MDR-sup S. pombe as a model organism. 
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4.3 Indolotryptoline as subject for mode of action study 
Natural products have traditionally served as the most prolific source of new 
antineoplastic agents. Natural products or natural product inspired structures comprise 
approximately 80% of FDA approved anticancer drugs (6). The natural products 
screening model that led to the discovery of most anticancer agents is based on the 
premise that there is a positive correlation between small molecule structural novelty and 
the ability of compounds to interact with new molecular targets (196). Ultimately, novel 
compounds that have successfully transitioned into clinically useful cancer chemotherapy 
drugs (e.g. doxorubicin, mitomycin, paclitaxel) tend to exhibit very potent (nM - pM) 
antiproliferative activity against diverse cancer cell lines in vitro (196, 197). 
Indolotryptoline-based natural product cytotoxins satisfy both of these criteria (i.e. 
structural uniqueness and high potency), making them appealing targets for mode of 
action studies (127). 
The most extensively studied tryptophan dimers are the indolocarbazoles, which 
differ from indolotryptolines by the presence of a tricyclic carbazole in place of the 
tryptoline moiety (Figure 17). A number of synthetic derivatives of the indolocarbazoles 
staurosporine and rebeccamycin, which are protein kinase (48) and DNA topoisomerase I 
(49) inhibitors, respectively, have been introduced into clinical trials as cancer 
therapeutic agents (46, 47). Indolotryptolines show nanomolar in vitro cytotoxicity which 
is similar to the activity seen for the most potent natural indolocarbazoles; however, 
structural differences between these two compound families suggest they likely have 
distinct modes of action (127). There have been two previous reports on the potential 
molecular target of indolotryptoline-based metabolites, but in both instances, assays were 
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carried out against only a single molecular target of interest. The first study, as described 
in Chapter 3.3, tested the indolotryptoline borregomycin A against a panel of protein 
kinases in vitro and found it to be most active against the pCaMKII∂ kinase (128). The 
second study identified the indolotryptoline BE-54017 as a hit in a high-throughput 
screen for compounds that inhibit vacuolar H+-ATPase (V-ATPase) activity in a human 
cell line (198). We reasoned that a resistant mutant selection approach would provide a 
more systematic in vivo analysis of the mode of action of indolotryptolines and 
potentially even provide residue level details about the binding site of this family of 
natural products. We have thereby chosen BE-54017 (1) and cladoniamide A (2), two 
most potent members of the indolotryptoline family of antiproliferative natural products, 
as subjects for the resistant mutant screening-based mode of action study.  
4.4 Mutations conferring indolotryptoline resistance 
BE-54017 and cladoniamide A show similar in vitro cytotoxicity against human 
cell and MDR-sup S. pombe (IC50 BE-54017: 15 nM; cladoniamide A: 32 nM), 
suggesting the potential for a common mode of action in both organisms. In contrast, the 
S. pombe strain from which MDR-sup S. pombe was derived (MDR-active S. pombe) is 
approximately 50 times less sensitive to these natural products (IC50 BE-54017: 780 nM; 
cladoniamide A: 1600 nM) and is likely prone to off target effects not seen in human 
cells. As an initial step to resistant mutant screening study, methylnitronitrosoguanidine 
(NTG) mutagenized MDR-sup S. pombe was plated on media containing either BE-
54017 or cladoniamide A (Figure 40). For both metabolites, concentrations ranging from 
2 to 6 fold above the IC50 (BE-54017: 35-70 nM; cladoniamide A: 89-178 nM) were used  
for resistant mutant selections, which yielded between one and ten resistant colonies per 
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100,000 mutagenized cells. For each target compound, we picked 12 resistant colonies 
for further analysis (BE-54017 = S. pombe strains B1-B12, cladoniamide A = S. pombe 
strains C1-12). These 24 mutants were re-examined for indolotryptoline resistance and 
tested for cross-resistance to the unrelated cytotoxin, brefeldin A. Strains that failed to 
show resistance when re-screened against indolotryptolines (B2, B9, C1, C11) and those 
showing cross-resistance to brefeldin A (C7) were abandoned. All of the remaining  
strains were found to be resistant to both BE-54017 and cladoniamide A, suggesting a 
 
Figure 40. Four-step schematic of molecular target identification using S. pombe. 1) 
Mutagenesis: The S. pombe strain with multidrug resistance (MDR) response 
suppressed (MDR-sup) through five-gene knockouts (KO) is randomly mutagenized 
with methylnitronitrosoguanidine (NTG). 2) Selection: NTG mutagenized cells are 
plated on drug containing solid media to select for resistant mutants. 3) Backcrossing: 
Drug-resistant mutants (orange) are crossed with un-mutagenized MDR-sup (white), 
resulting in the formation of ascus containing four spore progeny with a reduction in the 
number of mutations. Progeny retaining drug resistance (orange) are maintained. 4) 
Sequencing: The genome of each backcrossed mutant is sequenced and compared to the 
un-mutagenized parent genome to identify the specific mutation that confers drug 
resistance. 
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common mode of action and drug binding site. The IC50 for these resistant mutants ranged 
from 2 to 8 fold above the IC50 determined for un-mutagenized MDR-sup S. pombe 
(Figure 41, Appendix 5).  
Random NTG mutagenesis results in the introduction of multiple mutations into 
the genome of each strain, complicating the identification of the specific mutations that 
are relevant to the mode of action. A key benefit of using fission yeast as a model for the 
resistance selection approach is that the complexity of the mutagenized genetic 
 
Figure 41. Data from BE-54017 (B#) and cladoniamide A (C#) resistant mutant strains. 
Compilation of data from either A) fully sequenced or B) vma3, vma11, or zhf1 PCR 
sequenced resistant mutants. Genes containing mutations, the amino acid change 
encoded by each mutations and the fold-difference in whole-cell cytotoxicity (IC50) 
relative to un-mutagenized strain are shown. BE = BE-54017; Cla = Cladoniamide A; 
Baf = Bafilomycin A1; Con = Concanamycin A; Bre = Brefeldin A; N/D = not 
determined; number in asterisk (*) represents the average value. C) Examples of dose 
response curves used to determine whole-cell cytotoxicity and fold-differences in IC50. 
Curves for BE-54017 and bafilomycin A1 against mutant B1, mutant B7 or un-
mutagenized MDR-sup S. pombe are shown. 
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background can be significantly simplified through backcrossing with un-mutagenized 
yeast (Figure 40). Backcrossing serves to replace non-drug resistance associated 
mutations with wildtype allelles from the un-mutagenized strain, thereby preventing 
irrelevant mutations from complicating downstream genome-wide bioinformatics 
analyses. Six representative mutant strains showing varying levels of resistance (B1, B5, 
B7, B12, C3, C6) were backcrossed four to six times with un-mutagenized MDR-sup S. 
pombe (Figure 41). Consistently, two of the four progeny from each backcross retained 
drug resistance, suggesting that a single mutation was responsible for the observed 
resistant phenotype in each strain. The final backcrossed clones were subjected to 
Illumina whole-genome sequencing and the resulting reads were mapped onto the un-
mutagenized MDR-sup genome to identify differences in protein coding sequences. Upon 
comparison to the un-mutagenized MDR-sup genome, the six backcrossed strains were 
found to contain between one and four point mutations (Figure 41A). While various one 
off mutations were observed in this strain collection, all resistant strains had mutations in 
either the zinc transporter gene, zhf1 (B1, B5, C3) or in genes encoding the c (vma3; B7, 
B12) or c’ (vma11; C6) subunits of the vacuolar H+-ATPase complex (V-ATPase), 
suggesting that zinc transporter and V-ATPase activity were likely linked to the 
molecular mechanism of indolotryptoline cytotoxicity. In no cases did we detect 
mutations that might traditionally be associated with a generic MDR-like phenotype, 
highlighting one of the key advantages of using the MDR-sup strain.  
The zhf1, vma3 and vma11 genes from the thirteen resistant strains that were not 
analyzed by Illumina whole-genome sequencing were PCR amplified and individually 
sequenced (Figure 41B). All thirteen strains were found to contain a mutation in one of 
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these three genes. Eight strains contain the same zhf1 mutation (W324L) observed 
previously, making it the most common mutation we detected. Two strains were found to 
contain previously identified vma3/11 mutations and the remaining three strains 
contained new variants of vma3 (C8), vma11 (B10) and zhf1 (B3). 
The genetic tractability of yeast allows for a specific mutation of interest to be 
easily introduced into a clean background to provide a genetic validation of its role in 
conferring resistance. To confirm the relevance of the vma and zhf mutations to 
indolotryptoline resistance, each unique vma3/11 point mutations (B7, B10, B12, C6, C8) 
and the common W324L zhf1 mutation (B1) were introduced into the un-mutagenized 
MDR-sup S. pombe strain by homologous recombination. The resulting strains, which 
were shown by PCR amplicon sequencing to harbor the desired mutation, were all found 
to be resistant to indolotryptolines at the same level as the randomly mutagenized clones 
containing the same mutation. The individual vma3, vma11 and zhf mutations we 
detected are therefore necessary and sufficient for conferring resistance to 
indolotryptoline-based compounds.  
4.5 V-ATPase proteolipid subunit as putative target of indolotryptoline 
Previous studies have observed a tight functional connection between zinc 
toxicity and V-ATPase activity. The inactivation of the V-ATPase in diverse organisms 
from yeasts to plants, by either a gene knockout or a small-molecule inhibitor, is known 
to result in increased sensitivity to zinc, indicating that the V-ATPase plays a critical role 
in zinc homeostasis (199, 200). As would be expected for a V-ATPase inhibitor, we 
observed that MDR-sup S. pombe becomes more sensitive to BE-54017 and 
cladoniamide A with increasing concentrations of zinc in the growth medium (Figure 41).  
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Although V-ATPase activity in budding yeast has been investigated in vitro using 
isolated vacuolar membranes (201), the purification of similar membrane fractions from 
S. pombe has proved challenging, thereby precluding comparable in vitro biochemical 
analyses (202). However, because V-ATPase is responsible for maintaining the 
acidification of cellular organelles, in vivo V-ATPase activity can be monitored using 
acidic staining dyes (e.g. quinacrine) that form fluorescent puncta in vacuoles at reduced 
pH (203). As previously reported for known V-ATPase inhibitors (204, 205), the addition 
of indolotryptolines to culture media at sub-minimum inhibitory concentrations resulted 
in the loss of fluorescent puncta formation in a dose dependent manner in un-
mutagenized MDR-sup S. pombe (Figure 43A). In vivo V-ATPase inhibition by 
indolotryptolines (MIC BE-54017: 69 nM; cladoniamide A: 143 nM) occurs at 
concentrations similar to those needed for whole-cell cytotoxicity (MIC BE-54017: 35  
 
Figure 42. Sensitivity of the un-mutagenized MDR-sup S. pombe to cytotoxins in the 
presence of increasing concentrations of zinc. A) Summary of fold-differences in whole-
cell cytotoxicity (IC50) relative to media without the addition of ZnCl2. B) Dose response 
curve for un-mutagenized MDR-sup when exposed to BE-54017 in the presence of 
different concentrations of ZnCl2. 
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nM; cladoniamide A: 72 nM). Acidic staining experiments were carried out using strains 
containing each unique vma3 (B7, B12, C8) and vma11 (B10, C6) mutation, as well as a 
representative strain with the common W324L zhf1 (B1) mutation (Figure 43B, Appendix 
6). All vma3 and vma11 mutants showed increased tolerance to puncta disruption by 
indolotryptolines, while the zhf1 mutant responded like non-mutant MDR-sup in these 
experiments. Taken together, these experiments indicate that indolotryptolines inhibit V-
ATPase activity and that the primary deleterious effect of V-ATPase inhibition is likely 
the downstream disruption of zinc homeostasis.  
Indolotryptoline resistant strains were tested for cross-resistance to the well-
characterized plecomacrolide-type V-ATPase inhibitors, bafilomycin and concanamycin 
(Figure 41, Appendix 5). The W324L Zhf1 mutant confers resistance to both known V-
ATPase inhibitors. With the exception of the Vma3 M130I mutant, which confers a two-
 
Figure 43. Visualization of in vivo V-ATPase activity by acidic organelle staining. A) 
Nomarski and fluorescent images of quinacrine-stained un-mutagenized MDR-sup S. 
pombe upon incubation with BE-54017 (BE) or brefeldin A (Bre). Fluorescent puncta 
formation is inhibited at higher concentrations of BE, with no puncta observed in >95% 
of the cells at 69 nM (MIC). Bre has no effect on puncta formation. B) Summary of 
fold-difference in in vivo V-ATPase MIC relative to un-mutagenized MDR-sup. Cla = 
Cladoniamide A. 
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fold increase in resistance to bafilomycin, V-ATPase mutants did not show cross-
resistance to either bafilomycin or concanamycin. The fact that V-ATPase mutants are 
largely compound class specific, while Zhf1 mutants confer resistance irrespective of the 
compound class, further supports a model in which the V-ATPase, and not zinc 
transporter, is the likely molecular target of indolotryptolines; zinc toxicity is likely the 
downstream deleterious consequence of V-ATPase inhibition.  
4.6 Putative indolotryptoline binding site in V-ATPase 
The V-ATPase is a multi-protein complex that consists of two domains: a 
peripheral ATP binding domain V1 and a membrane associated proton translocating pore 
domain V0 (Figure 44A) (206, 207). In yeast, the V0 domain contains a hexameric 
cylinder that is known as the proteolipid ring. The catalytic V1 subunit hydrolyzes ATP, 
which drives the rotation of the proteolipid ring that in turn allows for protons to 
translocate across the membrane. The proteolipid ring is thought to be composed of c 
(vma3), c’ (vma11) and c’’ (vma16) subunits that assemble in a 4:1:1 (c:c’:c’’) 
stoichiometry (206-208). As is the case with plecomacrolide resistance conferring 
mutations, indolotryptoline conferring mutations are found in the proteolipid subunits. 
Based on the fact that four of the five vma3/11 mutations that confer resistance to 
indolotryptolines do not show cross-resistance to plecomacrolide-type metabolites and 
that the fifth mutation only confers low-level resistance to bafilomycin (Figure 41), the 
indolotryptoline-binding site is likely distinct from, but proximal to, the plecomacrolide-
binding pocket in the proteolipid ring. 
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The detailed molecular structure of the yeast V-ATPase is not known; however, 
the proteolipid substructure from the vacuolar Na+-ATPase from the bacterium, 
Enterococcus hirae, has been determined by X-ray crystallography (209). Despite 
phylogenetic and functional differences, the high sequence homology seen between the E. 
hirae proteolipid subunits and those found in eukaryotic V-ATPase complexes has led to 
the use of the E. hirae V-ATPase structure as a model for eukaryotic V-ATPase studies 
 
Figure 44. Structure of V-ATPase. A) Schematic of yeast V-ATPase architecture, which 
consists of the catalytic V1 domain (green) and the membrane translocating V0 domain 
(yellow and beige). Proteolipid subunits c/c’/c’’ (beige) are part of the V0 domain and 
form a hexameric ring structure. B, C, D) Side (B), close up (C) and top (D) view of the 
crystal structure of a proteolipid subunit from the E. hirae V-ATPase (PDB ID: 2BL2). 
The peptide backbone is represented as a green stick model. Residues found to be 
involved in conferring resistance to indolotryptolines are shown in red. Residues 
reported to be involved in plecomacrolide resistance in previous studies are shown in 
blue. 
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(208, 210). In particular, the residues that confer resistance to V-ATPase inhibitors have 
been mapped onto E. hirae V-ATPase structure to predict putative inhibitor binding sites. 
Residues reported to confer resistance to plecomacrolide-like inhibitors generally cluster 
midway between the cytoplasmic and luminal face of proteolipid ring, and point out from 
the four helix bundle that makes up each of the proteolipid subunit (208). In contrast, 
indolotryptoline resistance conferring mutations map near the cytoplasmic face and 
mostly point into the center of the bundle (Figure 44), suggesting indolotryptolines bind 
at a unique site within the proteolipid four-helix bundle near its cytoplasmic face. Based 
on the significant structural differences between indolotryptolines and known V-ATPase 
inhibitors (Figure 44) (211), it is not surprising that they would bind at a distinct site. 
Tryptophan dimers, including the closely related indolocarbazole family of 
natural products, have been observed to interact with proteins containing nucleotide-
binding sites (i.e. ATP or DNA) through mimicry of a nucleotide base (46-49). While the 
V-ATPase uses ATP, the proteolipid subunits of V-ATPase are not known to contain a 
nucleotide-binding site, suggesting that tryptophan dimer binding motifs can extend 
beyond simple nucleotide mimicry. This should encourage the continued discovery and 
mode of action analysis of new natural tryptophan dimers. Disruption of the planar 
indolocarbazole ring system through the sp3 hybridization of the two carbons at the base 
of the pyrrole ring in the indolotryptoline structure is likely a key factor in the altered 
binding mode of this class of tryptophan dimers. Ultimately, an indolotryptoline-
proteolipid co-crystal structure will likely be required to confirm these binding motif 
hypotheses.  
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4.7 Summary of MDR-sup S. pombe resistant mutant screening 
Through whole-genome sequencing of the indolotryptoline resistant mutants, we 
identified point mutations in the proteolipid (c/c’) subunits of V-ATPase and the zinc 
transporter Zhf1 that conferred resistance to this family of natural products. Acid vacuole 
staining, cross-resistance studies, and direct c/c’ subunit mutagenesis indicate that the 
primary resistance mechanism to indolotryptolines is the mutation in V-ATPase and that 
the V-ATPase, as opposed to the zinc transporter, is the likely molecular target of 
indolotryptolines. The mapping of the resistance conferring mutations onto a model V-
ATPase proteolipid structure predicts that indolotryptolines bind at the interface of the 
four helix bundle of a single proteolipid subunit near its cytoplasmic face, in a site that is 
distinct from previously described V-ATPase inhibitors.  
 
Figure 45. Chemical structure of previously characterized V-ATPase inhibitors. 
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V-ATPase is a highly conserved protein complex in eukaryotes that plays a role in 
acidifying a variety of organelles (206, 207). V-ATPase inhibitors have been explored as 
cancer therapeutic agents due to their cytotoxicity towards diverse cancer cell lines (212, 
213). Cell lines from cancers that are especially malignant, aggressive and unresponsive 
to current therapies are known to be sensitive to V-ATPase inhibitors, possibility due to 
the involvement of an acid microenvironment in tumor progression and multidrug 
resistance (212, 213). The unique indolotryptoline V-ATPase binding site proposed in 
this study should help guide the development of a new class of V-ATPase inhibitors that 
can be explored for anticancer activity.  
Resistant mutant analysis provides insight to both the molecular target and 
binding site of the small molecule, while not requiring any chemical modification of the 
target compound, preliminary prediction of the target, or construction of a custom-made 
genetic library. As such, the resistant mutant selection of MDR-sup S. pombe serves as a 
convenient alternative approach for mode of action studies of cytotoxic natural products. 
The characterization of a cytotoxic natural product’s molecular target using human cells 
has traditionally been costly, time consuming, and technically cumbersome. Resistant 
mutant screening using MDR-sup S. pombe should serve as a powerful and generally 
applicable alternative target identification technique that fits nicely into diverse drug 
discovery pipelines, including this metagenomics-based TD discovery platform, for gene-
level target identification of cytotoxins.      
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Chapter 5: Discussions 
5.1 Conclusions and future directions 
We have hereby illustrated the metagenomics-based natural product discovery 
and development pipeline that provides a means of exploring the biosynthetic capacity of 
thousands of bacterial genomes simultaneously regardless of their culturability. Its utility 
was demonstrated by recovering 16 unprecedented gene clusters by homology-based 
screening that targets the CPA synthase gene contained within TD pathways. 
Heterologous expression of eDNA-derived gene clusters permitted the functional 
characterization of three novel TD families with members that exhibit clinically relevant 
bioactivities. One of the TD family, indolotryptoline, was further developed by 
elucidating its molecular mode of action. 
This study focuses on the discovery of TD natural products, and while iterations 
of this approach should lead to the isolation of additional compounds from the TD class, 
this pipeline can be generalized to other natural product classes, depending on the design 
of the degenerate primer set for PCR screening. Homology-based screening strategies 
have been employed to isolate novel natural products from the isocyanide natural product 
(214), type II polyketide (42, 82, 95, 215, 216), and glycopeptide-type non-ribosomal 
peptide (41, 43, 88) class in our laboratory, and from the cyanobactin-type ribosomal 
peptide (217) and the trans-acyltransferase (trans-AT) polyketide (218) class by other 
groups (Figure 46A) . As for non-ribosomal peptides and polyketides, studies are 
currently underway in our laboratory to sequence and catalog the conserved adenylation 
and ketosynthase domains for the recovery of these types of gene clusters on an on- 
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Figure 46. Chemical structure of natural product classes that have been (A) or could 
be (B) surveyed by homology-based screening. C is a marine-derived TD. 
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demand basis (43, 219). Of other natural product classes that could be of interest for 
homology-based screening include lyngbyatoxin-type non-ribosomal peptides (since 
isoprene-containing compounds are generally underexplored in bacteria and the gene 
cluster is relatively small, thereby amenable for genetic manipulation) (220), mitomycin-
type natural products (clinical relevance and relatively unique biosynthetic pathway) 
(221), aminoglycosides (clinical relevance) (222), ansamycins (clinical relevance, 
common 3-amino-5-hydroxybenzoic acid (AHBA) biosynthetic motif) (223), and the 
various types of ribosomal peptide natural products (RiPPs; growing class of bacterial 
metabolites) (224) (Figure 46B). Moreover, since natural products discovered from 
marine bacteria are generally found to have drastically different chemical structures 
compared to soil bacterial metabolites (225), including the recently discovered marine 
actinomycetes-derived TD compound spiroindimicins (Figure 46C) (226), screening TD 
gene clusters in eDNA libraries constructed from marine samples should also be fruitful. 
The seven-step overview (Figure 7) of our metagenomic natural product 
discovery and development pipeline can be further generalized into four phases: 1) 
metagenomic library construction, 2) gene cluster screening, 3) natural product 
heterologous expression and production, and 4) natural product characterization and 
development. Improvements and alternative strategies to these four stages will be 
discussed as future directions. As described previously, soil eDNA library construction 
can routinely be conducted in our laboratory (28) and requires no major advancement for 
homology-based screening, aside from the possibility of DNA extraction from other 
environmental samples (e.g. marine samples). BAC (85-87) and P1 phage vector (227)-
based library construction approaches may be explored for the accommodation of larger 
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insert sizes (>40 kb), but it is not as important, considering that the complete gene cluster 
does not need to be contained in a single cosmid for homology-based screening. 
Therefore, the rest will be devoted to the discussion of expanding on the remaining three 
phases. In particular, we examine the utility of CPA synthase gene phylogeny and 
violacein reporter construction in gene cluster screening, as well explore the roles of 
synthetic biology in the heterologous expression of cryptic gene clusters and pathway 
engineering for the generation of natural product analogs as a compound development 
strategy. 
5.2 CPA-guided analysis of metagenomic TD biodiversity 
 The characterization of unique TD substructures from distinct clades in the CPA 
synthase gene phylogenetic tree suggests that CPA synthase gene sequences diverge in 
concert with the functional outputs of their respective TD gene clusters, making CPA 
gene sequences alone a good marker to guide the discovery of novel TDs. Since the 
publication of our first CPA-guided TD discovery study (127), several reports have been 
made regarding the use of CPA targeting primer set for the detection and discovery of TD 
gene clusters from various genetic sources, establishing the CPA synthase gene as a 
suitable sequence tag for TD gene clusters (226, 228, 229). To further explore TD 
diversity in the environment, DNA extracted directly from 20 soil samples from 
geographically distinct sites in New Mexico was screened by PCR using our CPA 
synthase degenerate primers, and the resulting PCR amplicons were sequenced 
(Appendix 7). A phylogenetic analysis of these sequences shows that they form new 
clades both within (e.g. NMCC27) and outside (e.g. NMCC11) the characterized TD 
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groups, suggesting these CPA synthase homologs may appear in gene clusters that 
encode novel TD with known substructures as well as novel TD substructures (Figure 47). 
Our study has thereby only uncovered the tip of the iceberg of bacterial TD 
biodiversity and within the massive pool of the bacterial metagenome lies even greater 
number of unprecedented TDs and their corresponding biosynthetic pathways that remain 
to be discovered. For subsequent TD discovery efforts, the CPA synthase gene amplicons 
can be sequenced in parallel in multiple environmental samples to identify the 
 
 
Figure 47. ClustalW-based phylogenetic tree of trimmed CPA synthase gene amplicons.  
The eDNA-derived sequences (boxed) fall into known TD groups A-E (colored), and 
form new clades (black) that encode potentially novel TD core substructures. 
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appropriate soil sample for eDNA library construction, either based on the diversity of 
novel clades for the general discovery of new TD substructures, or the plethora of novel 
members of a specific clade for the focused discovery of new derivatives from a 
biologically significant TD class. 
Natural product discovery programs have long relied on the random screening of 
culture broth extracts to identify metabolites with bioactive properties. Unfortunately, it 
has become increasingly difficult to isolate new members of biomedically interesting 
classes of compounds using random screening strategies due to the phenomenon of 
redundant isolation (230). Homology-based screening of metagenomes, guided by 
phylogenetic profiling, offers a solution to this dilemma by allowing the targeted 
recovery of novel biosynthetic pathways, from the level of the selection of soil samples 
for eDNA library construction to the choice of eDNA-derived gene clusters for 
heterologous expression efforts. In particular, CPA synthase gene-guided analysis not 
only allows for the exclusion of sequences that are likely associated with gene clusters 
encoding for previously encountered metabolites, but also predict the type of the TD 
substructure that they encode. Thus, CPA synthase gene phylogenetics should greatly 
facilitate future metagenomic TD natural product discovery programs. 
5.3 Violacein reporter-based screening of TD gene clusters 
Homology-based screening of gene clusters from eDNA libraries suffers from 
several limitations. First, the collection of eDNA-derived TD gene clusters that are 
uncovered from the library will necessarily be biased by primer design because the 
primer sequence cannot possibly be degenerate enough to amplify all possible CPA 
synthase genes, while specific enough to not be overwhelmed by false positives. Future 
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directions to TD screening efforts should therefore include the design of other degenerate 
primers to broaden the recovery of TD gene clusters with diverse CPA synthase gene 
sequences, but on the other hand, a screening methodology that is independent of 
sequence bias is also preferable.  
Second, while certain biosynthetic genes may be functionally conserved within a 
particular natural product class, the genes with no conserved regions in their DNA 
sequences for primer design cannot be targeted for homology-based screening. As 
described in Chapter 2.2, this was observed in the case of IPA-imine synthase genes 
(Figure 8), where the staO/rebO genes from indolocarbazole clusters do not share 
significant sequence homology to the vioA gene from the violacein cluster, although these 
genes are known to be functionally equivalent (94, 163, 164). Despite that the known 
bacterial TD gene clusters contain both the IPA-imine synthase and the CPA synthase 
genes, some known TD and TD-like natural products can be predicted to be 
biosynthesized via IPA-imine synthase-, but not CPA synthase-mediated catalysis, such 
as nortopsentin A (similar to violacein, but the internal ring consist of two, instead of one, 
 
 
Figure 48. TD- and TD-like natural products that are predicted to be biosynthesized via 
IPA-imine synthase, but not CPA synthase, mediated reactions. 
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nitrogen atoms) (231), granulatimide (coupling of tryptophan and histidine) (232), and 
ancorinazole (anti, instead of syn, dimerization of indoles) (233) (Figure 48). Therefore, a 
screening approach that can target IPA-imine synthase and other genes should expand the 
capability of recovering diverse TD and TD-like natural product gene clusters. 
Third, while homology-based screening allows for biosynthetic gene clusters that 
do not necessarily have to be expressed in the library host, this implies that a significant 
number of gene clusters that are recovered in this manner are cryptic, as demonstrated in 
our study, thereby requiring considerable time and cost expenditures for heterologous 
expression efforts. An approach that can selectively screen for functional gene clusters 
should be useful. 
Taking into account these limitations, we envision that a violacein reporter-based 
complementation screening should serve as an appropriate alternative strategy to 
metagenomic TD discovery. As described previously, violacein is a purple TD compound 
that also consists of IPA-imine synthase and CPA synthase in its pathway (Figure 8) (94, 
163, 164). As such, a bacterial colony expressing violacein can easily be detected on an 
agar plate by purple pigmentation. A reporter construct can thus be made that contains 
the violacein gene cluster (155), but with one of the genes knocked out, such as the IPA-
imine synthase gene. The co-expression of the cosmid eDNA clone along with the 
reporter construct should allow for a visual detection of a bacterial colony expressing a 
functional IPA-imine synthase gene, which will complement the reporter construct and 
yield a purple-pigmented phenotype (Figure 48). The three previously mentioned 
limitations that restrict homology-based screening are nonexistent in this approach, since 
the screening criterion is based on phenotype and not on sequence. Moreover, as opposed 
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to the traditional phenotype-based screening, the encoding small molecule does not have 
to provide any phenotype, such as coloration or zone of inhibition, to the bacterial colony 
for detection, and the entire gene cluster does not have to be contained in a single cosmid, 
since only the IPA-imine synthase gene has to be expressed for pigmentation. 
Preliminary study of reported-based screening using IPA-imine synthase gene-
deficient construct in a small E. coli-based eDNA library resulted in the recovery of 
several putative biosynthetic gene clusters, one of which is even predicted to encode for 
small molecules of a different natural product class, namely isocyanide-containing 
natural products (27, 214, 234). By cloning the violacein pathway operon under the 
control of a host-specific artificial promoter, we also found that violacein can be 
 
 
Figure 49. Reporter-based complementation screening of TD gene clusters. The vioA-
deficient violacein gene cluster is used as a reporter to detect eDNA clones that express 
a functional IPA-imine synthase gene.  
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produced in different heterologous hosts, including S. albus. By conducting this reporter-
based screening in various hosts, we anticipate the discovery of novel natural product 
gene clusters that we could otherwise not find using homology-based screening. 
Considering the isolation of an isocyanide natural product gene cluster, we could also 
engineer different reporter constructs with each biosynthetic gene of the violacein 
pathway knocked out, and recover a variety of gene clusters in that matter, with the intent 
of combining eDNA-derived genes from non-TD related pathways to reconstruct and 
build a synthetic violacein pathway.  
5.4 Synthetic biology in heterologous natural product expression 
 Due the limited capability for any particular bacterial host to recognize and utilize 
foreign DNA, heterologous expression becomes a major bottleneck in metagenomic and 
other genome-driven natural product discovery programs. This is well portrayed in our 
study, where we have yet to express five of the 14 novel gene clusters. Here we discuss 
some of the strategies overlapping with the field of synthetic biology for the heterologous 
expression of gene clusters, particularly the cryptic clusters that remain recalcitrant to 
expression using traditional methods. Approaches can broadly be divided into the 
engineering of biosynthetic pathways or the host strain. 
 Pathway manipulation is not only critical to the refactoring of cryptic gene cluster, 
but also in the general assembly of overlapping fragments. As mentioned previously, the 
complete biosynthetic gene cluster does not have to be contained in a single eDNA 
cosmid clone for its detection by homology-based screening. However, if the entire gene 
cluster spans multiple overlapping cosmids, genetic engineering tools must then be used 
to combine and assemble these separate fragments into one seamless entity for 
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heterologous expression. Such technique was not used in our study because all of the TD 
gene clusters were found to be contained on a single cosmid clone. However, if required, 
our laboratory routinely uses a method called transformation associated recombination 
(TAR) for the assembly of multiple overlapping clones (215). The robust homologous 
recombination machineries found in budding yeast (Saccharomyces cerevisiae) are 
exploited in this approach (235). By the transformation of linearized overlapping cosmid 
clones along with a capture vector carrying homology arms corresponding to sequences 
flanking the gene cluster in S. cerevisiae, these genetic elements undergo in vivo 
homologous recombination to yield a stable plasmid containing the complete intact gene 
cluster (236). Another method that utilizes S. cerevisiae is “DNA assembler,” which also 
allows for the stitching of an entire gene cluster using in vivo homologous recombination 
(237). Bacterial in vivo homologous recombination methods, such as linear plus circular 
homologous recombination (LCHR) (238, 239), and linear plus linear homologous 
recombination (LLHR) (100), have also been developed for the assembly or direct 
cloning of biosynthetic gene clusters. 
 However, if the assembled gene cluster remains cryptic in a heterologous host, the 
pathway can be engineered to modify their native genetic elements, a process known as 
synthetic refactoring (125, 126). Much of the successful refactoring efforts for natural 
product biosynthetic gene clusters have been the replacement of native promoters with 
strong artificial promoters to drive transcription at high levels (123, 124, 240). 
Techniques not only include the cloning of individual genes or operons in expression 
vectors, as demonstrated in our study, but also using homologous recombination to 
exchange the promoter regions of the gene cluster. Synthetic refactoring becomes 
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increasingly time consuming and cumbersome with increasing size of gene cluster and 
number of genes/operons, and therefore the refactoring of natural product gene clusters 
has long been a challenging task. The in vivo homologous recombination approaches that 
allows for the rapid assembly of genetic elements, as previously described, should help 
facilitate this process. Moreover, since synthetic refactoring involve several artificial 
genetic elements, in vitro genetic engineering tools, such as Gibson assembly (241), 
sequence- and ligation-independent cloning (SLIC) (242), and Golden Gate assembly 
(243), should also prove to be useful for the construction of “synthetic” gene clusters. 
 Nevertheless, even with the use of strong artificial promoters, small molecule may 
still not be produced, or produced at very low levels. Issues at the transcriptional level 
include the fact that maximal transcription of all biosynthetic genes often do not lead to 
high-level small molecule production because different genes tend to have varying 
optimal transcriptional levels to minimize negative effects of high transcription, including 
metabolic flux and toxicity of the encoding protein or small molecules (244, 245). In 
addition, premature transcription termination and other negative transcriptional effects 
encoded outside of promoter regions, can still occur (246). The artificial gene orientation 
in the “synthetic” gene clusters may also cause problems (126), such as polymerase 
collision. Addressing all of these problems is challenging, especially for eDNA-derived 
gene clusters that lack detailed information regarding expression in their native settings, 
but future advances in synthetic biology should help overcome these issues.  
 Other factors to consider beyond transcription include ribosomal binding sites and 
codon usage for the proper translation (105), molecular chaperones for the proper protein 
folding (107), auxiliary proteins for the proper functioning of the enzyme (e.g. 
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phosphopantetheinyl transferase (PPTase) for NRPS and PKS) (247), stability of 
biosynthetic enzymes that may be susceptible to proteolytic activity (98), availability of 
necessary precursors (247, 248), and self-resistance. Ribosomal binding sites (rbs) and 
codon usage can be addressed using pathway manipulation by encoding rbs alongside 
with the promoters (105) and codon optimizing or randomizing the coding sequences 
(126), respectively. The remaining issues may be more appropriately addressed as part of 
the strain optimization process, a second synthetic biology-based approach to 
heterologous expression. 
  As in the case of the mar (NM343) cluster with the IPA-imine synthase, some 
gene clusters may not have all the biosynthetic genes necessary for small molecule 
production encoded within the gene cluster and rely on elements encoded within the 
endogenous host. Other prominent examples include deoxysugar biosynthetic genes, 
which are not present in certain actinomycetes-derived gene clusters that encode for 
compounds involving the attachment of that sugar for their biosynthesis (249). Similarly, 
other factors can also be considered as a deficiency in certain biochemical elements in a 
particular heterologous host that prevents small molecule production, including the lack 
of molecular chaperones, auxiliary proteins, stability factors, resistance elements. Even 
transcriptional and translational deficiencies can be attributed to the lack of the proper 
polymerases, transcriptional regulators, and transfer RNAs (tRNAs) in the heterologous 
host (98). Specific elements that are predicted to be necessary can be co-expressed with 
the gene cluster on a case-by-case basis, like the IPA-imine synthase gene for the mar 
cluster. Alternatively, considering that many of these elements are necessary for the 
expression of various biosynthetic gene clusters, they can be stably maintained in the 
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bacteria for the design of a universal heterologous host. Commercially available Rosetta 
(Novagen) E. coli strain that expresses rare tRNAs (250) and BAP1 E. coli strain with a 
chromosomally integrated Sfp PPTase for non-ribosomal peptide and polyketide 
biosynthesis (247), are some of the examples of bacterial hosts that have been optimized 
for heterologous expression.  
The consideration of necessary biosynthetic precursors not just involves the 
addition of the appropriate biosynthetic genes, but also the engineering of the host strain 
to tune their metabolic flux. For example, several Streptomyces heterologous hosts have 
their genome minimized, or their endogenous secondary metabolite pathways knocked 
out, such that common biosynthetic precursors are not channeled into endogenous 
pathways (112, 251, 252). Another prominent example is the tuning of E. coli and S. 
cerevisiae strains for high-level production of farnesyl pyrophosphate (FPP) in their 
native ergosterol pathway, such that the anti-malarial drug artemisinin can be produced in 
these hosts at increased levels by the introduction of the appropriate biosynthetic genes 
(253, 254). 
 The necessity in our current natural product discovery pipeline to introduce the 
eDNA-derived pathways into multiple heterologous hosts implies that all of the possible 
factors that contribute to the successful heterologous expression of foreign biosynthetic 
gene clusters have not yet been characterized and cannot yet be implemented in a single 
bacterial strain. However, advances in synthetic biology should allow us to increase both 
the success rate and speed in the heterologous expression of eDNA-derived natural 
product pathway by permitting further improvements in both pathway manipulation and 
host optimization. 
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 5.5 Metagenomic toolbox for natural product analog biosynthesis 
  The eDNA-derived TD gene clusters that have functionally been characterized to 
produce natural products can now be further leveraged to yield small molecules that will 
ordinarily not be made by the endogenous host. Such metabolites produced through the 
use of biosynthetic enzymes and thereby have structural resemblance to natural products, 
but are not exactly the compound encoded by the naturally-occurring biosynthetic gene 
clusters, are referred to as natural product analogs (255) or unnatural products (256). 
Here we do not consider total synthesis, biomimetic synthesis, and semisynthesis that 
utilize organic synthesis as a means to generate compounds, but discuss on the use of 
biosynthetic enzymes contained in the eDNA-derived gene clusters for small molecule 
production. 
 One of the key features of TD biosynthesis is the high reactivity of TD 
intermediates (e.g. activated tryptophan). Once the biosynthetic pathway is allowed to 
proceed by the oxidation of tryptophan by IPA-imine synthase (e.g. StaO) or the 
dimerization of oxo-tryptophan by CPA synthase (e.g. StaD), many chemical reactions 
have been known to occur spontaneously, such as the cyclization of the pyrrole ring to 
form CPA from the conserved tryptophan dimer intermediate (Figure 34, 38) (45). As 
such, a number of biosynthetic enzymes, like VioE in violacein (94, 163, 164) and 
RebC/StaC in rebeccamycin/staurosporine biosynthesis (134), have been suggested to 
exhibit no catalytic activity, but nonetheless serve as a structural scaffold that directs the 
formation of a single desired product from a collection of shunt products that would 
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otherwise form spontaneously. Likely owing to the reactivity of these TD intermediates, a 
simple random mutagenesis of a violacein-producing bacterial strain in a previous study 
resulted in the production of various unnatural TDs (257). Using this strategy, referred to 
as mutasynthesis (256), a library of randomly mutagenized eDNA-derived gene clusters 
can similarly be introduced into the heterologous host for the production and isolation of 
novel unnatural products. The mutagenesis of biosynthetic genes can also be directed. For 
example, a targeted mutagenesis of a set of residues converted the FAD-binding 
monooxygenase RebC (from rebeccamycin pathway) to have StaC (from staurosporine 
pathway)-like functionality, thereby allowing for RebC to produce a staurosporine-like 
pyrrolinone indolocarbazole core instead of the usual maleimide indolocarbazole core, 
and vice versa (96, 97). As we gain further knowledge regarding the eDNA-derived TD 
biosynthetic enzymes, we should also be able to engineer them to have particular 
functions of interest, ultimately leading to the production of natural product analogs. 
 Instead of engineering the biosynthetic enzymes, the substrates that are to be fed 
into the enzymes can be modified as well, taking into advantage of substrate promiscuity 
in certain biosynthetic enzymes. This is referred to as chemoenzymatic synthesis, which 
is actually a more general term used to describe a process that utilizes a biosynthetic 
enzyme to conduct a particular chemical transformation on a compound (258). However, 
chemoenzymatic synthesis is the appropriate terminology to describe this unnatural 
product generation approach because a defined set of compounds (substrates) is generally 
fed into the biosynthetic enzyme for small molecule production. For example, a past 
study has grown a rebeccamycin-producing strain in a cultural broth containing high 
concentrations of bromide for the isolation of brominated rebeccamycin analogs (259). 
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Another study has fed different natural and synthetic indolocarbazole and 
indolocarbazole-like aglycons into the culture broth of bacterial host expressing the 
glycosyltransferase RebG, for the enzymatic generation of glycosylated indolocarbazole 
and indolocarbazole-like analogs (260). A similar strategy can also be done with eDNA-
derived biosynthetic enzymes and gene clusters by feeding various substrates.  
 Lastly, TD analogs have been produced in the past by combinatorial biosynthesis. 
In this approach, the biosynthetic genes from staurosporine and rebeccamycin pathways 
were mixed and match in a heterologous host (S. albus) for the production of natural 
product analogs, including compounds with the sugar moiety from staurosporine, but the 
aglycon moiety from rebeccamycin, and vice versa (114). Taking into advantage the 
substrate promiscuity of the glyosyltransferase StaG, sugar biosynthetic genes from 
unrelated gene clusters have also been mixed and matched to generate analogs with 
various sugars attached (113). The potential for the generation of novel natural product 
analogs increases exponentially with the recovery of more TD biosynthetic genes from 
the eDNA library. The discovery and characterization of eDNA-derived TD gene clusters 
thereby not only allow us to isolate novel natural products, but also expand the 
metagenomic toolbox for the generation of even more natural product analogs. 
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Chapter 6: Materials and methods 
Soil environmental DNA (eDNA) library construction. The three eDNA megalibraries, 
each consisting of over 10,000,000 unique cosmid clones, were constructed from the soil 
samples collected from the Anza-Borrego desert of California (AB), the Sonoran desert 
of Arizona (AR) and the Chihuahuan desert of New Mexico (NM), using published 
methods (28).  Briefly, soil was resuspended in lysis buffer (100 mM Tris-HCl, 100 mM 
EDTA, 1.5 M NaCl, 1% (w/v) CTAB, 2% (w/v) SDS, pH 8.0) and heated for 2 hr at 70 
°C. Soil particulates were removed by centrifugation (30 min, 4000 X g, 4 °C). Crude 
eDNA was precipitated from the resulting supernatant through the addition of 0.7 vol of 
isopropanol, pelleted (30 min, 4000 X g, 4 °C), washed with 70% ethanol, and pelleted 
once more (10 min, 4000 X g, 4 °C) to yield crude eDNA. 
High molecular weight (HMW; >25 kb) eDNA was purified from crude eDNA by 
agarose gel electrophoresis (1% agarose gel, 16 hr, 20 V). The electroeluted (2 hr, 100V) 
HMW eDNA was concentrated (100 KDa molecular weight cut off), blunt-ended (End-
It), ligated into cosmid vector, packed into λ phage (MaxPlax), and transfected into E. 
coli (EC100, Epicentre). The eDNA libraries were archived as unique sublibraries, each 
containing 4000-5000 clones. Matching DNA miniprep and glycerol stock pairs were 
generated for each sublibrary. DNA minipreps were arrayed such that sets of 8 
sublibraries were combined to generate unique “row pools.” 
eDNA library homology guided screening of chromopyrrolic acid (CPA) synthase 
gene. A degenerate primer set was designed based on conserved regions of known CPA 
synthase genes from culture-based studies (accession no.: vioB AF172851.1, staD 
AB088119.1, rebD AJ414559.1, inkD DQ399653.1, atmD DQ297453.1.) Primers: 
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StaDV-F: GTS ATG MTS CAG TAC CTS TAC GC, StaDV-R: YTC VAG CTG RTA 
GYC SGG RTG (Table 3). The eDNA libraries were screened by performing PCR on 
miniprep DNA from each of the unique “row pools”.  Each 20 µL reaction consisted of 
8.3 µL of water, 10 µL of FailSafe PCR Buffer G (Epicentre), 0.5 µL each of StaDVF 
and StaDVR primers (final concentration of 2.5 µM each), 0.5 µL of template “row pool” 
eDNA (100 ng), and 0.2 µL Taq DNA polymerase (New England Biolabs). PCR cycling 
conditions were as follows: 1 cycle of 95°C for 5 min; 7 cycles of 95°C for 30 sec, 65°C 
for 30 sec with 1°C decrement per cycle to 59°C, 72°C for 40 sec; 30 cycles of 95°C for 
30 sec, 58°C for 30 sec, 72°C for 40 sec; 1 cycle of 72°C for 7 min; 4°C hold. Amplicons 
of the correct size (~561 base pairs) were gel purified, re-amplified and sequenced using 
the same degenerate primers. Amplicons that were confirmed to be CPA synthase gene 
sequences based on BLASTX homology searches (NCBI) were used to guide the 
recovery of the corresponding cosmid clones from within our eDNA megalibraries. 
Recovery of cosmid clones harboring tryptophan dimer (TD) gene clusters. Cosmid 
clones containing CPA synthase genes were recovered from the archived eDNA libraries 
using a serial dilution approach. For each amplicon of interest, a specific PCR primer set 
was designed to recognize the sequence of that particular amplicon.  These primers were 
used to identify, from a given “row pool,” the corresponding sublibrary that contains the 
clone of interest. The sublibrary glycerol stock was resuspended into LB to an OD600 of 
0.5, diluted 2 x 105 fold and arrayed as 60 µL aliquots (about 25 cells) into 4 sterile 96 
well plates. Upon overnight growth, the well containing the clone of interest was 
identified by whole cell PCR.  The culture broth from this well was then spread onto LB 
plates and single colonies were screened by colony PCR to identify the specific clone 
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harboring the targeted CPA synthase gene.  Cosmid clones were de novo sequenced at the 
Sloan Kettering Institute DNA Sequencing Core Facility using 454 pyrosequencing 
technology (Roche).  Clone assemblies were annotated using FGENESB (Softberry) or 
CloVR (261) for gene prediction and BLASTP (NCBI) for protein homology 
relationships. 
Phylogenetic tree construction of CPA synthase genes. The ClustalW alignment was 
performed on the sequences of culture-derived and eDNA-derived CPA synthase genes 
using MacVector version 12.0.3 (Open Gap Penalty: 10.0; Extend Gap Penalty: 5.0; 
Pairwise Alignment Mode: Slow). The corresponding phylogenetic tree was constructed 
from the alignment using the non-TD pathway related CPA synthase-like hypothetical 
gene Riv7116_4841 from Rivularia sp. PCC 7116 (accession no.: CP003549.1) as an 
outgroup for rooting (Best Tree Mode; Tree Building Method: Neighbor Joining; 
Distance: Tajima-Nei). 
Retrofitting and conjugation of cosmid clones into S. albus. Each cosmid clone 
containing the TD pathway (e.g. AB1650, AB1091) was digested with AanI and ligated 
with the 6.8 kb DraI fragment from the E. coli/Streptomyces shuttle vector pOJ436. This 
fragment contains the origin of transfer (oriT), apramycin resistance marker, and the 
Streptomyces ϕC31 integration system (115). The retrofitted pathways were each 
transformed into S. albus by conjugation with E. coli S17.1 using published methods 
(115). Exconjugants were selected on mannitol soy flour medium (MS) using an 
apramycin (25 μg/mL) and naladixic acid (25 μg/mL) overlay. Successful exconjugants 
were re-struck on MS plates and grown for an additional 5 days before harvesting spores. 
Isolation and purification of AB1650 specific metabolites. Tryptone soya broth 
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(Oxoid) seed cultures grown for 18 h at 30 °C (200 rpm) were used to inoculate 8 liters of 
R5A media (3). After 12 days (30 °C, 200 rpm) the entire culture was extracted with 2 
volumes of ethyl acetate. The resulting crude extract was partitioned by silica gel flash 
chromatography using a CHCl3:MeOH step gradient. Compounds 1 and 3 - 6 were 
purified from the 99:1 (CHCl3:MeOH) fraction using reversed phase HPLC (linear 
gradient from 55:45 H2O:MeOH to 30:70 H2O:MeOH over 30 min, XBridge C18, 150 X 
10 mm, 5 µm). Compound 1 (21.5 mg) eluted with 36:64 H2O:MeOH. Compound 4 (12.7 
mg) eluted with 45:55 H2O:MeOH. Compound 6 (3.9 mg) eluted with 48:52 
H2O:MeOH. Compounds 3 (1.8 mg) and 5 (5.3 mg) co-eluted with 42:58 H2O:MeOH and 
were separated from each other using an isocratic (48:52 H2O:MeOH) HPLC step. NMR 
data was recorded on a 600-MHz spectrometer (Bruker). HRMS data was obtained using 
Thermo LTQ-Orbitrap mass spectrometer (Rockefeller University). Analytical LC/MS 
data was recorded on a Waters Micromass ZQ instrument. 
Transposon mutagenesis. A library of transposon mutants was generated using the 
HyperMu <KAN-1> insertion kit from Epicentre following the manufacturer’s protocol. 
Transposon insertions were located by single pass sequencing (MCLAB) using a 
transposon-specific primer (Epicentre). S. albus recombinants harboring AB1650 
cosmids containing transposon insertions in individual genes of interest were grown in 
R5A media (2 liters) as described above. Ethyl acetate extracts from these cultures were 
initially fractioned by silica gel flash chromatography using the methods outlined above. 
Compound 2 (2.9 mg), compound 7 (1.6 mg) and compound 8 (1.9 mg) eluted with 99:1 
CHCl3:MeOH fractions and were purified by reversed phase HPLC using 65:35, 60:40, 
and 70:30 H2O:CH3CN isocratic conditions, respectively. HRMS data was obtained using 
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a Waters LCT Premier XE mass spectrometer (Sloan-Kettering Institute). 
Bioactivity assays. For cytotoxicity assays against bacteria and yeast, overnight cultures 
(37°C, 200 rpm) were diluted 10-6 fold and arrayed as 100 μl aliquots into sterile 96 well 
microtiter plates. An ampicillin control and compounds resuspended in dimethylsulfoxide 
(DMSO) were added at an initial concentration of 25 μg/mL (or 50 μg/mL in some cases) 
and serially diluted 2-fold across the plate such that the final concentrations were 25, 13, 
6.3, 3.1, 1.6, 0.78, 0.39, 0.20, 0.098, 0.049, 0.024, 0.012 μg/mL. A DMSO control was 
similarly diluted across one row of the plate. Plates were incubated at 30 °C for 24 hr. 
The lowest concentration with no observable growth (OD < 0.05) is reported as the 
minimum inhibitory concentration (MIC) for each metabolite. 
 For cytotoxicity assay against human colon tumor cell line HCT116 (ATCC: 
CCL-247), the cells were grown in McCoy’s 5A Media (modified, Invitrogen) 
supplemented with 10% fetal bovine serum and 1% (w/v) Penicillin/Streptomycin (37 °C 
with 5% CO2). Cells were seeded as 100 μl aliquots into sterile 96 well plates at 
approximately 1,000 cells per plate and incubated for 24 hr before adding compounds. A 
DMSO control and compounds resuspended in DMSO were dissolved in fresh media and 
added to the cells at final concentrations of 50, 25, 13, 6.3, 3.1, 1.6, 0.78, 0.39, 0.20, 
0.098, 0.049, 0.024 μg/mL and grown for additional 72 hr. The cell density in each well 
was then determined with a crystal violet assay (262). Briefly, the cells were washed with 
phosphate buffered saline and fixed with 4% formaldehyde in phosphate buffered saline 
(10 min, 24 °C). After an additional wash with phosphate buffered saline, the cells were 
stained with 0.1% (w/v) filtered crystal violet solution (30 min, 24 °C), washed with 
water and air-dried. 10% acetic acid was added to the stained cells to extract the dye and 
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the absorbance at 590 nm was measured using a microplate spectrophotometer (Epoch, 
BioTek). The normalized absorbance values were plotted and curve fitted using 
Graphpad Prism to determine the half maximal inhibitory concentrations (IC50). 
BorR expression. BorR was PCR amplified from AB1091 using Phusion polymerase 
(New England Biolabs) and the following primer pair: BorR-F: 
GAGACATATGAAGACTCTGCCGGGTCG, BorR-R: 
GAGATTAATTAACTACCGCGCTTCTCGGAG (NdeI and PacI sites added for cloning 
are shown in italics; Table 3). PCR cycling conditions: 1 cycle of 98°C for 1 min; 40 
cycles of 98°C for 10 sec, 63°C for 25 sec, 72°C for 1 min 30 sec; 1 cycle of 72°C for 7 
min; 4°C hold. NdeI/PacI digested PCR product was cloned into NdeI/PacI digested 
pIJ10257. (263). This construct was then moved by conjugation into S. albus harboring 
the bor pathway and resulting exconjugants were selected using hygromycin (100 
μg/mL). Successful exconjugants were re-struck on MS plates and grown for an 
additional 5 days before harvesting spores. 
Borregomycin production and isolation. S. albus AB1091 spore stocks (both with and 
without the pIJ10257 borR expression construct) were used to inoculate 50 mL aliquots 
of R5A media (57) in 200 mL baffled flasks (10 liters total). After 12 days (30°C, 200 
rpm) the cultures were pooled and extracted with 2 volumes of ethyl acetate. The 
resulting crude extract was dried in vacuo, dissolved in 90:10 methanol:water and then 
partitioned with hexane, methylene chloride, and ethyl acetate using modified Kupchan 
scheme (264). The methylene chloride fraction was separated by silica gel RediSep flash 
chromatography (RediSepRf 12 gram silica flash column: 5 min 100% hexane, 35 min 
linear gradient from 100% hexanes to 100% ethyl acetate, 5 min of 100% ethyl acetate). 
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Compounds 9 and 14 co-eluted with the 75:25 hexanes:ethyl acetate fraction, 10 eluted 
with the 70:30 hexanes:ethyl acetate fraction, 11 eluted with the 65:35 hexanes:ethyl 
acetate fraction, 12 eluted with the 60:40 hexanes:ethyl acetate fraction and 13 eluted 
with the 10:90 hexanes:ethyl acetate fraction. Compounds were purified from these 
fractions using isocratic reversed phase HPLC (XBridge C18, 150 X 10 mm, 5 μm). 9 
(0.7 mg) and 14 (0.7 mg) were separated from each other using 62:38 methanol:water. 10 
(1.4 mg) was purified using 65:35 methanol:water. 11 (1.8 mg) was purified using 57:43 
methanol:water. 12 (0.6 mg) was purified using 50:50 methanol:water. 13 (0.5 mg) was 
purified using 52:48 methanol:water. Analytical LC/MS data was recorded on a 
Micromass ZQ instrument (Waters). NMR data was obtained using a 600-MHz 
spectrometer (Bruker). HRMS data was acquired using a LCT Premier XE mass 
spectrometer (Waters) at the Sloan Kettering Institute Analytical Core Facility and LTQ-
Orbitrap mass spectrometer (Thermo Scientific) at the Rockefeller University Proteomics 
Resource Center. Specific rotation was measured using P-1020 Polarimeter (Jasco). 
KinaseProfiler assay. Compounds were submitted to EMD Millipore to determine their 
inhibitory activity against a panel of kinases (KinaseProfiler) and for IC50 (IC50Profiler) 
measurements. Radiometric and homogenous time-resolved fluorescence (HTRF) based 
methods were used to measure the incorporation of phosphate into the substrate in the 
presence of the compound for protein and lipid kinase assays, respectively. The activity 
values were normalized against readings taken in the absence of any added compound. 
Please refer to the EMD Millipore website (www.millipore.com) for additional protocol 
details. 
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Synthetic refactoring of the esp gene cluster. The biosynthetic genes from the esp gene 
cluster in cosmid clone AB339 were amplified using the manufacturer’s recommended 
Phusion Hot Start Flex DNA polymerase reaction conditions (New England Biolabs). 
PCR primers are listed in Table 3. PCR cycling conditions were as follows: 1 cycle of 
95°C for 5 min; 30 cycles of 95°C for 10 sec, 62°C for 30 sec, 72°C for 30 sec/kb; 1 
cycle of 72°C for 7 min; 4°C hold. The resulting amplicons were digested and cloned into 
the following Duet vectors: EspM NdeI/MfeI site of pCDFDuet-1; EspX NcoI/HindIII 
site of pCDFDuet-1; EspO NcoI/HindIII site of pCOLADuet-1; EspD NdeI/MfeI site of 
pCOLADuet-1; EspP NcoI/HindIII site of pETDuet-1. 
Induced expression analysis of refactored esp gene cluster. Electrocompetent E. coli 
BL21 cells were transformed with constructs containing various combinations of esp 
genes, grown in LB medium in the presence of the appropriate antibiotics (spectinomycin 
100 µg/mL; kanamycin 30 µg/mL; ampicillin 100 µg/mL) and induced at OD600 of 0.5 by 
the addition of IPTG to a final concentration of 0.1 mM. After growth for between 6 and 
36 h (200 rpm, 25 °C), the culture was extracted with ethyl acetate and dried in vacuo. 
Upon resuspension in methanol, the samples were subjected to reversed phase LC/MS 
analysis (150 X 4.6 mm, 5 µm XBridge C18: linear gradient of 80:20 water:methanol to 
0:100 water:methanol). Analytical LC/MS was obtained using Micromass ZQ mass 
spectrometer (Waters). 
Isolation and purification of the erdasporines. For compound 15, 2 liters of EspODPM 
expressing E. coli BL21 culture was grown for 12 hr (200 rpm, 25 °C) after IPTG 
induction.  The culture was pelleted by centrifugation (10 min, 4000 X g, 25 °C) and the 
resulting supernatant was added to 2 liters of EspX expressing E. coli BL21 culture that 
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had been grown for 15 minutes after IPTG induction. The combined culture was then 
grown for 6 hr (200 rpm, 25 °C) before extraction with 2 volumes of ethyl acetate. 
For compounds 16 and 17, 2 liters of EspODPM expressing E. coli BL21 culture 
grown for 12 hr (compound 16) or 36 hr (compound 17) after IPTG induction was 
extracted with 2 volumes of ethyl acetate. 
Organic extracts were separated by silica gel RediSep flash chromatography 
(RediSepRf 12 gram silica flash column: 3 min 100% chloroform, 27 min linear gradient 
from 100% chloroform to 90:10 chlorofom:methanol). Compound 16 eluted with 99:1, 
17 eluted with 96:4 and 15 eluted with 95:5. Compounds 15-17 were purified from these 
fractions using isocratic reserved phase HPLC (150 X 10 mm, 5 µm XBridge C18). 16 
(2.3 mg) was purified using 64:38 water:acetonitrile.  17 (1.1 mg) was purified using 
68:32 water:acetonitrile. Compound 15 was first fractionated using 70:30 
water:acetonitrile and subsequently purified (0.4 mg) using silica gel flash 
chromatography (0.5 gram of Silica Gel 60 packed in a glass pipette) with an isocratic 
70:30 hexane:ethyl acetate mobile phase. HRMS data was obtained using a LTQ-Orbitrap 
mass spectrometer (Thermo Scientific). NMR data was acquired using a 600-MHz 
spectrometer (Bruker). Specific rotation was measured using a P-1020 Polarimeter 
(Jasco). 
Induced expression analysis of eDNA-derived Group F clusters. The pathway-specific 
methyltransferase and monooxygenase genes from the Group F clusters found in cosmid 
clones AB234, AB1149, NM1499 and AB1521 were amplified using the same PCR 
reaction and cycling conditions that was done for clone AB339 amplification reactions. 
PCR primers are listed in Table 3.  The methyltransferase and the monooxygenase 
 119 
amplicons were cloned into the NdeI/MfeI or NcoI/HindIII sites of pCDFDuet-1, 
respectively. 
The heterologous expression was conducted in a similar manner to that used to 
study the esp gene cluster. Briefly, 25 mL of each methyltransferase/EspODP co-
expressing E. coli BL21 culture was grown for 12 hr after IPTG induction.  This culture 
was pelleted by centrifugation and the resulting supernatant was added to 25 mL of a 
monooxygenase expressing E. coli BL21 culture that had been grown for 15 minutes after 
IPTG induction. The cultures were then grown for an additional 6 hr and then extracted 
with ethyl acetate.  Extracts were subjected to reversed phase LC/MS analysis as 
described above. 
Cloning of genes from the mar and violacein (vio) gene clusters. Individual genes were 
amplified from the mar and vio clusters using clones NM343 and CSL51 (155) as 
templates, respectively, using Phusion Hot Start Flex DNA polymerase kit (New England 
Biolabs).  Primers are shown in Table 3.  PCR cycling conditions: 1 cycle of 95°C for 5 
min; 30 cycles of 95°C for 10 sec, 62°C for 30 sec, 72°C for 30 sec/kb; 1 cycle of 72°C 
for 7 min; 4°C hold.  Gel purified amplicons were restriction digested and cloned into the 
following Duet (Novagen) vectors: MarB NcoI/SalI sites of pCOLADuet-1; MarC 
NcoI/HindIII sites of pETDuet-1; MarE NdeI/KpnI sites of pETDuet-1; MarM NcoI/SalI 
sites of pCDFDuet-1; VioA NdeI/MfeI sites of pCOLADuet-1; VioB NcoI/HindIII sites 
of pCOLADuet-1; VioE NdeI/KpnI sites of pETDuet-1. 
Heterologous expression of mar and vio biosynthetic genes. For expression studies, 
electrocompetent E. coli BL21 cells were transformed with Duet vectors harboring 
various combinations of mar and vio biosynthetic genes and grown in LB medium with 
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required antibiotic combination for selection (30 µg/mL kanamycin, 100 μg/mL 
ampicillin, 100 μg/mL spectinomycin).  Gene expression was induced in cultures grown 
to an OD600 of 0.5 with the addition of IPTG (final concentration of 0.1 mM).  Thirty-six 
hours (200 rpm, 25 °C) post induction, the cultures were extracted with ethyl acetate that 
was acidified to pH ~3-4 with the addition of hydrochloric acid. Extracts dried in vacuo 
were dissolved in methanol and subjected to reversed phase LC/MS analysis (150 X 4.6 
mm, 5 µm XBridge C18: linear gradient of 80:20 water:methanol to 0:100 
water:methanol with 0.1% formic acid). Commercially available methylarcyriarubin (i.e. 
Bisindolylmaleimide V, Santa Cruz Biotechnology), arcyriarubin A (i.e. 
Bisindolylmaleimide IV, Santa Cruz Biotechnology), and indole-3-pyruvic acid (Sigma-
Aldrich) were run on the LC/MS, under the same conditions. Because chromopyrrolic 
acid and prodeoxyviolacein were not commercially available, these standards were 
prepared from the heterologous expression of well-defined biosynthetic genes from the 
violacein pathway. Chromopyrrolic acid and prodexoyviolacein were produced from 
VioAB and VioABE expressing E. coli cultures, respectively.  They were each purified 
from culture broth extracts by HPLC using conditions based on previous violacein 
pathway studies (94, 163, 164). Analytical LC/MS data was acquired using Micromass 
ZQ mass spectrometer (Waters). 
Large-scale production and isolation of methylarcyriarubin (21) from E. coli 
cultures expressing mar genes. Cultures of VioA + MarBCEM expressing E. coli BL21 
cells (2 liters) grown for 36 hr (200 rpm, 25 °C) after IPTG induction was extracted with 
ethyl acetate (4 liters). This extract was initially fractionated by silica gel RediSep flash 
chromatography (RediSepRf 12 gram silica flash column: 3 min 100% chloroform, 27 
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min linear gradient from 100% chloroform to 85:15 chlorofom:methanol). Compound 21 
eluted with 99:1 chloroform:methanol.  Compound 21 was then purified (1.6 mg/L) from 
the 99:1 fraction by 65:35 water:acetonitrile isocratic reserved phase HPLC (150 X 10 
mm, 5 µm XBridge C18). LTQ-Orbitrap mass spectrometer (Thermo Scientific) and 600-
MHz spectrometer (Bruker) were used to acquire HRMS and NMR data, respectively, for 
structure elucidation studies. 
MarE protein expression analysis. A liquid culture (100 mL) of E. coli harboring 
vioE/pETDuet-1 was grown to an OD600 of 0.5. The culture was subsequently split into 
two, with one uninduced and the other induced with the addition of IPTG (final 
concentration of 0.1 mM).  Two hours (200 rpm, 37 °C) post induction, an aliquot (1 mL) 
was removed from each culture and the cells were pelleted by centrifugation (1 min, 
13,000 X g). The cells were resuspended in native purification buffer (200 μL; 0.5 M 
NaCl, 50 mM NaH2PO4, pH 8.0) and lysed by sonication (30 cycles of 1 sec pulse on and 
2 sec pulse off, 45% amplitude; Sonic Dismembrator, Fisher Scientific). The cell debris 
and the insoluble proteins were collected by centrifugation (15 min, 13,000 X g, 4 °C). 
Aliquots (20 μL) of the supernatant were mixed with SDS loading buffer (50 mM Tris-
HCl pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, 0.02% 
bromophenol blue), heated (10 min, 95 °C) and run on a polyacrylamide gel (4-20% 
Mini-PROTEAN TGX Gel with Precision Plus Protein Dual Color Standards, Bio-Rad).  
Gels were stained with coomassie (Coomassie Brilliant Blue R-250 Staining Solution, 
Bio-Rad) and imaged using Gel Doc XR+ System (Bio-Rad). 
Reagents and strains for resistant mutant screening. The multidrug resistance-
suppressed (MDR-sup) S. pombe, SAK84 and SAK690, and the MDR-active S. pombe 
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SAK1, from which MDR-sup S. pombe was derived, were generously provided by Dr. 
Tarun M. Kapoor (Laboratory of Chemistry and Cell Biology, The Rockefeller 
University). The genotypes (265) of these strains are listed in Table 4. The 
indolotryptoline-based compounds, BE-54017 and cladoniamide A, were isolated from 
Streptomyces albus harboring the abe gene cluster, as described previously. Bafiolomycin 
A1, concanamycin A, and brefeldin A were purchased from a commercial supplier (Santa 
Cruz Biotechnology). 
Schizosaccharomyces pombe whole-cell cytotoxicity assay. Freshly struck multidrug 
resistance-suppressed (MDR-sup) S. pombe SAK84 was inoculated into liquid YE4S 
media and grown (30˚C, 300 rpm) to log phase (OD595 = 0.5). The culture was diluted 50-
fold and distributed as 100 µl aliquots into a sterile 96 well microtiter plate. BE-54017 or 
cladoniamide A resuspended in DMSO were added to the first well at the initial 
concentration of 0.50 µg/ml and were serially diluted 2-fold across the plate (final 
concentrations 0.50, 0.25, 0.13, 0.063, 0.031, 0.016, 0.0078, 0.0039, 0.0020, 0.0010, 
0.00050, 0.00025 µg/ml). A compound-free DMSO control was similarly diluted across 
the plate. After outgrowth (36 hr, 30˚C, 300 rpm), the absorbance (OD595) of each well 
was measured using a microplate reader (Epoch Microplate Spectrophotometer; BioTek). 
Using Graphpad Prism, the normalized absorbance values were plotted and curve-fitted 
to determine the half maximal inhibitory concentration (IC50) for each indolotryptoline. 
The same method (using different initial drug concentrations) was used to determine 
IC50s for bafilomycin A1, concanamycin A and brefeldin A against resistant and non-
mutant strains. 
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Selection of indolotryptoline resistant S. pombe mutants. 20 ml of log phase S. pombe 
SAK84 was pelleted by centrifugation (3000 x g, 3 min) and resuspended in TM buffer 
(50 mM Tris, 50 mM maleic acid, 7.5 mM (NH4)2SO4, 0.4 mM MgSO4, pH6.0) 
containing 50 µg/ml methylnitronitrosoguanidine (NTG) to randomly mutagenize the 
genome. After 30 min at 32˚C (250 rpm), the mutagenized cells was pelleted, washed 
twice with 10 ml sterile water, resuspended in 20 ml fresh YE4S, and allowed to recover 
for 3 hr (32˚C, 250 rpm). The culture was adjusted to OD595 = 0.5 and 150 µl aliquots 
were spread onto YE4S plates containing different concentrations of the indolotryptolines. 
After 72 hr at 32˚C, resistant clones were picked from plates containing either ~10 (BE-
54017: 0.031 µg/ml; cladoniamide A: 0.078 µg/ml) or ~50 (BE-54017: 0.016 µg/ml; 
cladoniamide A: 0.039 µg/ml) colonies. Each strain was then re-assessed for 
indolotryptoline resistance and cross-resistance to brefeldin A using the whole-cell 
cytotoxicity assay described above.  
Backcrossing of indolotryptoline resistant mutants. Resistant strains were crossed 
with non-mutant MDR-sup strain SAK690, which only differs in genetic background 
from SAK84 by having a different mating type (h-). Both resistant and non-mutant S. 
pombe strains grown on YE4S plates were resuspended in water to produce suspensions 
with an OD595 = ~1. These were mixed in equal volumes and 10 µl aliquots were spotted 
onto an SPA plate. After 40 hr at 25˚C, the mixture was struck onto a YE4S plate. Using 
a dissecting microscope/micromanipulator (Axioskop 40, Zeiss), zygotic asci (mating 
products), were isolated from the YE4S plate and incubated (37˚C, 6 hr) to permit native 
digestion of the ascus wall. The four spores from each zygotic ascus were then separated 
and individually grown on YE4S plate (30˚C, 5 days). The resulting colonies were tested 
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for resistance to indolotryptolines and resistant colonies were used in subsequent rounds 
of backcrossing. For additional rounds of backcrossing, the progeny that retained 
resistance were crossed, depending on its mating type, with either SAK84 or SAK690. 
Whole-genome sequencing and bioinformatics. Backcrossed mutants were grown in 
YE4S and genomic DNA was isolated from these cultures using zymolyase treatment 
followed by phenol/chloroform extraction (266). Genomic DNA from six resistant 
mutants and two non-mutant strains (SAK84 and SAK690) was sequenced at the 
Rockefeller University Genomics Resource Center using Illumina HiSeq 2000 
technology (50 bp single-end, ~150 million reads in total). Reads from resistant mutants 
were compared to non-mutant samples to identify resistant mutant specific somatic 
mutations that altered the wildtype amino acid sequence with > 4x coverage and >50% 
mutation allele frequency. In brief, the variant detection pipeline consisted of the 
mapping of Illumina reads to the S. pombe genome (193) using BWA, removal of 
duplicates, indel-based realignment using GATK, base quality score recalibration, 
mutation calling for single nucleotide variant using GATK Unified Genotyper, and 
annotation using SnpEff (Sloan Kettering Bioinformatics Core). 
PCR sequencing of V-ATPase proteolipid subunit genes. A fresh colony of each 
resistant strain that was not sequenced by HiSeq was resuspended in 0.2% SDS and 
heated at 95°C for 10 min. One µl of this crude cell lysate was used as template in PCR 
reactions designed to amplify the vma3, vma11 and zhf1 genes (Phusion Hot Start Flex 
DNA polymerase kit, New England Biolabs). Primers are shown in Table 3. PCR cycling 
conditions: 1 cycle of 95°C for 2 min; 30 cycles of 95°C for 10 sec, 58°C for 30 sec, 
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72°C for 30 sec/kb; 1 cycle of 72°C for 7 min; 4°C hold. The resulting amplicons were 
sequenced from both ends using the same set of primers that were used for PCR.  
Targeted mutagenesis of S. pombe genome. Vma3 or vma11 specific recombination 
cassettes containing point mutations of interest were amplified from the appropriate 
resistant mutant using the same Phusion Hot Start Flex PCR conditions described 
previously. Primers were designed (Table 3) to generate amplicons with ~500 bp 
homology arms flanking each side of the point mutation of interest. The PCR cassette 
was introduced into SAK84 by lithium acetate-assisted transformation (266). The 
transformation reaction was spread onto YE4S plates containing defined concentrations 
of indolotryptoline to select for strains conferring drug resistance. The acquisition of drug 
resistance and point mutation were confirmed by whole-cell cytotoxicity assay and PCR 
sequencing, respectively. 
V-ATPase activity assay by acidic organelle staining. Log phase S. pombe was added 
to fresh indolotryptoline containing media (final concentrations = 0.50, 0.25, 0.13, 0.063, 
0.031, 0.016, 0.0078, 0.0039 µg/ml) to give 5 ml cultures with OD595 = 0.15. These 
cultures were grown at 30°C for 1 hr, pelleted (2 min, 3000 x g) and washed with YE4S 
buffered with 50 mM MOPS (pH 7.6). The cell pellet was then resuspended in buffered 
YE4S containing 200 µM quinacrine and staining was allowed to proceed at room 
temperature for 10 min. After washing with buffered YE4S, the samples were 
resuspended in the same media and transferred to an 8-chambered coverglass. Cells were 
imaged at the Rockefeller University Bio-Imagining Resource Center under a fluorescent 
microscope using 100x objective lens with DIC optics for Nomarski imaging or with 
FITC filter set for quinacrine visualization (DeltaVision Image Restoration Microscope 
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System with Olympus IX-70 base microscope, Applied Precision). A minimal inhibitory 
concentration (MIC) was defined as the dose at which the formation of fluorescent puncta 
was inhibited in >95% of the cells. 
Mapping of resistance-conferring residues onto a V-ATPase structure. The 
Enterococcus hirae Na+-ATPase proteolipid subunit, NtpK (PDB ID: 2bl2), was imaged 
using PyMOL. A CLUSTALW alignment of the S. pombe V-ATPase proteolipid 
subunits Vma3 and Vma11 and NtpK was created to map residues between proteins from 
the two organisms. Residues that confer resistance to indolotryptoline and 
plecomacrolide compounds were identified in NtpK based on this alignment. Side chains 
for resistance conferring residues were converted to those seen in wildtype Vma3 or 
Vma11 and then represented as colored sticks on the NtpK structure. 
TD diversity analysis from crude eDNA. Topsoil was collected from 20 distinct sites in 
New Mexico. Crude eDNA was extracted from each sample using the same initial 
protocol as described for eDNA library construction. However, instead of purifying 
HMW eDNA by gel electrophoresis, crude eDNA was cleaned with two rounds of 
column based purification (PowerClean DNA Clean-Up Kit, MO-BIO). 
For crude eDNA screening, the forward primer of the degenerate primer (StaDV-F) was 
modified at the 5’ end to permit the direct 454 sequencing (Roche) of amplicons from all 
20 samples simultaneously. Forward primers each contained a 454 sequencing adapter 
tag (CGTATCGCCTCCCTCGCGCCATCAG), followed by a unique 8 base pair barcode 
for each soil sample and then the StaDV-F degenerate sequence.  A unique StaDV-
F/StaDV-R pair was then used to amplify CPA synthase gene fragments from each soil 
sample.  Each 20 µL PCR reaction consisted of 8.3 µL of water, 10 µL of FailSafe PCR 
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Buffer D (Epicentre), 0.5 µL each of modified StaDV-F and StaDV-R primers (final 
concentration of 2.5 µM each), 0.5 µL of template crude eDNA (100 ng) and 0.2 µL Taq 
DNA polymerase (New England Biolabs). PCR cycling conditions were as follows: 1 
cycle of 95°C for 5 min; 30 cycles of 95°C for 30 sec, 59°C for 30 sec, 72°C for 40 sec; 1 
cycle of 72°C for 7 min; 4°C hold. Amplicons of the correct size (561 base pairs) were 
gel purified and processed for single-end read sequencing using the 454 GS-GLX 
Titanium platform at the Sloan Kettering Institute DNA Sequencing Core Facility. 
The raw reads were initially processed using the Qiime software suite (version 
1.6) which utilizes size cutoff, quality cutoff, insertion/deletion removal and chimera 
removal filters to retain only high quality reads.   Only reads with lengths >500 base pairs 
were retained and they were subsequently trimmed to 450 base pairs (from the 3’ end 
where sequencing errors occur most frequently).  Reads were then clustered at 95% 
identity and only the amplicon sequences that were populated with more than 30 reads 
from a single soil sample were retained for phylogenetic analysis. Consensus amplicons 
that were either unrelated to CPA synthase genes or were potentially chimeric based on 
BLASTX homology searches (NCBI) were also removed, leaving 31 sequences for 
analysis (Appendix 7). 
A ClustalW alignment was performed on these 31 amplicon sequences plus all 
known full-length CPA synthase genes using MacVector version 12.0.3 (Open Gap 
Penalty: 10.0; Extend Gap Penalty: 5.0; Pairwise Alignment Mode: Slow).  Using this 
alignment as a guide, full-length CPA synthase genes were trimmed to match the 450 bp 
amplicon sequences and a final phylogenetic tree was constructed using the hypothetical 
gene Riv7116_4841 as an outgroup for rooting (Best Tree Mode; Tree Building Method: 
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Neighbor Joining; Distance: Tajima-Nei). This tree was reformatted to a circular display 
using iTOL.  
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Table 3. PCR primer list. Underlined sequences indicate the restriction sites added for 
ligation. 
Gene Sequence 
StaDV-F  GTSATGMTSCAGTACCTSTACGC 
StaDV-R YTCVAGCTGRTAGYCSGGRTG 
BorR-F GAGAcatATGAAGACTCTGCCGGGTCG 
BorR-R GAGAttaattaaCTACCGCGCTTCTCGGAG 
EspM-F  GAGAcatATGACTTGGAGCCCAGGAATG 
EspM-R  GAGAcaattgGCCATTGTGGTCATCGCG 
EspX-F  GAGAacatgtctATGGTGCATGACGTTGACGTG 
EspX-R  GAGAaagcttCTCATCCCACCTCACTGAAG 
EspO-F GAGAccatggcaATGAGGTGGGATGAGGCG 
EspO-R  GAGAgcggccgcCACTCATCACGACACCTCC 
EspD-F  GAGAcatATGAGTGTTTTTGATCTGCCCC 
EspD-R  GAGAcaattgCGTCATTGTTCGTCCTCGG 
EspP-F  GAGAtcatgatcATGACGCAGCGCGGTACA 
EspP-R  GAGAaagcttCGTTCACAGCGGATCGAC 
234M-F GAGAcatATGACAGAACAGCGGCTGAC 
234M-R GAGAcaattgTCTCAAGCCGTCTTGACCTC 
234X-F GAGAacatgtctATGAAGTTCGACGTTGACGTGC 
234X-R GAGAaagcttTCACGTCCACCACTCTTTTTCG 
1149M-F GAGAcatATGGATGACACCAACCAGCAAAC 
1149M-R GAGAcaattgATTGCTTCGCGGGTGATGC 
1149X-F GAGAacatgtctATGAAACACGACGTCGATGTCC 
1149X-R GAGAaagcttCGATGGGTATTCGAGCCG 
1499M-F GAGAcatATGACATCCGGACCCGATC 
1499M-R GAGAcaattgTTGGATGGTCGGCGGTCA 
1499X-F GAGAacatgtctATGCAAGACGACGTGGAAGTG 
1499X-R GAGAaagcttGGTGGAAGATCAGCAAGCC 
1521M-F GAGAcatATGGACGACACCAACCAGC 
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1521M-R GAGAcaattgTGGGTGACACGGGTACGA 
1521X-F GAGAacatgtctATGGAAACCCCAGACGTTGATG 
1521X-R GAGAaagcttCTTCATGGCAGTCTCCTTGC 
MarB-F GAGAccatggcaATGAGCATCCTGGAATTTCCGC 
MarB-R  GAGAgtcgacCCTCACAAGAGTGGAACGG 
MarC-F  GAGAtcatgatcATGCTGAGCGCCGAAGACA 
MarC-R  GAGAaagcttCTCATGCGGTCTCCTTGC 
MarE-F  GAGAcatATGAGCGCCGCCCGC 
MarE-R  GAGAggtaccGAGGATTGTTGGTCTGCTGAC 
MarM-F GAGAacatgtctATGACAACTCAGGGAACGCC 
MarM-R GAGAgtcgacGCTCAGCGTTCTTTCGTGC 
VioA-F GAGAcatATGACAAACTATTCCGACATTTGC 
VioA-R GAGAcaattgGGAAATCCAGAATGCTCATGC 
VioB-F GAGAccatggcaATGAGCATTCTGGATTTCCCC 
VioB-R GAGAaagcttTGCATATCAAGCCTCTCTAGAC 
VioE-F GCGCcatATGCCGATGCCTGTCCAC 
VioE-R GCGCggtaccCACAAACGGAACAGGACTCAGT 
seq-vma3-F CGACATTGTAAAAGCCAGCT 
seq-vma3-R TCCCACCATAGAGATTCTC 
seq-vma11-F CAACGAAATACTACATCGACA 
seq-vma11-R TGATTAGCCTTAGAGAAAGTC 
seq-zhf1-F ATATAGCAAGTTTGCGCCTC 
seq-zhf1-R GTGACACAATAGATTAACCACG 
mut-vma3-F CGATACGACATTGTAAAAGCC 
mut-vma3-R CGTGAAGTACATGCTTATACG 
mut-vma11-F AGAACTTGTGCCAAAAGTCC 
mut-vma11-R GCCTTAGAGAAAGTCAACAAG 
mut-zhf1-F TTGTGGTAAACGCGATTAGTG 
mut-zhf1-R CTAACGAGAAGAATCAAACC 
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Table 4. Schizosaccharomyces pombe strain list. 
Name Genotype 
SAK1 h+; ade6-M210 leu1 ura4-D18 
SAK84 
h+; ade6 leu1 pap1::kanr bfr1::hygr pmd1::natr caf5::kanr mfs1::natr erg5* 
dnf2* 
SAK690 
h-; ade6 leu1 pap1::kanr bfr1::hygr pmd1::natr caf5::kanr mfs1::natr erg5* 
dnf2* 
* indicates frameshift mutation 
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Appendix 
Appendix 1: Tryptophan dimer gene cluster annotation 
AB1650 gene cluster (A/N: JF439215) 
 
 
 
 
 
 
 
 
 
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  
1	   M2	   230	   methyltransferase type 11	   49/60	   Saccharopolyspora erythraea 
NRRL 2338	  
2	   X1	   533	   PheA/TfdB family FAD-binding 
monooxygenase	   36/50	   Pseudomonas fluorescens Pf-5	  
3	   M1	   231	   methyltransferase type 12	   35/49	   Actinosynnema mirum DSM 
43827	  
4	   D	   1015	   chromopyrrolic acid synthase 
RebD	   52/66	   Lechevalieria aerocolonigenes	  
5	   X2	   407	   monooxygenase FAD-binding 
protein	   53/66	   Stackebrandtia nassauensis DSM 44728	  
6	   M3	   336	   O-methyltransferase, family 
protein 2	   49/65	   Mycobacterium smegmatis str. MC2 155	  
7	   H	   515	   tryptophan 6-halogenase KtzR	   64/77	   Kutzneria sp. 744	  
8	   T	   412	   cation/H+ antiporter	   45/58	   Streptomyces bingchenggensis 
BCW-1	  
9	   F	   160	   flavin reductase KtzS	   57/66	   Kutzneria sp. 744	  
10	   Y	   264	   alpha/beta hydrolase	   47/58	   Amycolatopsis mediterranei U32	  
11	   O	   513	   L-amino acid oxidase StaO	   53/70	   Streptomyces sp. TP-A0274	  
12	   C	   533	   putative monooxygenase RebC	   57/70	   Lechevalieria aerocolonigenes	  
13	   P	   392	   cytochrome P450	   56/69	   Salinispora arenicola CNS-205	  
14	   R	   932	   ATP-dependent transcription 
regulator LuxR	   36/51	   Salinispora arenicola CNS-205	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AB1091 gene cluster (A/N: JX827455) 
  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  	  	  1	   R	   958	   putative	  regulatory	  protein	   42/56	   Actinomadura	  melliaura	  2	   P	   421	   putative	  cytochrome	  P450	  enzyme	   45/59	   Actinomadura	  melliaura	  3	   D	   1096	   chromopyrrolic	  acid	  synthase	   60/71	   Streptomyces	  uncialis	  4	   O	   480	   tryptophan	  2-­‐monooxygenase	   55/66	   Streptomyces	  venezuelae	  ATCC	  10712	  5	   T1	   174	   ABC	  transporter,	  ATP-­‐binding	  protein	   32/48	   Streptomyces	  griseoflavus	  Tu4000	  6	   T2	   258	   ABC	  transporter	  ATP-­‐binding	  protein	   36/51	   Streptomyces	  scabiei	  87.22	  7	   F	   196	   flavin	  reductase	  domain-­‐containing	  protein	   59/71	   Salinispora	  tropica	  CNB-­‐440	  8	   H	   529	   putative	  tryptophan	  halogenase	   71/82	   Streptomyces	  sp.	  Tu6071	  9	   M1	   248	   methyltransferase	   60/72	   Streptomyces	  uncialis	  10	   C	   538	   monooxygenase	   60/72	   Streptomyces	  sp.	  TP-­‐A0274	  11	   X2	   417	   flavin	  monooxygenase	   61/72	   Streptomyces	  uncialis	  12	   Y1	   153	   hypothetical	  protein	   33/50	   Microlunatus	  phosphovorus	  NM-­‐1	  13	   Y2	   104	   monooxygenase	  (low	  homology)	   35/52	   Streptomyces	  hygroscopicus	  subsp.	  jinggangensis	  5008	  14	   T3	   721	   drug	  exporter	  of	  the	  RND	  superfamily-­‐like	  protein	   58/72	   Modestobacter	  marinus	  15	   X3	   411	   cytochrome	  P450	   46/63	   Frankia	  sp.	  EUN1f	  	   	   	   	   	   	  16	   X1	   555	   flavin	  monooxygenase	   58/67	   Streptomyces	  uncialis	  17	   M2	   242	   methyltransferase	   45/59	   Streptomyces	  uncialis	  18	   M3	   520	   O-­‐methyltransferase	   50/63	   Saccharomonospora	  azurea	  NA-­‐128	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AB339 gene cluster (A/N: KF551865) 
 
 
 
 
 
AB234 gene cluster (A/N: KF551864) 
 
 
 
 
 
AB1149 gene cluster (A/N: KF551867) 
 
 
 
 
 
 
 
  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  1	   M	   347	   O-­‐methyltransferase	   64/75	   Kutzneria	  sp.	  744	  2	   X	   553	   FAD-­‐binding	  monooxygenase	   64/74	   Kutzneria	  sp.	  744	  3	   O	   515	   tryptophan	  2-­‐monooxygenase	  	   57/71	   Streptomyces	  venezuelae	  ATCC	  10712	  4	   D	   1105	   chromopyrrolic	  acid	  synthase	  StaD	  	   62/71	   Streptomyces	  sp.	  TP-­‐A0274	  5	   P	   421	   cytochrome	  P450	  StaP	   56/69	   Streptomyces	  longisporoflavus	  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  1	   M	   352	   O-­‐methyltransferase	   53/70	   Streptomyces	  tubercidicus	  2	   X	   550	   FAD-­‐binding	  monooxygenase	   54/66	   Streptomyces	  venezuelae	  ATCC	  10712	  3	   O	   499	   tryptophan	  2-­‐monooxygenase	  	   57/72	   Streptomyces	  venezuelae	  ATCC	  10712	  4	   D	   1104	   chromopyrrolic	  acid	  synthase	  StaD	  	   61/70	   Streptomyces	  sp.	  TP-­‐A0274	  5	   P	   468	   cytochrome	  P450	   54/66	   Salinispora	  arenicola	  CNS-­‐205	  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  1	   M	   339	   O-­‐methyltransferase	   63/76	   Kutzneria	  sp.	  744	  2	   X	   542	   FAD-­‐binding	  monooxygenase	   64/74	   Kutzneria	  sp.	  744	  3	   Y	   120	   hypothetical	  protein	   35/50	   Actinoplanes	  friuliensis	  DSM	  7358	  4	   O	   531	   tryptophan	  2-­‐monooxygenase	  	   56/71	   Streptomyces	  venezuelae	  ATCC	  10712	  5	   D	   1100	   chromopyrrolic	  acid	  synthase	  StaD	  	   60/70	   Streptomyces	  sp.	  TP-­‐A0274	  6	   P	   423	   cytochrome	  P450	  StaP	   58/70	   Streptomyces	  sp.	  TP-­‐A0274	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AB1521 gene cluster (A/N: KF551869)  
 
 
 
 
 
 
 
 
 
 
 
 
NM1499 gene cluster (A/N: KF551861) 
 
 
 
 
 
 
 
 
 
 
AR1973 gene cluster (A/N: KF551873) 
 
 
  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  1	   M	   340	   O-­‐methyltransferase	   60/70	   Kutzneria	  sp.	  744	  2	   X	   548	   FAD-­‐binding	  monooxygenase	   61/72	   Kutzneria	  sp.	  744	  3	   Y	   122	   hypothetical	  protein	   33/50	   Actinoplanes	  friuliensis	  DSM	  7358	  4	   O	   535	   tryptophan	  2-­‐monooxygenase	  	   57/70	   Streptomyces	  venezuelae	  ATCC	  10712	  5	   D	   1205	   chromopyrrolic	  acid	  synthase	  StaD	  	   61/69	   Streptomyces	  sp.	  TP-­‐A0274	  6	   P	   427	   cytochrome	  P450	  StaP	   55/68	   Salinispora	  arenicola	  CNS-­‐205	  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  1	   O	   515	   tryptophan	  2-­‐monooxygenase	  	   59/71	   Streptomyces	  venezuelae	  ATCC	  10712	  2	   D	   1096	   chromopyrrolic	  acid	  synthase	  StaD	  	   56/67	   Streptomyces	  sp.	  TP-­‐A0274	  3	   P	   407	   cytochrome	  P450	  StaP	   55/65	   Streptomyces	  sp.	  TP-­‐A0274	  4	   M	   337	   O-­‐methyltransferase	   55/69	   Kutzneria	  sp.	  744	  5	   X	   525	   FAD-­‐binding	  monooxygenase	   61/73	   Kutzneria	  sp.	  744	  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  1	   X	   346	   FAD-­‐binding	  monooxygenase	  (truncated)	   51/60	   Kutzneria	  sp.	  744	  2	   O	   536	   tryptophan	  2-­‐monooxygenase	  	   56/69	   Streptomyces	  venezuelae	  ATCC	  10712	  3	   D	   1091	   chromopyrrolic	  acid	  synthase	  StaD	  	   59/72	   Kutzneria	  sp.	  744	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NM343 gene cluster (A/N: KF551863) 
 
 
 
 
 
 
 
 
 
 AR1455 gene cluster (A/N: KF551872) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AB1350 gene cluster (A/N: KF551868) 
  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  1	   M	   351	   hydroxyneurosporene-­‐O-­‐methyltransferase	   52/67	   Synechococcus	  sp.	  PCC	  6312	  2	   B	   1142	   chromopyrrolic	  acid	  synthase	  StaD	  	   44/57	   Streptomyces	  sp.	  TP-­‐A0274	  3	   C	   445	   Rieske	  (2Fe-­‐2S)	  domain-­‐containing	  protein	   49/64	   Pusillimonas	  noertemannii	  4	   E	   198	   prodeoxyviolacein	  synthase	  VioE	   46/60	   Pseudoalteromonas	  sp.	  520P1	  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  	  	  1	   N2	   85	   cytochrome	  P450	  	   61/74	   Nonomuraea	  longicatena	  2	   C	   545	   monooxygenase	   76/85	   Streptomyces	  purpureus	  3	   MB	   277	   methyltransferase	   75/86	   Streptomyces	  purpureus	  4	   E	   207	   epimerase	   74/85	   Streptomyces	  sp.	  TP-­‐A0274	  5	   I	   369	   aminotransferase	   82/89	   Amycolatopsis	  orientalis	  6	   K	   73	   ketoreductase	   61/78	   Streptomyces	  sp.	  TP-­‐A0274	  7	   K	   273	   ketoreductase	   70/78	   Streptomyces	  sp.	  TP-­‐A0274	  8	   J	   473	   dehydratase	   75/85	   Amycolatopsis	  decaplanina	  9	   MA	   272	   methyltransferase	   64/74	   Streptomyces	  sp.	  TP-­‐A0274	  10	   P	   410	   cytochrome	  P450	   62/72	   Streptomyces	  sanyensis	  11	   D	   1025	   chromopyrrolic	  acid	  synthase	   65/73	   Streptomyces	  sp.	  TP-­‐A0274	  12	   MA	   500	   tryptophan	  oxidase	   71/84	   Streptomyces	  sp.	  TP-­‐A0274	  13	   G	   433	   glycosyltransferase	   75/85	   Salinispora	  arenicola	  14	   N	   407	   cytochrome	  P450	   83/89	   Streptomyces	  purpureus	  15	   R1	   677	   transcriptional	  regulator	   41/55	   Streptomyces	  uncialis	  16	   R2	   357	   transcriptional	  regulator	   48/58	   Streptomyces	  uncialis	  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  	  	  1	   G	   410	   N-­‐glycosyltransferase	   79/83	   Lechevalieria	  aerocolonigenes	  2	   O	   477	   L-­‐tryptophan	  oxidase	   86/91	   Lechevalieria	  aerocolonigenes	  3	   D	   1096	   chromopyrrolic	  acid	  synthase	   80/87	   Lechevalieria	  aerocolonigenes	  4	   C	   529	   monooxygenase	   80/85	   Lechevalieria	  aerocolonigenes	  5	   P	   397	   P450	  protein	   80/85	   Lechevalieria	  aerocolonigenes	  6	   M	   273	   methyltransferase	   82/91	   Lechevalieria	  aerocolonigenes	  7	   R	   924	   regulatory	  protein	   67/76	   Lechevalieria	  aerocolonigenes	  8	   F	   170	   flavin	  reductase	   81/88	   Lechevalieria	  aerocolonigenes	  9	   U	   420	   integral	  membrane	  transporter	   74/84	   Lechevalieria	  aerocolonigenes	  10	   H	   530	   tryptophan	  halogenase	   85/91	   Lechevalieria	  aerocolonigenes	  11	   T	   468	   integral	  membrane	  transporter	   82/86	   Lechevalieria	  aerocolonigenes	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AB857 gene cluster (A/N: KF551866) 
 
 
AB1533 gene cluster (A/N: KF551870)  
  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  	  	  1	   R	   875	   transcriptional	  regulator	   43/58	   Actinomadura	  melliaura	  2	   F	   190	   flavin	  reductase	   63/72	   Lechevalieria	  aerocolonigenes	  3	   U	   426	   PyrJ1	  membrane	  transporter	   52/67	   Streptomyces	  rugosporus	  4	   H1	   530	   tryptophan	  halogenase	  RebH	   75/85	   Lechevalieria	  aerocolonigenes	  5	   G	   412	   glycosyltransferase	   63/73	   Lechevalieria	  aerocolonigenes	  6	   O	   490	   tryptophan	  oxidase	   69/82	   Lechevalieria	  aerocolonigenes	  7	   D	   1093	   chromopyrrolic	  acid	  synthase	   61/73	   Kutzneria	  albida	  DSM	  43870	  8	   C	   40	   FAD-­‐monooxygenase	   70/85	   Kutzneria	  albida	  DSM	  43870	  9	   P	   410	   cytochrome	  P450	   58/70	   Kutzneria	  albida	  DSM	  43870	  10	   H2	   512	   tryptophan	  halogenase	   74/83	   Streptomyces	  sp.	  FxanaC1	  11	   Z	   214	   hypothetical	  protein	   37/54	   Cyanobacterium	  PCC	  7702	  12	   M1	   273	   methyltransferase	  RebM	   62/76	   Lechevalieria	  aerocolonigenes	  13	   X1	   253	   cytochrome	  P450	  hydroxylase	   53/63	   Saccharopolyspora	  spinosa	  14	   X2	   130	   cytochrome	  P450	  hydroxylase	   52/66	   Arthrobacter	  globiformis	  15	   M2	   123	   glyoxalase	  resistance	   76/84	   Arthrobacter	  crystallopoietes	  16	   M2	   343	   methyltransferase	   45/59	   Streptomyces	  davawensis	  JCM	  4913	  17	   Y	   285	   aldo/keto	  reducatse	   72/82	   Mycobacterium	  parascrofulaceum	  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  	  	  1	   M1	   281	   methyltransferase	  RebM	   50/63	   Lechevalieria	  aerocolonigenes	  2	   R	   908	   transcriptional	  regulator	   38/52	   Actinomadura	  melliaura	  3	   F	   178	   flavin	  reductase	   54/70	   Lechevalieria	  aerocolonigenes	  4	   H1	   530	   tryptophan	  halogenase	  RebH	   75/86	   Lechevalieria	  aerocolonigenes	  5	   G	   434	   glycosyltransferase	   60/72	   Lechevalieria	  aerocolonigenes	  6	   O	   489	   tryptophan	  oxidase	   63/76	   Lechevalieria	  aerocolonigenes	  7	   D	   1093	   chromopyrrolic	  acid	  synthase	   55/68	   Kutzneria	  albida	  DSM	  43870	  8	   C	   538	   FAD-­‐monooxygenase	   57/67	   Actinomadura	  melliaura	  9	   P	   425	   cytochrome	  P450	   49/63	   Salinispora	  arenicola	  10	   H2	   515	   tryptophan	  halogenase	   68/79	   Streptomyces	  sp.	  FxanaC1	  11	   Z1	   191	   hypothetical	  protein	   36/55	   Calothrix	  sp.	  PCC	  7103	  12	   Z2	   195	   putative	  SWIM	  Zn-­‐finger	   39/50	   Rhodococcus	  qingshengii	  13	   E	   637	   SNF2	  related	  domain	  helicase	   56/67	   Salinispora	  arenicola	  14	   M2	   355	   methyltransferase	   44/57	   Streptomyces	  lavendulae	  15	   T1	   508	   MFS	  transporter	   38/58	   Kutzneria	  sp.	  744	  16	   R2	   146	   MarR	  trancriptional	  regulator	   59/72	   Actinoalloteichus	  spitiensis	  17	   T2	   456	   ion	  antiporter	   57/71	   Amycolatopsis	  alba	  18	   I	   275	   indole-­‐3-­‐glycerol-­‐phosphate	  synthase	   55/63	   Streptomyces	  albulus	  19	   L	   447	   phospho-­‐2-­‐dehydro-­‐3-­‐deoxyheptonate	  aldolase	   72/79	   Saccharopolyspora	  spinosa	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NM747 gene cluster (A/N: KF551862)  
 
 
 
AR2194 gene cluster (A/N: KF551874)  
  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  	  	  1	   X	   415	   cytochrome	  P450	   59/71	   Streptomyces	  sulphureus	  2	   N	   407	   cytochrome	  P450	  StaN	   51/70	   Salinispora	  pacifica	  3	   G	   381	   glycosyltransferase	   64/75	   Salinispora	  pacifica	  4	   M1	   129	   methyltransferase	   63/71	   Salinispora	  pacifica	  5	   M2	   127	   methyltransferase	   77/86	   Streptomyces	  purpureus	  6	   D	   1092	   chromopyrrolic	  acid	  synthase	   63/74	   Kutzneria	  albida	  DSM	  43870	  7	   C1	   546	   flavin	  monooxygenase	   57/66	   Streptomyces	  uncialis	  8	   O	   502	   tryptophan	  oxidase	   59/72	   Streptomyces	  sp.	  TP-­‐A0274	  9	   C2	   538	   FAD-­‐binding	  monooxygenase	   62/72	   Streptomyces	  purpureus	  10	   P	   438	   cytochrome	  P450	   54/67	   Kutzneria	  albida	  DSM	  43870	  11	   I	   158	   indole-­‐3-­‐glycerol-­‐phosphate	  synthase	   69/81	   Promicromonospora	  sukumoe	  12	   R	   805	   transcriptional	  regulator	   38/52	   Nonomuraea	  longicatena	  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  	  	  1	   R	   903	   transcriptional	  regulator	   45/56	   Lechevalieria	  aerocolonigenes	  2	   F	   198	   flavin	  reductase	   63/71	   Lechevalieria	  aerocolonigenes	  3	   H1	   530	   tryptophan	  halogenase	  RebH	   78/87	   Lechevalieria	  aerocolonigenes	  4	   T	   466	   transporter	   55/72	   Saccharothrix	  espanaensis	  DSM	  44229	  5	   G	   440	   glycosyltransferase	   66/76	   Lechevalieria	  aerocolonigenes	  6	   O	   485	   tryptophan	  oxidase	   67/79	   Lechevalieria	  aerocolonigenes	  7	   D	   1109	   chromopyrrolic	  acid	  synthase	   63/74	   Kutzneria	  albida	  DSM	  43870	  8	   C	   533	   FAD-­‐monooxygenase	   66/76	   Lechevalieria	  aerocolonigenes	  9	   P	   416	   cytochrome	  P450	   59/72	   Actinomadura	  melliaura	  10	   H2	   512	   tryptophan	  halogenase	   75/84	   Streptomyces	  sp.	  FxanaC1	  11	   Z	   218	   hypothetical	  protein	   32/48	   Calothrix	  sp.	  PCC	  7103	  12	   I	   380	   aminotransferase	   66/77	   Amycolatopsis	  rifamycinica	  13	   J	   439	   CalS14	  dehydratase	   56/66	   Micromonospora	  echinospora	  14	   M	   329	   methyltransferase	   53/64	   Streptomyces	  davawensis	  JCM	  4913	  15	   Y	   356	   glucose-­‐1-­‐phosphate	  thymidylyltransferase	   67/79	   Streptomyces	  coelicoflavus	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AR654 gene cluster (A/N: KF551871) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
N Gene 
Size 
(aa) Homolog 
ID/SM 
(%) Origin	  	  	  1	   R	   905	   transcriptional	  regulator	   42/57	   Nonomuraea	  longicatena	  2	   P	   401	   cytochrome	  P450	   68/77	   Nonomuraea	  longicatena	  3	   C	   529	   FAD-­‐monooxygenase	  InkE	   72/79	   Nonomuraea	  longicatena	  4	   D	   995	   chromopyrrolic	  acid	  synthase	   64/72	   Nonomuraea	  longicatena	  5	   O	   496	   tryptophan	  oxidase	   69/78	   Nonomuraea	  longicatena	  6	   G	   438	   glycosyltransferase	   67/75	   Nonomuraea	  longicatena	  7	   N	   404	   cytochrome	  P450	   79/84	   Nonomuraea	  longicatena	  8	   M1	   378	   methyltransferase	   69/81	   Nonomuraea	  longicatena	  9	   X1	   394	   cytochrome	  P450	  hydroxylase	   81/88	   Nonomuraea	  longicatena	  10	   X2	   399	   cytochrome	  P450	  hydroxylase	   49/61	   Nonomuraea	  longicatena	  11	   M2	   297	   methyltransferase	   65/73	   Nonomuraea	  longicatena	  12	   X3	   413	   cytochrome	  P450	   40/55	   Bradyrhizobium	  japonicum	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Appendix 2: Compound spectral data summary 
BE-54017 A (1): [α]18D -364 (c 0.1, methanol); UV (methanol) λmax 209, 243, 320 (sh), 
350, 373 nm; 1H NMR (600 MHz, acetone-d6) δ2.97 (3H, s, H3-14), 4.09 (3H, s, H3-15), 
4.18 (3H, s, H3-16), 6.40 (1H, bs, OH-4c), 6.67 (1H, bs, OH-7a), 7.16 (1H, t, J = 7.2 Hz, 
H-10), 7.26 (1H, m, H-2), 7.27 (1H, m, H-9), 7.52 (1H, d, J = 8.7 Hz, H-1), 7.73 (1H, d, J 
= 8.0 Hz, H-11), 8.09 (1H, d, J = 2.0 Hz, H-4), 8.23 (1H, d, J = 8.5 Hz, H-8); 13C NMR 
(150 MHz, acetone-d6) δ25.3 (C-14), 34.1 (C-16), 62.8 (C-15), 75.6 (C-4c), 87.7 (C-7a), 
104.6 (C-4b), 112.4 (C-1), 114.7 (C-12a), 116.7 (C-8), 118.9 (C-11), 121.0 (C-4), 121.3 
(C-10), 123.4 (C-11a), 123.7 (C-2), 125.0 (C-9), 127.0 (C-4a), 127.2 (C-3), 132.9 (C-
12b), 137.8 (C-7c), 138.1 (C-12), 139.3 (C-13a), 171.7 (C-7), 174.7 (C-5); HR-ESI-MS 
m/z 452.1019 [M+H]+ (calcd for C23H19N3O5Cl, 452.1013). 
Cladoniamide A (2): [α]18D -331 (c 0.1, methanol); UV (methanol) λmax 212, 238, 328 
(sh), 349, 370 nm; 1H NMR (600 MHz, acetone-d6) δ2.94 (3H, s, H3-14), 4.11 (3H, s, H3-
15), 6.40 (1H, bs, OH-4c), 6.73 (1H, bs, OH-7a), 7.10 (1H, t, J = 7.6 Hz, H-10), 7.13 
(1H, dd, J = 8.6, 2.0 Hz, H-2), 7.21 (1H, t, J = 7.5 Hz, H-9), 7.45 (1H, d, J = 8.6 Hz, H-
1), 7.69 (1H, d, J = 8.0 Hz, H-11), 8.02 (1H, d, J = 1.6 Hz, H-4), 8.19 (1H, d, J = 8.5 Hz, 
H-8), 10.93 (1H, bs, NH-13); 13C NMR (150 MHz, acetone-d6) δ24.4 (C-14), 62.0 (C-
15), 75.8 (C-4c), 87.9 (C-7a), 103.7 (C-4b), 113.9 (C-1), 114.8 (C-12a), 116.5 (C-8), 
118.9 (C-11), 120.8 (C-4), 121.3 (C-10), 122.8 (C-11a), 123.5 (C-2), 124.5 (C-9), 126.7 
(C-3), 127.5 (C-4a), 130.2 (C-12b), 137.6 (C-7c), 138.1 (C-12), 138.4 (C-13a), 171.7 (C-
7), 174.5 (C-5); HR-ESI-MS m/z 438.0844 [M+H]+ (calcd for C22H17N3O5Cl, 438.0778). 
BE-54017 B (3): UV (methanol) λmax 224, 278, 297, 360 nm; 1H NMR (600 MHz, 
acetone-d6) δ2.76 (3H, d, J = 4.5 Hz, H3-14), 4.21 (3H, s, H3-16), 4.22 (3H, s, H3-15), 
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6.00 (1H, bs, OH-4c), 7.24 (1H, dd, J = 8.8, 2.0 Hz, H-2), 7.38 (1H, t, J = 7.3 Hz, H-10), 
7.45 (1H, t, J = 7.3 Hz, H-9), 7.54 (1H, d, J = 8.8 Hz, H-1), 7.77 (1H, d, J = 1.8 Hz, H-4), 
7.81 (1H, d, J = 7.8 Hz, H-11), 8.04 (1H, bs, NH-6), 8.50 (1H, d, J = 8.2 Hz, H-8); 13C 
NMR (150 MHz, acetone-d6) δ27.2 (C-14), 34.6 (C-16), 63.2 (C-15), 78.0 (C-4c), 103.7 
(C-4b), 113.4 (C-1), 117.8 (C-8), 118.2 (C-12a), 120.6 (C-11), 120.8 (C-4), 124.8 (C-2), 
126.2 (C-10), 126.8 (C-11a), 127.3 (C-4a), 127.4 (C-3), 128.7 (C-9), 130.7 (C-12b), 
136.3 (C-7c), 140.1 (C-13a), 141.4 (C-12), 170.2 (C-7a), 171.4 (C-5); HR-ESI-MS m/z 
424.1048 [M+H]+ (calcd for C22H19N3O4Cl, 424.1064). 
BE-54017 C (4): UV (methanol) λmax 224, 259, 286, 309, nm; 1H NMR (600 MHz, 
acetone-d6) δ2.76 (3H, d, J = 4.5 Hz, H3-14), 4.22 (3H, s, H3-15), 4.36 (3H, s, H3-16), 
6.93 (1H, bs, OH-7a), 7.15 (1H, t, J = 7.5 Hz, H-10), 7.28 (1H, t, J = 7.7 Hz, H-9), 7.37 
(1H, dd, J = 8.7, 2.1 Hz, H-2), 7.66 (1H, d, J = 8.7 Hz, H-1), 7.70 (1H, d, J = 8.4 Hz, H-
8), 7.82 (1H, d, J = 8.0 Hz, H-11), 7.96 (1H, bs, NH-6), 8.11 (1H, d, J = 2.0 Hz, H-4); 13C 
NMR (150 MHz, acetone-d6) δ26.5 (C-14), 34.6 (C-16), 63.1 (C-15), 87.1 (C-7a), 107.2 
(C-4b), 113.2 (C-1), 114.3 (C-8), 115.2 (C-12a), 120.5 (C-11), 120.7 (C-4), 121.6 (C-10), 
122.8 (C-11a), 125.1 (C-2), 126.3 (C-9), 126.8 (C-4a), 129.6 (C-3), 138.9 (C-7c), 139.5 
(C-13a), 140.6 (C-12), 143.3 (C-12b), 168.5 (C-7) 184.7 (C-4c); HR-ESI-MS m/z 
424.1068 [M+H]+ (calcd for C22H19N3O4Cl, 424.1064). 
BE-54017 D (5): UV (methanol) λmax 210, 245, 323 (sh), 352, 376 nm; 1H NMR (600 
MHz, acetone-d6) δ2.95 (3H, s, H3-14), 4.07 (3H, s, H3-15), 4.18 (3H, s, H3-16), 6.30 
(1H, bs, OH-4c), 6.60 (1H, bs, OH-7a), 7.15 (1H, t, J = 7.1 Hz, H-10), 7.16 (1H, t, J = 7.1 
Hz, H-3), 7.25 (1H, t, J = 7.7 Hz, H-9), 7.28 (1H, t, J = 7.7 Hz, H-2), 7.50 (1H, d, J = 8.3 
Hz, H-1), 7.71 (1H, d, J = 7.9 Hz, H-11), 8.07 (1H, d, J = 8.0 Hz, H-4), 8.22 (1H, d, J = 
 142 
8.5 Hz, H-8); 13C NMR (150 MHz, acetone-d6) δ25.2 (C-14), 33.8 (C-16), 62.7 (C-15), 
75.9 (C-4c), 87.8 (C-7a), 105.1 (C-4b), 110.9 (C-1), 115.2 (C-12a), 116.6 (C-8), 118.8 
(C-11), 121.7 (C-3), 121.2 (C-10), 121.8 (C-4), 123.6 (C-11a), 123.9 (C-2), 124.7 (C-9), 
126.2 (C-4a), 131.5 (C-12b), 137.5 (C-12), 137.7 (C-7c), 140.8 (C-13a), 171.8 (C-7), 
174.6 (C-5); HR-ESI-MS m/z 418.1383 [M+H]+ (calcd for C23H20N3O5, 418.1403). 
BE-54017 E (6): UV (methanol) λmax 226, 261, 288, 312 nm; 1H NMR (600 MHz, 
acetone-d6) δ2.75 (3H, d, J = 4.5 Hz, H3-14), 4.21 (3H, s, H3-15), 4.35 (3H, s, H3-16), 
7.14 (1H, t, J = 7.4 Hz, H-10), 7.26 (1H, t, J = 7.6 Hz, H-9), 7.31 (1H, t, J = 7.4 Hz, H-3), 
7.38 (1H, t, J = 7.5 Hz, H-2), 7.62 (1H, d, J = 8.2 Hz, H-1), 7.68 (1H, d, J = 8.4 Hz, H-8), 
7.80 (1H, d, J = 8.0 Hz, H-11), 7.91 (1H, bs, NH-6), 8.15 (1H, d, J = 7.7 Hz, H-4); 13C 
NMR (150 MHz, acetone-d6) δ26.5 (C-14), 34.3 (C-16), 63.1 (C-15), 87.1 (C-7a), 107.9 
(C-4b), 111.6 (C-1), 114.3 (C-8), 115.7 (C-12a), 120.3 (C-11), 121.6 (C-10), 121.7 (C-4), 
123.0 (C-11a), 124.2 (C-3), 125.2 (C-2), 125.8 (C-4a), 126.0 (C-9), 138.8 (C-7c), 140.1 
(C-12), 141.0 (C-13a), 142.3 (C-12b), 168.8 (C-7) 184.7 (C-4c); HR-ESI-MS m/z 
390.1457 [M+H]+ (calcd for C22H20N3O4, 390.1454).  
BE-54017 F (7): 1H NMR (600 MHz, DMSO-d6) δ7.37 (1H, t, J = 7.6 Hz, H-9), 7.57 
(1H, t, J = 7.6 Hz, H-10), 7.58 (1H, d, J = 8.2 Hz, H-2), 7.83 (1H, d, J = 8.2 Hz, H-11), 
7.87 (1H, d, J = 8.6 Hz, H-1), 8.98 (1H, bs, NH-6), 8.99 (1H, m, H-8), 9.00 (1H, m, H-4) 
11.07 (1H, bs, NH-12) 11.08 (1H, bs, NH-13); 13C NMR (150 MHz, DMSO-d6) δ112.1 
(C-11), 113.8 (C-1), 114.4 (C-7b), 115.8 (C-4b), 119.8 (C-4c), 120.3 (C-7a), 120.3 (C-9), 
121.5 (C-7c), 122.7 (C-4a), 123.2 (C-4), 124.2 (C-3), 124.3 (C-8), 126.4 (C-2), 126.9 (C-
10), 129.2 (C-12a), 129.9 (C-12b), 138.9 (C-13a), 140.4 (C-11a), 171.3 (C-7), 171.4 (C-
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5); HR-ESI-MS m/z 390.1457 [M+H]+ (calcd for C22H20N3O4, 390.1454). HR-ESI-MS m/z 
358.0385 [M-H]-(calcd for C20H9N3O2Cl, 358.0462). 
BE-54017 G (8): 1H NMR (600 MHz, acetone-d6) δ2.96 (3H, s, H3-14), 4.19 (3H, s, H3-
16), 5.44 (1H, bs, OH-4c), 5.46 (1H, bs, OH-7a), 7.13 (1H, t, J = 7.5 Hz, H-3), 7.13 (1H, 
t, J = 7.5 Hz, H-9), 7.17 (1H, t, J = 7.5 Hz, H-10), 7.22 (1H, t, J = 7.6 Hz, H-2), 7.47 (1H, 
d, J = 8.0 Hz, H-1), 7.47 (1H, d, J = 8.0 Hz, H-11), 8.19 (1H, d, J = 8.0 Hz, H-4), 8.19 
(1H, d, J = 8.0 Hz, H-8), 10.77 (1H, bs, NH-12); 13C NMR (150 MHz, acetone-d6) δ25.3 
(C-14), 31.9 (C-16), 77.6 (C-4c), 77.6 (C-7a), 109.3 (C-4b), 110.2 (C-1), 110.8 (C-7b), 
112.5 (C-11), 121.2 (C-3), 121.3 (C-9), 122.5 (C-8), 122.6 (C-4), 123.1 (C-2), 123.4 (C-
10), 127.4 (C-12a), 127.6 (C-4a), 127.8 (C-7c), 129.4 (C-12b), 138.9 (C-11a), 139.5 (C-
13a), 176.0 (C-7), 176.2 (C-5); HR-ESI-MS m/z 410.1119 [M+H]+ (calcd for 
C22H17N3O4Na, 410.1117). 
Borregomycin A (9): [α]18D +443 (c 0.097, DMSO); UV (MeOH) λmax 275, 302, 365; 1H 
NMR (600 MHz, DMSO-d6) δ2.87 (3H, s, H3-14), 3.62 (3H, s, H3-15), 3.64 (3H, s, H3-
16), 7.09 (1H, dd, J = 8.3, 1.6 Hz, H-10), 7.12 (1H, dd, J = 8.4, 1.8 Hz, H-3), 7.44 (1H, d, 
J = 1.6 Hz, H-1), 7.45 (1H, d, J = 1.6 Hz, H-8), 7.65 (1H, d, J = 8.2 Hz, H-11), 7.71 (1H, 
d, J = 8.4 Hz, H-4), 7.72 (1H, brs, OH-12a), 11.84 (1H, brs, H-13); 13C NMR (150 MHz, 
DMSO-d6) δ24.7 (C-14), 54.0 (C-15), 54.4 (C-16), 79.7 (C-4c), 85.7 (C-12a), 91.6 (C-
7a), 105.7 (C-4b), 112.1 (C-1), 115.4 (C-8), 118.5 (C-11a), 120.9 (C-3), 121.6 (C-10), 
122.0 (C-4), 122.7 (C-4a), 126.4 (C-11), 128.1 (C-2), 133.3 (C-12b), 137.7 (C-13a), 
143.4 (C-9), 157.0 (C-7c), 167.0 (C-5), 171.3 (C-7), 194.4 (C-12); HR-ESI-MS 
m/z500.0403 [M-H]- (calcd for C23H16N3O6Cl2, 500.0416).  
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Borregomycin B (10): UV (MeOH) λmax 230, 256, 272 (sh), 347 (sh), 364, 386; 1H NMR 
(600 MHz, acetone-d6) δ3.02 (3H, s, H3-14), 3.41 (6H, s, H3-15/H3-16), 7.16 (2H, dd, J = 
8.6, 1.7 Hz, H-3/H-9), 7.52 (2H, d, J = 1.6 Hz, H-1/H-11), 8.09 (2H, d, J = 8.6 Hz, H-
4/H-8), 10.97 (2H, brs, H-12/H-13); 13C NMR (150 MHz, acetone-d6) δ25.4 (C-14), 54.7 
(C-15/C-16), 82.0 (C-4c/C-7a), 108.4 (C-4b/C-7b), 112.4 (C-1/C-11), 122.1 (C-3/C-9), 
124.0 (C-4/C-8), 126.4 (C-4a/C-7c), 128.9 (C-2/C-10), 129.3 (C-12a/C-12b), 138.8 (C-
11a/C-13a), 174.1 (C-5/C-7); HR-ESI-MS m/z 468.0518[M-H]- (calcd for C23H16N3O4Cl2, 
468.0518). 
Borregomycin C (11): [α]18D +149 (c 0.13, DMSO); UV (MeOH) λmax 230, 256, 272 
(sh), 347 (sh), 363, 384; 1H NMR (600 MHz, acetone-d6) δ2.95 (3H, s, H3-14), 3.13 (3H, 
s, H3-15), 5.75 (1H, brs, OH-7a), 7.15 (1H, dd, J = 8.6, 1.7 Hz, H-9), 7.18 (1H, dd, J = 
8.6, 1.7 Hz, H-3), 7.51 (1H, d, J = 1.5 Hz, H-11), 7.54 (1H, d, J = 1.5 Hz, H-1), 8.13 (1H, 
d, J = 8.6 Hz, H-3), 8.17 (1H, d, J = 8.5 Hz, H-8), 10.73 (1H, brs, H-12), 10.91 (1H, brs, 
H-13); 13C NMR (150 MHz, acetone-d6) δ25.5 (C-14), 53.5 (C-15), 77.8 (C-7a), 81.5 (C-
4c), 106.0 (C-4b), 111.8 (C-7b), 112.3 (C-11), 112.5 (C-1), 121.8 (C-9), 122.3 (C-3), 
123.5 (C-4), 124.2 (C-8), 126.5 (C-4a), 126.8 (C-7c), 127.3 (C-12a), 128.8 (C-10), 128.9 
(C-2), 131.3 (C-12b), 138.7 (C-13a), 138.9 (C-11a), 174.9 (C-5), 175.3 (C-7).HR-ESI-
MS m/z456.0494 [M+H]+ (calcd for C22H16N3O4Cl2, 456.0518). 
Borregomycin D (12): UV (MeOH) λmax 230, 256, 272 (sh), 347 (sh), 363, 384;1H NMR 
(600 MHz, acetone-d6) δ2.98 (3H, s, H3-14), 5.58 (2H, brs, OH-4c/OH-7a), 7.14 (2H, dd, 
J = 8.6, 1.7 Hz, H-3/H-9), 7.49 (2H, d, J = 1.6 Hz, H-1/H-11), 8.14 (2H, d, J = 8.6 Hz, H-
4/H-8), 10.76 (2H, brs, H-12/H-13); 13C NMR (150 MHz, acetone-d6) δ25.4 (C-14), 77.2 
(C-4c/C-7a), 110.1 (C-4b/C-7b), 112.3 (C-1/C-11), 121.8 (C-3/C-9), 123.7 (C-4/C-8), 
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126.9 (C-4a/C-7c), 128.6 (C-2/C-10), 128.4 (C-12a/C-12b), 138.7 (C-11a/C-13a), 175.9 
(C-5/C-7); HR-ESI-MS m/z442.0338 [M+H]+ (calcd for C21H14N3O4Cl2, 442.0361). 
Dichlorochromopyrrolic acid (13): UV (MeOH) λmax 227, 265, 330 (sh); 1H NMR (600 
MHz, acetone-d6) δ6.79 (2H, dd, J = 8.5, 1.8 Hz, H-3/H-9), 7.14 (2H, s, H-12a/H-12b), 
7.16 (2H, d, J = 8.5 Hz, H-4/H-8), 7.31 (2H, d, J = 1.6 Hz, H-1/H-11), 10.17 (2H, brs, H-
12/H-13), 10.78 (1H, brs, H-6); 13C NMR (150 MHz, acetone-d6) δ109.7 (C-4b/C-7b), 
111.7 (C-1/C-11), 119.8 (C-3/C-9), 121.9 (C-4/C-8), 124.0 (C-4c/C-7a), 125.3 (C-5/C-7), 
127.0 (C-2/C-10), 127.1 (C-12a/C-12b), 127.7 (C-4a/C-7c), 137.3 (C-11a/C-13a), 161.6 
(HOOC-5/HOOC-7); HR-ESI-MS m/z452.0193 [M-H]- (calcd for C22H12N3O4Cl2, 
452.0205). 
O-methyl borregomycin A (14): [α]18D +90 (c 0.13, DMSO); UV (MeOH) λmax 275, 
302, 365;1H NMR (600 MHz, DMSO-d6) δ2.85 (3H, s, H3-14), 3.01 (3H, s, OCH3-12a), 
3.34 (3H, s, H3-15), 3.72 (3H, s, H3-16), 7.14 (1H, dd, J = 8.5, 1.7 Hz, H-3),7.17 (1H, dd, 
J = 8.3, 1.7 Hz, H-10), 7.43 (1H, d, J = 1.7 Hz, H-1), 7.54 (1H, d, J = 1.8 Hz, H-8), 7.69 
(1H, d, J = 8.4 Hz, H-4), 7.71 (1H, d, J = 8.2 Hz, H-11), 12.01 (1H, brs, H-13); 13C NMR 
(150 MHz, DMSO-d6) δ24.7 (C-14), 51.7 (C-15), 54.3 (OH3C-12a), 54.7 (C-16), 79.7 (C-
12a), 89.7 (C-4c), 92.0 (C-7a), 106.3 (C-4b), 112.2 (C-1), 116.2 (C-8), 119.3 (C-11a), 
121.2 (C-3), 122.1 (C-4), 122.5 (C-10), 122.5 (C-4a), 126.4 (C-11), 128.6 (C-2), 131.3 
(C-12b), 137.9 (C-13a), 144.2 (C-9), 158.1 (C-7c), 166.5 (C-5), 171.2 (C-7), 194.4 (C-
12); HR-ESI-MS m/z 514.0574 [M-H]- (calcd for C24H18N3O6Cl2, 514.0573). 
Erdasporine A (15): UV (methanol) λmax 231 (sh), 312, 325, 370, 388; 1H NMR (600 
MHz, DMSO-d6) δ3.94 (3H, s, H3-15), 6.70 (1H, dd, J = 8.5, 1.6 Hz, H-3), 6.98 (1H, d, J 
= 1.2 Hz, H-1), 7.23 (1H, t, J = 7.6 Hz, H-9), 7.33 (1H, t, J = 7.6 Hz, H-10), 7.69 (1H, d, 
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J = 8.2 Hz, H-11), 8.17 (1H, d, J = 3.1 Hz, H-5), 8.28 (1H, d, J = 7.8 Hz, H-8), 8.59 (1H, 
d, J = 8.6 Hz, H-4), 9.22 (1H, brs, OH-2), 11.07 (1H, brs, NH-12), 11.17 (1H, brs, NH-
13), 12.64 (1H, brs, NH-6); 13C NMR (150 MHz, DMSO-d6) δ50.9 (C-15), 96.1 (C-1), 
108.7 (C-7b), 108.8 (C-3), 109.7 (C-4b), 111.0 (C-7), 111.6 (C-11), 115.2 (C-5), 117.1 
(C-4c), 117.9 (C-7a), 118.4 (C-4a), 119.2 (C-9), 120.3 (C-8), 122.8 (C-10), 123.4 (C-7c), 
125.0 (C-12a), 125.5 (C-4), 126.9 (C-12b), 137.8 (C-11a), 139.5 (C-13a), 154.2 (C-2), 
161.2 (C-14); HR-ESI-MS m/z 368.1024 [M-H]- (calcd for C22H14N3O3, 368.1035). 
Erdasporine B (16): UV (methanol) λmax 238 (sh), 311, 323, 364, 384; 1H NMR (600 
MHz, acetone-d6) δ3.99 (3H, s, H3-15), 7.23 (1H, t, J = 7.5 Hz, H-3), 7.28 (1H, t, J = 7.4 
Hz, H-9), 7.31 (1H, t, J = 7.2 Hz, H-2), 7.36 (1H, t, J = 7.5 Hz, H-10), 7.60 (1H, d, J = 
8.0 Hz, H-1), 7.66 (1H, d, J = 8.0 Hz, H-11), 8.27 (1H, s, H-5), 8.28 (1H, d, J = 8.2 Hz, 
H-8), 9.07 (1H, d, J = 8.1 Hz, H-4), 10.63 (1H, bs, NH-12), 10.86 (1H, brs, NH-13), 
11.86 (1H, brs, NH-6); 13C NMR (150 MHz, acetone-d6) δ51.3 (C-15), 111.3 (C-4b), 
111.4 (C-1), 111.7 (C-7b), 112.4 (C-11), 113.0 (C-7), 115.4 (C-5), 118.9 (C-4c), 119.8 
(C-7a), 120.0 (C-3), 120.5 (C-9), 121.3 (C-8), 123.7 (C-2), 124.3 (C-7c), 124.7 (C-12a), 
124.8 (C-10), 126.2 (C-4a), 126.4 (C-4), 130.9 (C-12b), 139.4 (C-11a), 139.5 (C-13a), 
162.1 (C-14); HR-ESI-MS m/z 354.1237 [M+H]+ (calcd for C22H16N3O2, 354.1243). 
Erdasporine C (17): [α]18D ±0 (c 0.1, methanol); UV (methanol) λmax 220 (sh), 293, 331, 
343, 359; 1H NMR (600 MHz, acetone-d6) δ3.65 (3H, s, H3-15), 5.94 (1H, s, H-7), 7.28 
(1H, t, J = 7.3 Hz, H-3), 7.32 (1H, t, J = 7.5 Hz, H-9), 7.46 (1H, m, H-2), 7.48 (1H, m, H-
10), 7.65 (1H, d, J = 8.1 Hz, H-1), 7.70 (1H, d, J = 8.1 Hz, H-11), 7.85 (1H, brs, NH-6), 
8.38 (1H, d, J = 7.9 Hz, H-8), 9.41 (1H, d, J = 7.9 Hz, H-4), 10.76 (1H, brs, NH-12), 
10.96 (1H, brs, NH-13); 13C NMR (150 MHz, acetone-d6) δ52.8 (C-15), 60.6 (C-7), 111.8 
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(C-1), 112.4 (C-11), 115.9 (C-7b), 117.5 (C-4b), 120.3 (C-4c), 120.4 (C-3), 120.9 (C-9), 
123.3 (C-8), 123.4 (C-7c), 124.3 (C-4a), 126.3 (C-10), 126.5 (C-2), 126.8 (C-4), 127.3 
(C-12b), 129.5 (C-12a), 131.8 (C-7a), 140.7 (C-11a), 140.9 (C-13a), 171.4 (C-14), 173.4 
(C-5); HR-ESI-MS m/z 370.1186 [M+H]+ (calcd for C22H16N3O3, 370.1192). 
Methylarcyriarubin (21): UV (methanol) λmax 227, 276, 377, 475; 1H NMR (600 MHz, 
DMSO-d6) δ3.05 (3H, s, H3-13), 6.63 (2H, t, J = 7.5 Hz, H-10), 6.80 (2H, d, J = 8.0 Hz, 
H-11), 6.97 (2H, t, J = 7.5 Hz, H-9), 7.37 (2H, d, J = 8.1 Hz, H-8), 7.75 (2H, s, H-5), 
11.66 (2H, bs, N-4);13C NMR (150 MHz, DMSO-d6) δ24.0 (C-13), 105.6 (C-6), 111.7 
(C-8), 119.3 (C-10), 120.9 (C-11), 121.6 (C-9), 125.3 (C-12), 127.1 (C-3), 129.1 (C-5), 
136.0 (C-7), 171.8 (C-2); HR-ESI-MS m/z 342.1237 [M-H]+ (calcd for C21H16N3O2, 
342.1243). 
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Appendix 3: 1-D NMR spectra 
 
 
1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 1 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 2 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 3 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 4 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 5 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 6 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 7 in DMSO-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 8 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 9 in DMSO-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 10 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 11 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 12 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 13 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 14 in DMSO-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 15 in DMSO-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 16 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 17 in acetone-
d6. 
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1H NMR (top, 600 MHz) and 13C NMR (bottom, 150 HMz) of compound 21 in DMSO-
d6. 
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Appendix 4: KinaseProfiler results 
 
A and B) KinaseProfiler results against 59 diverse disease-relevant kinases (A) and 
CaMKI-related kinases (B) (Millipore). Numbers represent percentage of kinase target 
activity in the presence of 10 µM of borrgeomycin A (9) or B (10) normalized aganst a 
no-compound control. C) IC50Profiler result for compound 1 against CaMKIIδ 
(Millipore). For IC50 determination the % residual activity data was curve fitted using 
Graphpad Prism. Error bar represents standard deviation where n=2. 
  
 
 
 
 
 
 
Kinase Target 
Borreogmycin A  
@ 10 µM 
CaMKIIβ(h) 51 
CaMKIIγ(h) 76 
CaMKIδ(h) 108 
CaMKIIδ(h) 26 
CaMKIV(h) 91 
PhKγ2(h) 98 
 
 
 
 log10 Concentration (µM)
A
ct
iv
ity
 (%
 C
on
tr
ol
)
-4 -3 -2 -1 0 1 2
0
50
100
150
Kinase Target 
Borrgomycin A 
@ 10 µM 
Borregomycin B  
 @ 10 µM 
Abl(h) 87 101 
ALK(h) 88 98 
AMPKα1(h) 86 102 
ASK1(h) 111 109 
Aurora-A(h) 78 79 
c-RAF(h) 108 97 
CaMKI(h) 45 100 
CDK1/cyclinB(h) 102 109 
CDK2/cyclinA(h) 99 104 
CDK6/cyclinD3(h) 105 114 
CDK7/cyclinH/MAT1(h) 98 105 
CDK9/cyclin T1(h) 113 108 
CHK1(h) 92 107 
CK1γ1(h) 94 111 
CK2α2(h) 98 86 
DRAK1(h) 107 113 
eEF-2K(h) 97 146 
EGFR(h) 106 133 
EphA5(h) 97 108 
EphB4(h) 102 92 
Fyn(h) 84 104 
GSK3β(h) 95 72 
IGF-1R(h) 104 67 
IKKα(h) 108 109 
IRAK4(h) 100 114 
JAK2(h) 101 125 
KDR(h) 123 104 
LOK(h) 95 116 
Lyn(h) 104 81 
MAPKAP-K2(h) 104 118 
MEK1(h) 98 108 
MKK7β(h) 135 106 
MLK1(h) 102 123 
Mnk2(h) 99 96 
MSK2(h) 86 104 
MST1(h) 101 117 
mTOR(h) 104 107 
NEK2(h) 95 94 
p70S6K(h) 117 116 
PAK2(h) 77 89 
PDGFRβ(h) 94 133 
Pim-1(h) 93 76 
PKA(h) 85 79 
PKBα(h) 94 122 
PKCα(h) 107 110 
PKCθ(h) 98 109 
PKG1α(h) 106 98 
Plk3(h) 100 104 
PRAK(h) 79 66 
ROCK-I(h) 107 111 
Rse(h) 89 90 
Rsk1(h) 92 106 
SAPK2a(h) 100 102 
SRPK1(h) 105 103 
TAK1(h) 95 91 
PI3KCα(h) 98 77 
PI3KCβ(h) 92 83 
PI3KCγ(h) 82 81 
PI3KCδ(h) 90 69 
IC50 (CaMKIIδ) = 3.4 µM 
A B 
C 
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Appendix 5: Whole-cell cytotoxicity dose response curves 
 
 
Whole-cell cytotoxicity dose response curves of compounds tested in the target 
identificaiton study in resistant mutant and un-mutagenized MDR-sup S. pombe strains. 
The IC50 values determined from these dose response curves are noted on the legend of 
each graph. 
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Appendix 6: Fluorescent visualization of acidified vacuoles 
 
 
Fluorescent images of quinacrine-stained resistant mutants or un-mutagenized MDR-sup 
S. pombe upon incubation with either BE-54017 or cladoniamide A. The minimal 
inhibitory concentration (MIC) (red) for in vivo V-ATPase activity was defined as the 
minimal concentration of compound at which no fluorescent puncta was observed in 
>95% of the cells.  
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Appendix 7: CPA synthase amplicons from TD biodiversity study 
Chromopyrrolic acid (CPA) synthase amplicon sequences. Number of reads populating 
the amplicon sequences (NMCC_#) at 95% identity are tabulated by soil sample (NS1-
NS20), with the consensus sequences listed below. 
 
 
 
NMCC_72: 
GCGTACTCGGTGCCGACGTACGCGGCGGCCGAGGCCTTCGTCCACCGCGGTC
TGTGGACCCCCGAGCAGCTGCGGGTCGCCCTGGGTGACGGCGGAGAGACCCT
CGACGGCGGCGTCCGGGGAAAGCTGGTGGAGATCGCGCGCGAGGAGATGAT
CCATTTCCTCCTCGTCAACAACATCCTCATGGCTCTCGGTGAGCCCTTCTGCG
TCCCCGCGCTGGACTTCGGCGCGCTCGGCACCGACCTGCCGGTGCCCCTGGA
CCTGTGCCTCGAAGGGCTCGACATCGCCACCGTGGCGCGGTTCATCGCGATC
GAGCAGCCCGCGGTGGGCACGCCGGAGGTACGGCGACCCGACCTGCCCACC
ACCACCGGCGCGGCGGGTGCGGGCCGGTACGAGACGTTGAGCGAGATGTAC
GCGCGGATCCGTCAGGGGCTGCAGGACGTCCCG 
Amplicons NS1 NS2 NS3 NS4 NS5 NS6 NS7 NS8 NS9 NS10 NS11 NS12 NS13 NS14 NS15 NS16 NS17 NS18 NS19 NS20
NMCC_72 3 3 2 327 44 34 185 17 1 11
NMCC_29 17 6 1 8 298 14
NMCC_4 1 318
NMCC_350 231 1 4 1 32 6 1 3 12 4 1
NMCC_39 228 1 6 29 6 8 7 2 5 4
NMCC_1 136 85 1 61 1 8
NMCC_8 2 5 260 5 4 10 1
NMCC_30 18 156
NMCC_14 162 2
NMCC_11 96 2 13 2 27 1 3 1 6 6 2 2 2
NMCC_12 68 4 3 30
NMCC_24 70 5 5 7 1 10
NMCC_27 85
NMCC_6 6 7 19 44 6
NMCC_18 79
NMCC_15 68
NMCC_100 58
NMCC_241 52
NMCC_10 50
NMCC_206 48
NMCC_28 39 6
NMCC_166 1 43
NMCC_89 1 37 6
NMCC_22 2 41
NMCC_204 8 34
NMCC_278 40
NMCC_44 38
NMCC_268 1 1 34 1 1
NMCC_104 37
NMCC_81 36
NMCC_5 1 34
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NMCC_29: 
GCGTACTCGGTGCCGACGTACGGGGCGGCCGAGGACTTCGTCCACCGAGGTC
TGTGGACCCCCGAGCAGCTGCGGGTCACCGTGGGCGACGGCGGAGAGGCCCT
CGACGGCGGCGTCCGGGGAAAGCTGGTGGAGATCGCGCGCGAGGAGATGAT
CCATTTCCTCCTCGTCAACAACATCCTCATGGCGCTGGGCGAGCCCTTCTGCG
TGCCCGCACTGGACTTCGGCGCGCTCGGCTCCGACCTGCCGGTGCCCCTCGAC
CTCTGCCTCGAAGGGCTCGACATCGGCAGCGTGGCGCGGTTCATCGCGATCG
AGCAGCCCGCGGTGGGCACGCCGGAGGTGCGGCGACCCGACCTGCCCACCG
GCACCGACGCGGCGAGCGCCGGCCGGTACGAGACGTTGAGCGAGATGTACG
CGCGGATCCGCCAGGGCTTGGCGGACGTCCCGGA 
 
NMCC_4: 
GCGTACTCGGTGCCGACCTACGGGGCGGCCGAGACCTTCGTCCAGCGAGGTC
TGTGGACCCCCGAGCAGCTGCGGGTCACCCTTGGCGACGGCGGCGAGGCCCT
CGACGGCGGCGTCCGCGGAAAGCTGGTGGAGATCGCGCGCGAGGAGATGAT
CCATTTCCTCCTCGTCAACAACATCCTCATGGCGGTGGGGGAGCCCTTCTACG
TCCCGCGCTGGACTTCGGCGCGCTCGGCGCCGACCTGCCAGTGCCTCTCGACC
TCTGCCTCGAAGGGCTCGACACCGCCACCGTGGCGCGGTTCATCGCGATCGA
GCAGCCCGCGACCGAGACGCCGGTGGTCCGGCGACCCGACCTGCCCCCCACC
ACCGCACCGGGTGTCGGTACGAGACGTTGAGCGAGATGTACGCGCGGATCCG
CCGGGGCCTGGCGGACGTGCCGGATCTCTTC 
 
NMCC_350: 
GCGTACTCCGTGCCGACCTACGGCGTCGGCGCGGCGTGGGTGCGCGAGGGCC
GGTGGACCGCGGAACACCTCGAACTCGCCTGCGGCGACGGCGGGCGGACGC
TGCGCACCGGCATCCGGGGCGGCCTGCTCGGGGTCGCCCGCGAGGAGATGGC
GCACTACCTGGTCGTCAACAACGTCCTCATGGCCGTGGGCGAGCCGTTCCAC
GTGCCCGAGGTGGACTTCGCCACGATCAACGCCCGCATGCCGCTGCCGGTGG
ACTTCGCGCTCGAACCGCTGCACCTGGGCAGCGTGCAGCGGTTCATCGCCAT
CGAGGAACCCGACGACGGCCGGCCGGGCGGCGGGCCGTACCGGTCGCTGAG
 171 
CGAGCTGTACGGCGCCATCCGCGACGGCCTGACCCGGGTGCCCGACCTGTTC
GCGTCGAGCGCGGCAGGGGCGCGGCGAGCACCGA 
 
NMCC_39: 
GCGTACTCCGTGCCGACCTACGGCGTCGGCGCGGCGTGGGTGCGCGAGGGCC
GGTGGACCGCGGAACACCTCGAACTCGCCTGCGGCGACGGCGGGCGGACGC
TGCGCACCGGCATCCGGGGCGGCCTGCTCGGGGTCGCCCGCGAGGAGATGGC
GCACTACCTGGTCGTCAACAACGTCCTCATGGCCGTGGGCGAGCCGTTCCAC
GTGCCCGAGGTGGACTTCGCCACGATCAACGCCCGCATGCCGCTGCCGGTGG
ACTTCGCGCTCGAACCGCTGCACCTGGGCAGCGTGCAGCGGTTCATCGCCAT
CGAGGAACCCGACGACGGCCGGCCGGGCGGCGGGCCGTACCGGTCGCTGAG
CGAGCTGTACGGCGCCATCCGCGACGGCCTGACCCGGGTGCCCGACCTGTTC
GCGGTCGAGCGCGGCAGGGGCGGCGGCGAGCACCGC 
 
NMCC_1: 
GCGTACTCGGTGCCGACCTACGGCGTGGGCGAGGCGTGGGTGCGCGGGGCCG
GTGGACCGCGGAGCAGCTCGAACTCGCCTGCGGCGACGGCGGGCGGACGCT
GCACACCGGCATCCGGGGCGGCCTGCTCGGCGTCGCCCGCGAGGAGATGGTC
CACTACCTGGTCGTCAACAACATCCTCATGGCCGTCGGCGAACCGTTCCTGGT
GCCGCGGGTGGACTTCGCCACGATCAACGCGGACCTGCCGCTGCCGGTGGAC
TTCGCGCTCGAACCGCTGCACCTCGGCAGCGCGCAGCGGTTCGCCGCCATCG
AGGAGCCGGGCGACGGCGGCCCGGGCACCGGGCCGTACCGGTCGCTGAGCG
AGCTGTACGGCTCCATCCGCGACGGCCTGTCCCGGGTGCCGGACCTGTTCGC
GGTCGAGCGCGGCCGGGGCGGCGGCGAGCACCG 
 
NMCC_8: 
GCGTACTCGGTGCCGACGTACGCGGCGGCCGAGGCCTTCGTCCACCGCGGTC
TGTGGACCCCCGAGCAACTGCAGGTCACCCTGGGTGACGGCGGAGAGGCCCT
CGACGGCGGCGTCCGGGGAAAGCTGGTGGAGATCGCGCGCGAGGAGATGAT
CCATTTCCTCCTCGTCAACAACATCCTCATGGCTCTGGGCGAGCCCTTCTGCG
TCCCCGCGCTGGACTTCGGCGCGCTCGGCAGCGACCTGCCGGTGCCCCTGGA
 172 
CCTGTGCCTGGAAGGGCTCGACATCGCCACCGTGGCGCGGTTCATCGCGATC
GAGCAGCCCGCGGTGGGCACACCGGAGGTGCGGCGACCCGACCTGCCCCCC
ACACCAGCCCGGCGGGTGCGGGCCGGTACGAGACGTTGAGCGAGATGTACG
CGCGGATCCGCCAGGGGCTGCAGGACGTCCCGGAT 
 
NMCC_30: 
CTGTGGTCCATCCCCACCTACTCGGCGGGCGCCCAGTACGTCAGGCGGGGGA
GTGGACCCCCGAACAGCTCCGGCTGATGTGCGGCGCGGGGCCGCACCGCATC
GACGGAGGCGTCCGGCAGCGCCTGTTCGAGGTGGCCAGGGAGGAGATGATC
CATTTCCTGCTGATCAACAACATCGTCATGGCGACCGGGCAGCCGTTCCACCT
TCCGGCGATCGACTTCGGCACGGTGAACAACGAGCTGCCGGTGCCGCTCGAC
TTCTGCCTGGAGCCCTTCGGACGCGGCGCCCTGGAGCGGTTCATCGCGCTGG
AGCGGCCCTACGACCTGGTCAGGGACATCGCCGGGAACGACGCGCCGGCCG
GCGGCGTGCCCGAGGGGCGCGCCCCGTACGGTACGGCTCGCTGAGCGAGCTG
TACTCGGCCATCCGCGAAGCCGTCAGGCCATCC 
 
NMCC_14: 
GCCTACTCGGTACCCACCCACGGCGCCGGCGCGGAGTACGTACGCCGGGGCC
TGTGGACGCCCGACCAACTGCGGCTCGCGTGCGGTGACGGCGGGGAGACCCT
CGACGAGGGCATCCGCAGCATGCTGCTGACCATCGCCCGCGAGGAGATGATC
CACTTCCTCCTCGTCAACAACATCCTCATGGCGGTGGGCGAACCCTTCCACGC
GCCCCGGATCGACTTCGGCACCGTCAACCGACAGCTGGCCGTCCCGCTGGAC
TTCGCCCTGGAGCGCCTGGGGCCCGGCAGCGTGGAGCGGTTCGTACAGATCG
AACGCCCCGAGGACCTCGTCGACGAGGTACGGCGCGGCGACGCTCCGGCGCC
CCCGCCGCGTACGACGAGCGGCACCCGTACGCCTCGCTGAGCGAGCTGTACG
CGGACATCCGGGAAGGGCTGGAGAGCATCCCG 
 
NMCC_11: 
GCGTACTCCGTGCCGACCTACGGCGTCGGCGCGGCGTGGGTGCGCGAGGGCC
GGTGGACCGCGGAACACCTCGAACTCGCCTGCGGCGACGGCGGGCGGACGC
TGCGCACCGGCATCCGGGGCGGCCTGCTCGGGGTCGCCCGCGAGGAGATGGC
 173 
GCACTACCTGGTCGTCAACAACGTCCTCATGGCCGTGGGCGAGCCGTTCCAC
GTGCCCGAGGTGGACTTCGCCACGATCAACGCCCGCATGCCGCTGCCGGTGG
ACTTCGCGCTCGAACCGCTGCACCTGGGCAGCGTGCAGCGGTTCATCGCCAT
CGAGGAACCCGACGACGGCCGGCCGGGCGGCGGGCCGTACCGGTCGCTGAG
CGAGCTGTACGGCGCCATCCGCGACGGCCTGACCCGGGTGCCCGACCTGTTC
GCGGTCGAGCGCGCAGGGGCGCGGCGAGCACCGA 
 
NMCC_12: 
GCGTACTCGGTGCCGGCCTACGGGGCGGGGGAGGAGTACGTCCGGCGCGGG
CTGTGGACCCCCGAACAGCTGCGGCTCGCCTGTGGGGACGGCGGCCGGACCC
GCGACGGGGGCATCCGCGGCACGCTGCTCGGCATCGCCCGCGAGGAAATGAT
CCACTTCCTGATCGTCAACAACATCATCATGGCGATGGGCGAACCGTTCTAC
GTCCCCGACGTCGACTTCGGCACGATCAACAACACCCTGCCCGTGCCGCTGG
ACTTCGCCCTGGAGCCCCTCGGCGTGGGCAGCGTGCAGCGGTTCATCGCGAT
CGAACGGCCGGAGGACCAGGTCGGCGAGCTCCACCCCCCGGTCCCGGTTCGG
TTCCCCGCCGGCCGCCGAGCACCCTTACGCCTCGCTCAGCGAGCTGTACGGC
GACATCCGCGAGGCCTGCAACGGGTCCCCGACGTC 
 
NMCC_24: 
CTGTGGTCCATCCCCACCCACTCGGCCGGGACCGAGTACGTGCGGCGAGGCG
AGTGGACGCCCGGGCAGCTCCGGCTCATGTGCGGCGAGGGCCCGCACAGCCT
CGACGGCGGCGTCCGGCAGGACCTGTTCGCCGTCGCCCGCGAGGAAATGATC
CACTTCCTGCTGATCAACAACATCATCATGGCGACGGGTCAGCCGTTCCACCT
GCCCCGGATCGACTTCGGCACGGTGAACGGCGAGCTCCCGTCCCGTCGACCT
GTGCCTGGAGCCCTTCGGGCGGGGCAGCCTGCAACGGTTCGCCGCTCTGGAA
CGGCCCTACGACCTGGTCCGCGACCTGGCCGCCGACCGGCCACCGGTGACCG
CGCGCGACCCGTACCCCTACGGTTCGCTCAGCGAGCTGTACGGGGCCATCCG
CCAGGCGATCCAGGACATCCCGGACGTCTTCC 
 
NMCC_27: 
 174 
GCGTACTCGGTGCCGACGTACGGGGTGGCGGAGGCTTTTGTCCGGCGCGGTC
TGTGGACGCCCGAGCAACTGCAGGTCACCCTGGGCGACGGTGGCGAGGCGCT
CGACAGCGGCGTGCGGGGGAAGCTGATCGAGATCGCGCGCGAGGAGATGAT
CCATTTCCTCCTCGTCAACAACATCCTCATGGCCGTCGGCGAGCCCTTCTGCG
CCCCCGTACTGGACTTCGGGACGCTCGGCGACGATCTCCCGATCCCGCTGGA
CCTCTCCCTCGAGGGGCTCGACATCGGCAGCGTGCAGCGTTTCATCGCGATC
GAGCAGCCCGCGGTGGCCACGCCCGAGGTGAGGCGAGCCGACCTGCCGGTC
ACCACATCCGGACGCGGGTCCGGGCCGCTACGAGACGTTGAGCGAGATGTAC
GCGCGCATCCGGCCAGGGGCCTGGCAGGGACGGTC 
 
NMCC_6: 
GCGTACTCCATCCCGACCCACGGCGCCGGGGTGGAGCACGTCCGCCGCGGCC
TGTGGACCCCGCAGCAGCTGGAGCTGGCGTGCGGTGACGGCGGCGCCACCAC
CGCCGGCGGGCTGCGCGGCATGCTGCTCGGCGTGGCCCGCGAGGAGATGATC
CACTTCCTGCTGGTCAACAACATCATCATGGCGATGGGGGAGCCGTTCCACG
TGCCGGTGGTGGACTTCGGCACCGTCAACACCACCCTGCCGGTGCCGCTGGA
CGTCAGCCTGGAGGCCCTCAACCTCGGCAGCGTCCAACGGTTCATCGCCATC
GAGCGGCCGGACTGCGAGGTCGGCGAGCTGCGCCGGGCGCCGGGCACCGGA
GACCCGGCTCGCCGCCGACCCGGCCCGGTCGCCGCGCTGCTACGGCACCCGT
CAGCGAGCTGTACGCCGAGAGTCCGGGAGGGCC 
 
NMCC_18: 
GCGTACTCCATCCCGACCTACGGCGCCGGTGTGGAGTTGGTGCGGCAGGGCC
GGTGGACCACCGAACAGCTCGAGCTGGCCTGCGGCGACGGCGGCCAGACCCT
GGACACCGGGATGCGGGGCGGCCTGCTCGGCGTCGCCCGCGAGGAGATGGT
CCACTACCTTGTCGTCAACAACATCCTCATGGCCGTCGGCGAGCCGTTCTTCG
TGCCTCAGGTGGACTTCGGCACCATCAACGTCTCGCTGCCGGTACCGGTGGA
CTTCGCCCTCGAGCCGCTCGGCCTCGGCAGCGTGCAGCGGTTCGTCACCATCG
AGCAGCCGAGCGACGTCCCACCGGGCTCCGGACCGTACCGGTCGTTGAGCGA
GCTGTACGGCGCCATCCGCGACGGACTGTCCCGCGTGCCGGACCTGTTCATG
GTCGAACCCGGCAGGGGCGCGGGGAACAC 
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NMCC_15: 
CTGTGGTCCATCCCCACCCACTCGGCCGGGACCGAGCTCGTGCGGCGCGGGG
AGTGGACGCCCGGTCAGCTCCGGCTCATGTGCGGCGATGGCCCGCAGAGCCT
CGACGGCGGCATCCGGCATGCCCTGTTCGCCGTCGCCCGTGAGGAAATGATC
CACTTCCTGCTGATCAACAACATCATCATGGCGACCGGCCAGCCGTTCCACCT
GCCCCGAATCGACTTCGGAACGGTGAACACCGAGCTCCCCGTTCTCGTCGAC
CTGTGCCTGGAACCCTTCGGGCGGGGCAGCCTGCAGCGGTTCGCCGCACTGG
AACGCCCCCACGACACGGTCCGCGGCCTCGCAGAGGACCACCCGTCGGTGAC
CGCGTGCCACCCGTACCCCTACGGTTCGCTCAGCGAGCTGTACGGGGCCATC
CGCCAGGCCGTTCAGGACATCCCGGATGTCCT 
 
NMCC_100: 
ATGTGGTCGCTGCCGACTCACCGTATGGGGGCCGCGCTGGTCCACCAGGGCG
AGTGGACCGAGGACCAGTACACGCTGGTCTGCGGGCGCGGGCCGGCGACGG
CTGACGGGGGGATCCGGGGCGCTCTGTTCGGGGTGGCCCGAGAGGAGATGAT
TCATTTCCTCGTCATCAACAACATCATCATGGCCACGGGTCAGCCCTTCCACG
TGCCCGACATCAACTTCTCCTCGCTCAACGCGCAGATCGACCTGCCGATGGA
CTTCTGCCTGGAGCGGTTCGGCCTGTCCTCGCTGAGCAGGTTCGTCGAGTTTG
AAAGCCGTTTTCGCTCACCGTCGAGCCAGCGCCGGCACCGGGAGGCCCGCAG
CGAAAGGGTGCCCGTTACGGGTCGCTGAGCGAGCTCTACGCGTCGATCCGGG
ACGGCCTCGCCCGGTTCCCGAGGGCCTTCCT 
 
NMCC_241: 
GCGTACTCGGTGCCGACGTACGGGGTGGCGGAGGCTTTCGTCCGGCGCGGTC
TGTGGACGCCCGAGCAACTGCAGGTCACCCTGGGCGACGGTGGCGAGGCGCT
CGACAGCGGCGTGCGGGGGAAGCTGATCGAGATCGCGCGCGAGGAGATGAT
CCATTTCCTCCTCGTCAACAACATCCTCATGGCCGTCGGCGAGCCCTTCTGCG
CCCCCGTACTGGACTTCGGGACGCTCGGCGACGATCTCCCGATCCCGCTGGA
CCTCTCCCTCGAGGGGCTTGACATCGGCAGCGTGCAGCGTTTCATCGCGATCG
AGCAGCCCGCGGTGGCCACGCCCGAGGTGAGGCGAGCCGACCTGCCGGTCA
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CCACATCCGACGCGGGTCCGGGCCGCTACGAGACGTTGAGCGAGATGTACGC
GCGCATCCGCCAGGGCCTGCAGGAGGTCCCG 
 
NMCC_10: 
GCCTACTCGATCCCCACGTACGGCGCCGGCCAGGAGCACGTGCGCCGTGGGC
TGTGGACGCCCGAACAGCTCGCGCTGGTCTGCGGCGACGGCGGGGAGACCAC
CGCCGGCGGGATCCGTGGCACGTTGCTGTCCGTGGCGCGGGAAGAGATGATC
CACTTTTTGTTGATCAATAACGTGATCATGGCGATGGGTGAGCCGTTCTTCGT
GCCGACCGTCGACTTCGGCACCATCAACAACACCCTGCCACTCCCCCTCGAC
CTGGCGTTGGAGCAGTTCGGCATCGGCAGCGTCCAGCGGTTCATCGCCATCG
AACGACCCCACGCCCAGGACGGCGAGATCCAGATCGGCACCGACCAGGGCA
GCGGCGGGCCGCTCGCCGAACCGACCCACACCTACAGCTCGCTCAGTGGCCT
CTACGCCGACATCCGGGAAGGACTGCAGCGGG 
 
NMCC_206: 
GCCTACTCGATCCCCACGTACGGCGCCGGCCAGGAGCACGTGCGCCGTGGGC
TGTGGACGCCCGAACAGCTCGCGCTGGTCTGCGGCGACGGCGGGGAGACCAC
CGCCGGCGGGATCCGTGGCACGTTGCTGTCCGTGGCGCGGGAAGAGATGATC
CACTTTTTGTTGATCAATAACGTGATCATGGCGATGGGTGAGCCGTTCTTCGT
GCCGACCGTCGACTTCGGCACCATCAACAACACCCTGCCACTCCCCCTCGAC
CTGGCGTTGGAGCAGTTCGGCATCGGCAGCGTCCAGCGGTTCATCGCCATCG
AACGACCCCACGCCCAGGACGGCGAGATCCAGATCGGCACCGACCAGGGCA
GCGGCGGGCCGCTCGCCGAACCGACCCACACCTACAGCTCGGCTCAGTGGCC
CTCTACGCCGACATCCGGGAAGGACCTGCG 
 
NMCC_28: 
GCGTACTCCATCCCGACCTACGGCGCCGGCGTGGAGCAGGTACGGCGGGGCC
GATGGACCACCCAACAGCTAGAGCTGGCCTGCGGCGACGGCGGCCAGACCCT
GCACACCGGGATCCGGGGCGGCCTGCTCGGCGTCGCCCGCGAGGAGATGATC
CACTTCCTGGTCGTCAACAACATCCTCATGGCCGTCGGCGAACCGTTCTTCGT
GCCCCGAGTGGACTTCGGCACCCTCAACGCCGAACTTCCGCTCCCGGTGGAC
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TTCGCCCTCGAACCGCTACACCTTGGCAGCGTGCAGCGGTTCATCACCATCGA
GCGACCCAGCGACATCGCACCGAGCACCGGACCGTACCGGTCGCTGAGCGA
GCTGTACGGCGCCATCCGCGACGGCCTGTCCCGCGTACCGGACCTGTTCATG
GTCGAACCCGGCAGAGGCGGCGGGGAACACCA 
 
NMCC_166: 
GCGTACTCCGTCCCGACCCACGGTGCCGGGGTGGAGCACGTCCGCCGCGGCC
TGTGGACCCCGCACCAGCTGGAACTCGCCTGCGGTGATGGCGGCGCCACCAC
CGCCGGCGGGCTGCGCGGCATGCTGCTCGGCGTGGCCCGCGAGGAGATGATC
CACTTCCTGCTGGTCAACAACATCATCATGGCGATGGGGGAGCCGTTCCACG
TGCCGGTGGTGGACTTCGGCACCGTCAACACCACCCTGCCGGTGCCGCTGGA
CGTCAGTCTGGAGGCCCTCAACCTCGGCAGCGTCCAACGGTTCATCGCCATC
GAGCGGCCGGACTGCGAGGTCGGCGAGCTGCGCCGGGCGCCGGGCACCGGA
GAACCGCTCGCCCACCGACCCGGCCGGTCGCCGCGCTGCTACGGCACCGTCA
GCGAGCTGTACGCCGAGACGTCCGGGAGGGCCT 
 
NMCC_89: 
GCGTACTCGGTGCCGGCCTACGGGGCGGGGGAGGAGTACGTCCGGCGCGGG
CTGTGGACCCCCGAGCAGCTGCGGCTCGCCTGTGGGGACGGCGGCCGGACCC
GCGACGGGGGCATCCGCGGCACGCTGCTCGGCATCGCCCGCGAGGAGATGAT
CCACTTCCTGATCGTCAACAACATCATCATGGCGATGGGCGAACCGTTCCAC
GTCCCCGACGTCGACTTCGGCACGATCAACAACACCCTGCCCGTGCCGCTGG
ACTTCGCCCTGGAGCCCCTCGGTGTGGGCAGCGTGCAGCGGTTCATCGCGAT
CGAACGGCCGGAGGACCAGATCGGCGAGCTCCAGCCGCCGTCCCGGTACGG
CTCCCCGCGGCCGCCGAGCACCAGTACGCCTCGCTCAGCGAGCTGTACGGCG
ACATCCCGCGAGGGCCGCCAACCGGGTCCCCG 
 
NMCC_22: 
GGCTATTCGGTCCCCACGCACGGCACGGGGTTCGCGTACGTGCGCAGCGGGG
TGTGGACCCCGCGTCAGCTCCGGCTCGCGTGCGGGGACGGCGGGGAGACCCT
CGCCAAGGGGGTCAGGGACAGCCTCTTCGACGTGGCCCGCGAGGAGATGAT
 178 
GCACTTCCTCGTCGTCAACAACATCCTGATGGCCATGGGCGAGCCCTTCCACG
TCCCGGAGATCGACTTCGGCACGCCGGGCCGGCTGCCGCTGCCGCTCGACTT
CGCCCTCGAACCGCTGCACCTGGGAAGCCTCCAGCGGTTCATCGCCATCGAG
CGGCCCGAGCGCCTCGCGGGCGGCACGGGAGCCGTGGACGGGCCCGGCCCG
TTCGGTTCGCCGAGCGAGCTGTACGCGGGGATCAGGGAGGGCCTGACCCGGG
TCCCCGACCCTGTTCCCCGTGGACCGGGGGCGG 
 
NMCC_204: 
CTGTGGTCCATCCCCACCCACTCGGCCGGGATCGAGTACGTGCGGCGACGCG
AGTGGACGCCCGGGCAGCTCCGGCTCATGTGCGGCGAGGGCCCGCACAGCCT
CGACGGCGGCGTCCGGCAGGACCTGTTCGCCGTCGCCCGCGAGGAAATGATC
CACTTCCTGCTGATAAACAACATCATCATGGCGACGGGTCAGCCGTTCCACCT
GCCCCGGATCGACTTCGGCACAGTGAACGGCGAGCTCCCGTCCCATCGACCT
GTGCCTGGAGCCCTTCGGGCGGGCAGCCTGCAACGGTTCGCCGCGCTGGAAC
GGCCCTACGATCTGGTCCGCGACCTCGCCGCCGACCGGCCACCGGTGACCGC
GTGCGACCCGTATCCCTACGGTTCGCTCAGCGAGCTGTACAAGGCCATCCGC
CAGGCGATCCAGGGACATCCCGGACGT 
 
NMCC_278: 
GCCTACTCGGTACCCACCCACGGCGCCGGCGCGGAGTACGTACGCCGGGGCC
TGTGGACGCCCGACCAACTGCGGCTCGCGTGCGGTGACGGCGGGGAGACCCT
CGACGAGGGCATCCGCAGCATGCTGCTGACCATCGCCCGCGAGGAGATGATC
CACTTCCTCCTCGTCAACAACATCCTCATGGCGGTGGGCGAACCCTTCCACGC
GCCCCGGATCGACTTCGGCACCGTCAACCGACAGCTGGCCGTCCCGCTGGAC
TTCGCCCTGGAGCGCCTGGGGCCCGGCAGCGTGGAGCGGTTCGTACAGATCG
AACGCCCCGAGGACCTCGTCGACGAGGTACGGCGCGGCGACGCTCCGGCGCC
CCCGCCGCGTACGACGAGCGGCACCCGTACGCCTCGCTGAGCGAGCTGTACG
CGGACAGTCCCGGGGAAGGGC 
 
NMCC_44: 
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GCCTGGTCGATCCCGACGGCCGGCGCCGCCGCCGAGTTCGTCCGCCGCGGCG
AATGGACGCCGGAGCAGCTGCGGCTGGCGTGCGGCGACGGCGGACCCACCC
TCGACTACGGGATGCGCGGCACGCTGCTCAACGTGGCCCGCGAGGAAATGAT
CCACTTCCTGGTCATCAACAACATCATCACCGCGACCGGCGACGCGTTCCAC
GTGCCGGCGATCGACTTCGGCACCCTCAACGAGCAGCTGCCGGTGCCGCTGG
ACTTCAGCCTGGAGGCGTTCGGGCTGGGGCCGCTGCAACGCTTCATCGCCAT
CGAACGGCCGGACGACCAGACCGTCGAGTTCGCCGGGACCGACACGCTGCTC
GACCGGGGCGACGCGCTGTACCCGTACGGCTCGCTCAGCGAGCTCTACGCGG
CCATCCCGCGAGGGGCCATTCCCAGCCGGGGT 
 
NMCC_268: 
GCGTACTCGGTGCCGACGTACGGGGCGGCCGAGGACTTCGTCCACCGAGGTC
TGTGGACCCCCGAGCAGCTGCGGGTCACCGTGGGCGACGGCGGAGAGGCCCT
CGACGGCGGCGTCCGGGGAAAGCTGGTGGAGATCGCGCGCGAGGAGATGAT
CCATTTCCTCCTCGTCAACAACATCCTCATGGCGCTGGGCGAGCCCTTCTGCG
TGCCCGCACTGGACTTCGGCGCGCTCGGCTCCGACCTGCCGGTGCCCCTCGAC
CTCTGCCTCGAAGGGCTCGACATCGGCAGCGTGGCGCGGTTCATCGCGATCG
AGCAGCCCGCGGTGGGCACGCCGGAGGTGCGGCGACCCGGACCTGGCCCAC
CGGCACCGACGCGGCGAGCGCCGGCCGGTACGAGACGTTGAGCGAGATGTA
CGCGCGGATCCGGCCAGGGCTTGGGGG 
 
NMCC_104: 
GCGTACTCCATCCCCACCCACGGGGCGGGCAGCCGGTACGTCGCGTCGGGGG
AGTGGAGCGAGGACCAGTTCCGGCTCGCCTGCGGTGACGGGGCCCAGACGTT
GAGCAACGGCATCCGCGGCAGCCTGCTGAACGTGGCACGCGAGGAGATGAT
GCACTTCCTCGCCATCAACAACATCATCATGGCCGCGGGCAGGCCGTTCTGC
CTGCCGCGCCTGGACTTCGGCGAGATCAACAACCAGATCCCGGTGCCGATCG
AGTTCGCGCTCGAACCGTTCGGGCTGGGCAGCGTGCAGCGGTTCGTCGAGCT
GGAGAAGCCGCACGACCTGATCATGGACGTGGCCGGGACCGAACCAGCCGG
CAAGCGGGAGAACGGCGAGCCCTACCGGTACGGTCGCTCAGCGAGCTGTAC
GAGGCCATCCGCGAGGGCGTCCGAGCGGGTGCCGG 
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NMCC_81: 
GCCTACTCGGTGCCGACCTACGGCGCCGGGCTGGCACTCGTGCGGCGCGGCC
TGTGGACGCCGGAGCAGCTCGACCTCGCCTGCGGCGACGGCGGGCGGACGC
GGCACACCGGGGTTCGCGGCGCCCTGCTCGGCGTCGCGCGCGAGGAGATGAT
CCACTTCCTGGTCGTCAACAACATCCTGATGGCCATCGGCGAGCCGTTCTTCA
GCCCGGCCGTCGACTTCGGCACCGTCAACACCGAACTGCCGGTGCCGGTGGA
CTTCGCGCTCGAACCGCTGAACGTCGGCAGCGTGCAGCGGTTCGTCGCCCTG
GAGCGGCCCGCCGACCCGGAGCAGGTGGCCGGCCCCTACCGGTCGCTCAGCG
AGCTGTACGGCGCCATCCGCGAAGGCTTGCGGCGGTACCCGACCTGTTCCTG
GTGCGGCCGGGCCGGGGCGGCGGCGAGCACCGAC 
 
NMCC_5: 
GCCTACTCGATACCGACGTACGGGTCGGGGCTGGCGTACGTCCGGCGCGGGC
TGTGGACGCCCGAGCAGCTGGCACTCGCCTGCGGCGACGGCGGTGCGACGCT
GGCCAACGGGATGCGGGGCAGCCTGCTGTCCGTCGCCCGCGAGGAGATGATC
CATTTCCTGGTCATCAACAACGTCATCATGGCGATGGGCGAGGCGTTCACCG
TCCCGGCCATCGACTTCGGCACCGTCAACGGCTCGTTGCCGGTCCCGGTGGA
CTTCGCCCTGGAACGTTTCGGGGTCGGTAGCGTGCAACGGTTCATCGCGATC
GAACAGCCCGAGTCCCTCGTCGGCGAGGTACCCCGGGAGTTCGGCAGCGGGT
CCGGTACGTCAGAGCCGACACCCACCTACCGGTCCCTCAGCGAGCTGTACGG
CGCGATCCGGGAGGGCTGCAGCGGGTGCCCGACT 
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